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Abstract 
Asthma is characterised by airway inflammation, hyper-responsiveness and airway 
remodelling. Features of airway remodelling include hypertrophy/hyperplasia of 
airway smooth muscle cells (ASMC), which possess an important synthetic capacity 
in addition to their contractile function. Patients with severe asthma respond poor to 
even high-dose corticosteroids and consume enormous healthcare resources. 
Corticosteroid insensitivity in peripheral blood mononuclear cells and alveolar 
macrophages of severe asthma has been reported. It is still unclear whether ASMC 
display a similar phenotype. I hypothesised that corticosteroid insensitivity exists in 
ASMC of severe asthma, and the underlying mechanisms were investigated. ASMC 
were obtained from endobronchial biopsy and were experimented with at passage 4-
5.  
 
TNF-α induced CCL11, CXCL8 and CXCL10 expression in ASMC. IFN-γ suppressed 
TNFα-induced CCL11 and CXCL8, through attenuation of NF-κB (p65) recruitment to 
the gene promoters, but potentiated induced CXCL10. CX3CL1 was induced 
synergistically only by combined both cytokines. Baseline and TNFα-induced CCL11 
expression in non-severe asthma were greater than the healthy and severe asthma, 
while IFNγ-induced CXCL10 was increased in severe asthma. Whereas TNFα-
induced p65 expression was increased in severe asthma, there was no difference in 
nuclear translocation or recruitment to the gene promoters between groups. The 
effect of dexamethasone was reduced in terms of suppressing induced CCL11 and 
CXCL8 expression in severe asthma, while the potentiating effect on CX3CL1 was 
not different between groups. Of the mitogen-activated protein kinases (MAPK), p38 
5 
activation was heightened in severe asthma, and p38 inhibition restored the 
corticosteroid sensitivity. Expression of glucocorticoid receptor (GR) was decreased 
in asthma, while nuclear translocation of GR was impaired only in severe asthma. 
 
In conclusion, there is differential expression of inflammatory chemokines in ASMC 
of asthma. Corticosteroid insensitivity exists in ASMC of severe asthma in terms of 
suppressing induced chemokines, partially attributed to heightened p38 MAPK 
activity and impaired nuclear translocation of GR. 
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Chapter 1. Introduction 
1.1 Asthma 
Asthma is a disorder defined by its clinical, physical, and pathological characteristics. 
The predominant feature of the clinical history is episodic shortness of breath, 
particularly at night, often accompanied by cough. Wheezing appreciated on 
auscultation of the chest is the most common physical finding. The main 
physiological feature of asthma is episodic airway obstruction characterised by 
expiratory airflow limitation. The dominant pathological feature is airway inflammation, 
sometimes associated with airway structural changes. 
 
A common referenced formal definition is that published in the Global Initiative for 
Asthma Guideline (GINA 2011), which proposes an operational description of 
asthma as:  
A chronic inflammatory disorder of the airways in which many cells and 
cellular elements play a role. The chronic inflammation is associated with 
airway hyper-responsiveness that leads to recurrent episodes of wheezing, 
breathlessness, chest tightness, and coughing, particularly at night or in the 
early morning. These episodes are usually associated with widespread, but 
variable, airflow obstruction within the lung that is often reversible either 
spontaneously or with treatment. 
 
Asthma is one of the commonest diseases and affects patients of all ages and both 
genders. Generally beginning early in life, asthma can have its onset at any age. 
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Global burden of disease estimates suggest that at least 300 million people 
worldwide have asthma, and the frequency of this disease has increased greatly 
since the 1980s (Bousquet, Khaltaev et al. 2007), with the potential for an additional 
100 million more cases by the year 2025 (Masoli, Fabian et al. 2004). The World 
Health Organization (WHO) estimates that 15 million disability-adjusted life years are 
lost annually due to asthma, representing 1% of the total global disease burden, and 
annual worldwide deaths from asthma are estimated at 250,000/year (Cote, Cartier 
et al. 1997). 
 
The pathophysiology of asthma includes persistent airway inflammation, reversible 
airway obstruction, airway hyper-responsiveness, and airway remodelling. These 
characteristics are described below. 
  
1.1.1 Airway inflammation in asthma 
The clinical spectrum of asthma is highly variable, and different cellular patterns 
have been observed, but the presence of airway inflammation in asthma is persistent 
even though symptoms are episodic (Cohn, Elias et al. 2004). The inflammation 
affects all airways including the upper respiratory tract and the nose but its 
physiological effects are most pronounced in medium-sized bronchi (Jeffery 1999).  
 
It is evident that no single inflammatory cell is able to account for the complex 
pathophysiology of asthma, but some cells predominate in asthmatic inflammation. 
The characteristic pattern of inflammation found in allergic diseases is exemplified by 
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asthma, with activated mast cells, increased numbers of activated eosinophils, 
increased number of T cell receptor invariant natural killer (NK) T cells and T helper 
2 lymphocytes, which release mediators that contribute to symptoms. Structural cells 
of the airways also produce inflammatory mediators and contribute to the 
persistence of inflammation in various ways (Fig 1.1).  
Figure 1.1. Inflammatory cells involved in asthma. Epithelial cells play an 
important role in orchestrating the inflammation of asthma through release of multiple 
cytokines (CKs), including stem cell factor (SCF; which maintains mast cells in the 
airways) and thymic stromal lymphopoietin (TSLP; which acts on dendritic cells to 
chemoattract Th2 cells). Th2 cells release CKs to stimulate B cells to synthesise 
immunoglobin E (IgE), attract eosinophils (which cause tissue damage through 
release of major basic protein (BP)) and stimulate mast cell proliferation. Mast cells 
play an important role in asthma through release of histamine (H), cysteinyl-
leukotrienes (C-LT), and prostaglandin (PG), which causes bronchoconstriction (BC) 
(Finiasz, Otero et al. 2011). 
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1.1.1.1 T-lymphocytes 
An increased understanding of the development and regulation of airway 
inflammation in asthma follows the discovery and description of subpopulations of 
lymphocytes, most importantly T helper 1 (Th1) and T helper 2 (Th2) cells, with 
distinct inflammatory mediator profiles and effects on airway function (Fig. 1.2). After 
the discovery of these distinct lymphocyte subpopulations in animal models of 
allergic inflammation, evidence emerges that, in human asthma, a predilection 
towards the Th2-cytokine profile results in the eosinophilic inflammation 
characteristic of asthma (Cohn, Elias et al. 2004). In addition, generation of Th2 
cytokines, such as interleukin-4 (IL-4), IL-5 and IL-13, also accounts for 
overproduction of IgE, presence of eosinophils and development of airway hyper-
responsiveness. Although it is an oversimplification of a complex process as a Th2 
disease, recognizing the importance of the families of cytokines and chemokines has 
advanced our understanding of the development of airway inflammation in asthma.  
 
A subset of cluster of differentiation (CD) 4+ T-cells expressing CD25, termed T-
regulatory cells (Treg), are capable of suppressing both Th1 and Th2-mediated 
adaptive immune responses through release of transforming growth factor-beta 
(TGF-β) or IL-10 (Taylor, Verhagen et al. 2006). An imbalance between allergen-
specific Treg and effector Th2 cells is shown in allergic diseases (Ling, Smith et al. 
2004). 
 
Another recently described CD4+ T-cell subpopulation, Th17, secrete IL-17 and 
several other cytokines. Th17 cells are characterised by the production of IL-17A and 
IL-17E (also named IL-25) (Finiasz, Otero et al. 2011). These cytokines have been 
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linked to neutrophilic inflammation by inducing the release of CXCL1 and CXCL8 
from airway epithelial cells (Laan, Lotvall et al. 2001), which may be associated with 
pathogenesis of severe asthma (Al-Ramli, Prefontaine et al. 2009). Th17 cells also 
produce IL-21, which is important for the differentiation of these cells and thus acts 
as a positive auto-regulatory mechanism (Barnes 2008) (Al-Ramli, Prefontaine et al. 
2009). 
Figure 1.2. Interaction between Th1/Th2 lymphocytes in immunopathogenesis 
of asthma. Th2 cells predominate in most patients with asthma and differentiate 
from uncommitted precursor T cells on exposure to allergens, orchestrating allergic 
inflammation through release of IL-4, IL-5 and IL-13. Smoking or viral infection 
activates Th1 as well as cytotoxic T cells through CXCR3 chemokines CXCL9-11. 
Both inflammatory profiles may either counter-regulate or co-exist to varying degrees 
in asthma (Brightling, Gupta et al. 2011). 
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1.1.1.2 Mast cells 
Mast cells are important in initiating the acute bronchoconstrictor response to 
allergen and other indirect stimuli, such as exercise and hyperventilation. Classically, 
mast cells are activated by allergens through an IgE-dependent mechanism via 
interactions with high-affinity IgE receptors (FcεRI and FcεRII) on the cell surface 
(Mauad, Poon et al. 2011), as well as by osmotic stimuli, which accounts for 
exercise-induced bronchoconstriction. Upon allergic inflammation, mast cells release 
pre- and newly formed mediators, such as histamine, cysteinyl-leukotrienes and 
prostaglandins, that play essential roles in the induction of acute allergic responses 
and the development of chronic allergic inflammation. Activation of mast cells plays a 
key role in the symptoms of asthma in the early phase and during acute 
exacerbation. In patients with asthma, there is infiltration of airway smooth muscle by 
mast cells (Brightling, Bradding et al. 2002), which is linked to hyper-responsiveness 
in this disease (Robinson 2004).  
 
1.1.1.3 Eosinophils 
Eosinophil infiltration is a characteristic feature of asthmatic airways and 
differentiates asthma from other non-infectious inflammatory conditions of the airway. 
Indeed, asthma was described as “chronic eosinophilic bronchitis” as early as 1916. 
Increased numbers of eosinophils exists in the airways of most, but not all, patients 
with asthma. In addition, numerous studies show that treating asthma with 
corticosteroids reduces circulating and airway eosinophils in parallel with clinical 
improvement. 
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Allergen inhalation results in a marked increase in eosinophils in bronchoalveolar 
lavage (BAL) fluid at the time of the late phase reaction, and there is a correlation 
between eosinophil counts in peripheral blood or BAL and airway hyper-
responsiveness. Eosinophils are linked to the development of airway hyper-
responsiveness through the release of basic protein and oxygen-derived free 
radicals (Simon and Simon 2009). In addition, the number of eosinophils in the 
diverse lung compartments is associated with disease severity and airway 
obstruction (Mauad, Poon et al. 2011). 
 
Eosinophils are derived from bone marrow precursors; the Th2 cytokine IL-5 is a 
unique mediator of eosinophil differentiation and survival in response to allergen 
provocation. After allergen challenge, eosinophils appear in BAL fluid during the late 
response, and this appearance is associated with a decrease in peripheral 
eosinophil counts and with the appearance of eosinophil progenitors in the 
circulation. The signal for increased eosinophil production is likely to be IL-5 derived 
from the inflamed airway. Eosinophil recruitment initially involves adhesion of 
eosinophils to vascular endothelial cells in the airway circulation, their migration into 
the submucosa, and their subsequent activation. There are several mediators 
involved in the migration of eosinophils from the circulation to the surface of the 
airway. Cysteinyl leukotrienes, through stimulation at the sys-LT1-receptor, are in 
part responsible for eosinophilopoiesis in human airways. Other mediators, such as 
chemokine CCL11 (eotaxin), also play a role by promoting recruitment to tissues in 
response to allergic provocation, via CCR3 receptors.  
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1.1.1.4 Neutrophils 
Although neutrophils are not a predominant cell type observed in the airways of most 
patients with mild-to-moderate asthma, they appear to be a more prominent cell type 
in airways and induced sputum of patients with severe asthma (Wenzel 2005). 
Cluster analyses of patients with asthma from the Severe Asthma Research 
Program study have shown that neutrophilia is associated with an absence of atopy, 
female sex and obesity in severe asthma (Moore, Meyers et al. 2010). These 
patients present with the lowest lung function, worse asthma control, and need more 
healthcare. 
 
Evidence suggests that airway neutrophilia may be associated with a more severe 
form of asthma. For example, in patients who die suddenly of asthma, large numbers 
of neutrophils are found in their airways (Sur, Crotty et al. 1993). In addition, there is 
an increase in neutrophil number in the sputum of patients with severe asthma 
compared to those with mild asthma and healthy subjects (Jatakanon, Uasuf et al. 
1999). Furthermore, rapid withdrawal of corticosteroids results in the appearance of 
neutrophils in the airways of patients with asthma (Maneechotesuwan, Essilfie-
Quaye et al. 2007). The mechanisms of neutrophilic inflammation are not yet well 
understood, but several mediators, including CXCL8 (IL-8), are likely to be involved. 
A recent study suggests the neutrophilic inflammatory phenotype may be associated 
with systemic inflammation in asthma, exemplified by elevated plasma C-reactive 
protein (CRP) and IL-6 in asthmatic patients with increased neutrophil count and 
CXCL8 levels in the sputum (Wood, Baines et al. 2012). 
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1.1.1.5 Structural cells 
Airway epithelial cells sense their mechanical environment, express multiple 
inflammatory proteins in asthma, and release cytokines, chemokines, and lipid 
mediators. Viruses and air pollutants also interact with epithelial cell to produce more 
inflammatory mediators or to injure the epithelium itself (Proud and Leigh 2011). The 
repair process following injury to the epithelium may be abnormal, thus furthering the 
obstructive lesions that occur in asthma (Holgate 2011). 
 
Airway smooth muscle cells (ASMC) are not only a target of the asthma response by 
undergoing contraction to result in airflow obstruction and airway hyper-
responsiveness, but also contribute to the disease via production of pro-inflammatory 
mediators (John, Clarke et al. 2008). As a consequence of airway inflammation and 
the generation of growth factors and cytokines, ASMC undergo proliferation, 
contraction and hypertrophy (Panettieri 2008); these events can influence airway 
dysfunction in asthma. The detailed role of ASMC in asthma will be described later in 
this chapter. 
 
Other cells involved in airway inflammation in asthma include: endothelial cells of the 
bronchial circulation recruits inflammatory cells from the circulation into the airway 
(Lee, Ma et al. 2011); fibroblasts and myofibroblasts produce connective tissue 
components, such as collagens and proteoglycans, which are involved in airway 
remodelling (Halwani, Al-Muhsen et al. 2010); cholinergic nerves may be activated 
by reflex triggers in the airways and cause bronchoconstriction and mucus secretion 
(Canning 2006), whilst sensory nerves, sensitized by inflammatory stimuli including 
substance P and neurotrophins, cause symptoms such as cough and  chest 
tightness (Groneberg, Quarcoo et al. 2004). 
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1.1.2 Airway obstruction 
In asthma, the dominant physiological event leading to clinical symptoms is airway 
narrowing and a subsequent interference with airflow. Several factors contribute to 
the development of airway obstruction in asthma.  
 
In acute exacerbations of asthma, bronchial smooth muscle contraction occurs 
quickly to narrow the airways in exposure to allergens or irritants. Allergen-induced 
acute bronchoconstriction results from an IgE-dependent release of mediators from 
mast cells, including histamine, tryptase, leukotrienes and prostaglandins, which 
directly contract airway smooth muscle.  Aspirin and other non-steroidal anti-
inflammatory drugs can also cause acute airway obstruction in some patients 
through a non-IgE-dependent reaction. In addition, other stimuli, such as exercise, 
cold air, and irritants, can cause acute airflow obstruction. The mechanisms 
regulating the airway response to these agents are less well defined, but the 
intensity of the response appears related to underlying airway inflammation. 
Furthermore, psychosocial stress may also play a role in precipitating asthma 
exacerbations (Ritz, Simon et al. 2011) and is negatively correlated with 
physiological markers of airway function (Vig, Forsythe et al. 2006). 
  
As the disease becomes more persistent and inflammation more progressive, other 
factors further limit airflow. Airway oedema due to increased microvascular leakage 
in response to inflammatory mediators may be particularly important during acute 
exacerbations. Mucus hypersecretion and formation of inspissated mucus plugs may 
lead to luminal occlusion. Airway remodelling due to structural changes is important 
in more severe disease (Halwani, Al-Muhsen et al. 2010), and these changes may 
not be reversed by the usual treatments. 
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1.1.3 Airway hyper-responsiveness 
Hyper-responsiveness is a characteristic functional abnormality of asthma and 
results in airway narrowing in exposure to stimuli that would be innocuous in normal 
people. In turn, this airway narrowing leads to variable airflow limitation and 
intermittent symptoms. The degree of airway hyper-responsiveness observed in 
response to methacholine correlates with the clinical severity of asthma (Cockcroft 
2010). The underlying mechanisms are multi-factorial and include excessive 
contraction of airway smooth muscle due to increased volume and contractility of the 
cells. Moreover, uncoupling of airway contraction as a result of inflammatory 
changes in the airway wall may lead to excessive airway narrowing and a loss of the 
maximal plateau of contraction found in normal airways when bronchoconstrictor 
substances are inhaled (DiCosmo, Geba et al. 1994).  
 
1.1.4 Airway remodelling 
In some patients who have asthma, airflow limitation may be only partially reversible. 
Permanent structural changes can occur in the airway, and these are associated 
with a progressive loss of lung function that may not be fully prevented or reversed 
by current therapy. Airway remodelling involves activation of many of the structural 
cells, leading to permanent changes in the airways and deterioration of airway 
obstruction and airway hyper-responsiveness, and thus renders the patients less 
responsive to therapy.  
34 
Firstly, subepithelial fibrosis results from the deposition of collagen fibres and 
proteoglycans under the basement membrane and is seen in all patients with asthma,   
even before the onset of symptoms. Additionally, hypertrophy and hyperplasia of 
airway smooth muscle contribute to the increased thickness of the airway wall. This 
process relates to disease severity (Pepe, Foley et al. 2005). Other factors such as 
blood vessel proliferation and dilatation, hyperplasia of goblet cells in the epithelium, 
as well as submucosal glands, also contribute to increased airway wall thickness 
(Halwani, Al-Muhsen et al. 2010) (Fig. 1.3). 
Figure 1.3. Structures of airways from subjects (left) with and (right) without 
asthma. Features of airway remodelling in asthma include subepithelial fibrosis, 
hypertrophy and hyperplasia of airway smooth muscle (ASM), blood vessel (V) 
proliferation and dilatation, and hyperplasia of globlet cells and submusocal gland 
(SG). Cited from http://sydney.edu.au/medicine/pharmacology/rrg/images/content/karens.gif. 
ASM 
Airway 
lumen 
Epi- 
thelium 
V 
SG 
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1.1.5 Severe asthma 
While most patients with asthma demonstrate a good therapeutic response to 
inhaled corticosteroid therapy, a proportion of patients do not acquire adequate 
control even under high-dose oral steroids. These patients, labelled as severe 
asthmatics, comprise of 5-10% of all asthmatic population. They account for more 
than half of the healthcare spending on asthma because patients with severe asthma 
consume more expensive drugs and are more likely to be hospitalized or require 
additional medical attention (Chung, Gibeon et al. 2011). The characteristics of these 
patients include the presence of frequent or severe exacerbations, low baseline lung 
function, reliance on high doses of inhaled or even oral corticosteroids and near daily 
symptoms. Quality of life is impacted and numerous comorbidities are often present 
either as a result of treatment or of the disease itself (Bousquet, Mantzouranis et al. 
2010).  
 
In the GINA 1995 and 2002 updates and the National Asthma Education and 
Prevention Programme (NAEPP) 1997 guidelines, overall asthma severity was 
primarily based on the patient’s clinical characteristics prior to commencing 
treatment. Off-treatment severity was classified into mild intermittent, mild persistent, 
moderate persistent and severe persistent, based on symptoms, short-acting β2-
agonist use, night time awakening and peak expiratory flow or the percentage 
predicted forced expiratory volume in 1 second (FEV1). This initial classification was 
used to determine the patient’s initial treatment but did not take into account disease 
responsiveness to treatment (Bel, Sousa et al. 2011). 
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 In 1999, a European Respiratory Society (ERS) Task Force defined 
“difficult/therapy-resistant asthma” as poorly controlled asthma and a continued 
requirement for short-acting β2-agonists despite delivery of a reasonable dose of 
inhaled corticosteroids and follow-up by a respiratory specialist for over six months 
(Chung, Godard et al. 1999). In 2000, an American Thoracic Society (ATS) 
Workshop adopted the term “refractory asthma” and developed a definition by 
consensus. The definition included one of the two major criteria (continuous high-
dose inhaled corticosteroids or oral corticosteroids for over 50% of the time during 
the previous year), with two out of seven additional minor criteria (ATS. 2000) (Table 
1.1). This definition was adopted by the National Institute of Health/National Heart, 
Lung and Blood Institute-sponsored Severe Asthma Research Program network 
(Moore, Bleecker et al. 2007). 
 
 
Table 1.1. ATS Workshop Consensus for severe/refractory asthma (ATS. 2000).  
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The European Network for Understanding Mechanisms of Severe Asthma 
(ENFUMOSA) defined “severe asthma” in 2003 as confirmed asthma (typical asthma 
symptoms, reversibility FEV1 or airway hyper-responsiveness) plus occurrence of 
one or more exacerbation in the previous year despite oral or high-dose inhaled 
corticosteroids (ENFUMOSA. 2003). In 2007, an international workshop was 
organised in Paris to discuss the important questions in severe asthma. This 
workshop agreed that a diagnosis of “severe asthma” should be reserved for those 
patients who have refractory asthma after an extensive re-evaluation of the correct 
diagnosis, aggravating comorbidities and environmental  factors and an appropriate 
observation period of at least six months (Chanez, Wenzel et al. 2007). 
 
In 2010, the WHO proposed a uniform definition of asthma severity, control and 
exacerbations. Severe asthma was defined as “Uncontrolled asthma which can 
result in risk of frequent severe exacerbations (or death) and/or adverse reactions to 
medications and/or chronic morbidity” (Bousquet, Mantzouranis et al. 2010). Severe 
asthma was further classified into three groups: i) untreated severe asthma; ii) 
difficult-to-treat severe asthma and iii) treatment-resistant severe asthma. The last 
group comprises the current concept of refractory and corticosteroid-resistant 
asthma and asthma that can be controlled only at the highest doses of treatment. 
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1.2 Airway smooth muscle cells (ASMC) and asthma 
1.2.1 Pleiotropic role of ASMC 
Airway remodelling is one of the key features of asthma, being characterised by 
thickening of the reticular basement membrane, an increase in smooth muscle mass 
through hypertrophy and hyperplasia of airway smooth muscle cells (ASMC), 
mucous gland hyperplasia, extracellular matrix deposition, and an increased mass of 
vessels. Airway remodelling is correlated with airflow limitation, airway hyper-
responsiveness and air trapping in asthma, suggestive of a close link between 
structural and functional changes (Horvath, Sorkness et al. 2011). Of these, 
increased mass of ASMC has been implicated in pathophysiology of asthma and has 
been correlated with disease severity (Macedo, Hew et al. 2009). 
 
ASMC were originally thought to be a passive partner in airway inflammation, 
contracting in response to pro-inflammatory mediators and neurotransmitters, and 
relaxing in response to endogenous and exogenous bronchodilators. It is now clear 
that ASMC have several other important properties of relevance to airway diseases 
including asthma (Fig.1.4). These functions include the ability to proliferate, undergo 
hypertrophy and migrate, and thereby contribute to the dysfunctional repair 
mechanisms that cause airway remodelling. In addition, ASMC can synthesise 
cytokine and growth factor and express cell-surface molecules, allowing their 
communication with the extracellular matrix and inflammatory cells (Howarth, Knox 
et al. 2004). Whereas the contraction of ASMC used to be regarded as an event 
secondary to the presence of inflammatory cells and mediators, it is accepted that 
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the cell itself can produce all these factors.  ASMC are now considered to play a 
central role in orchestrating the inflammatory response within the bronchial wall. 
Figure 1.4. Pleiotropic role of ASMC. (A) Cytokines and chemotaxins: Regulated 
upon Activation, Normal T-cell Expressed, and Secreted (RANTES) in response to 
TNF-α, which is inhibited by Th2 cytokines; IL-8 and IL-6 in response to IL-1β and 
TNF-α, which causes further chemotaxis and cell activation. (B) Bronchoprotective 
factors: PGE2 in response to bradykinin, IL-1β acetylcholine (Ach); nitrogen oxide 
(NO) in response to lipopolysaccharide (LPS). (C) Adhesion molecules: intercellular 
adhesion molecule (ICAM) and vascular cell-adhesion molecule (VCAM) up-
regulated by TNF-α. T-lymphocyte adhesion is promoted via these integrins and the 
non-integrin mechanism involving CD44 and hyaluronate. (D) Growth factors: 
platelet-derived growth factor (PDGF) in response to IL-1β stimulates growth by an 
autocrine mechanism; insulin-like growth factor (IGF) is up-regulated by leukotriene 
D4 (LTD4) (Howarth, Knox et al. 2004). 
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1.2.2 ASMC in asthma 
With the help of the availability of techniques to culture ASMC (Panettieri, Murray et 
al. 1989), as well as access to newer technologies such as laser capture 
microdissection and gene microarrays, the understanding of the biology and 
pharmacology of ASMC, in both the healthy and the diseased, has increased 
exponentially over the last two decades. Additionally, with the ability to culture ASMC 
via biopsies derived from patients with asthma, studies reveal important differences 
in the in vitro behaviour of ASMC of asthmatic and non-asthmatic volunteers. Firstly, 
ASMC of patients with asthma proliferate more rapidly than the non-asthmatic 
counterparts (Johnson, Roth et al. 2001). Interestingly, although glucocorticoids can 
inhibit proliferation of ASMC from healthy subjects, they fail to do so in cells of 
patients of asthma (Roth, Johnson et al. 2004). Secondly, ASMC of patients with 
asthma release increased connective tissue growth factor (CTGF) (Burgess, 
Johnson et al. 2003), decreased prostaglandin E2 (PGE2) (Chambers, Black et al. 
2003), and greater levels of chemokines such as CCL11 (Chan, Burgess et al. 2006), 
CXCL8 (John, Zhu et al. 2009) and CXCL10 (Brightling, Ammit et al. 2005). 
Furthermore, there is greater pro-inflammatory response to rhinovirus infection in 
ASMC of patients with asthma (Oliver, Johnston et al. 2006). Nevertheless, there are 
still few studies investigating the differential phenotype in ASMC of patients with 
asthma of different severities. 
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1.3 Cytokines 
Cytokines are signalling proteins, usually less than 80 kilodalton (kDa) in size, which 
regulate a wide range of biological functions including innate and acquired immunity, 
hematopoiesis, inflammation and repair, and proliferation through mostly 
extracellular signalling. They are secreted by many inflammatory cells (macrophages, 
mast cells, eosinophils and lymphocytes) as well as structural cells (epithelial, 
endothelial and smooth muscle cells) and act on closely adjacent cells in a paracrine 
fashion. They may also act at a distance by secretion of soluble products into the 
circulation (endocrine or systemic effect) and may have influence on the cell of origin 
itself (autocrine effect).  
 
1.3.1 Tumour necrosis factor-alpha (TNF-α) 
TNF-α is the most widely studied pleiotropic cytokine of the TNF superfamily. TNF-α 
is an import cytokine in the innate immune response, which plays a key role in the 
immediate host defence against invading microorganisms before activation of the 
adaptive immune system. It is principally produced by macrophages in response to 
activation of membrane-bound pattern-recognition molecules, such as Toll-like 
receptors (TLR), which detect common bacterial cell-surface products, such as 
lipopolysaccharides (LPS). TNF-α is also produced by several other cells, such as 
fibroblasts, epithelial cells, and ASMC (Brightling, Berry et al. 2008).  
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TNF-α is initially produced as a biologically active, 26-kd membrane-anchored 
precursor protein (mTNF-α), which is subsequently cleaved by TNFα-converting 
enzyme (TACE) to release the 17-kd free protein (Zheng, Saftig et al. 2004). These 
proteins form biologically active homotrimers that act on the ubiquitously expressed 
TNF receptor (TNFR) 1 and 2 (Brockhaus, Schoenfeld et al. 1990). This receptor-
ligand interaction causes intracellular signalling without internalization of the complex, 
leading to phosphorylation of IκBα and thus activation of nuclear factor-kappa B (NF-
κB), which then interacts with the DNA chromatin structure to increase transcription 
of pro-inflammatory genes, such as IL-1β, IL-6, CXCL8, and TNF-α itself (Fig. 1.5). 
The response to TNF-α activation is balanced by shedding of the extracellular 
domain of the TNF-α receptors (Brightling, Berry et al. 2008).  
Figure 1.5. TNF-α biology and signalling. mTNF-α is cleaved by TACE to release 
soluble TNF-α, which forms biologically active homotrimers and binds TNFR 1 and 2, 
causing intracellular signalling, including phosphorylation of IκBα and activation of 
NK-κB heterodimer, which interacts with the DNA to increase transcription of pro-
inflammatory genes (Brightling, Berry et al. 2008). 
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It is observed that TNF-α mRNA (Ying, Robinson et al. 1991) and protein (Bradding, 
Roberts et al. 1994) are increased in the airways of patients with asthma, implicating 
a possibility of this cytokine to be involved in the inflammation of asthma. Extensive 
genetic, biologic, and physiological evidence indicates that TNF-α plays a critical role 
in the initiation and amplification of airway inflammation in asthma (Fig. 1.6). 
Preformed TNF-α is stored by mast cells and rapidly released during IgE-mediated 
reactions that typify the asthmatic response to allergens. TNF-α perpetuates and 
amplifies inflammation by up-regulating adhesion molecules, which leads to 
increased migration of eosinophils and neutrophils into the airway. These key 
effector cells are activated by TNF-α to release cytotoxic mediators and reactive 
nitrogen and oxygen species that result in airway injury (Erzurum 2006). In addition 
to its effect on inflammation, TNF-α has direct effects on airway hyper-reactivity to 
methacholine and allergen, as shown in isolated tracheal-ring models (Pennings, 
Kramer et al. 1998). Importantly, administration of inhaled recombinant TNF-α leads 
to development of airway hyper-responsiveness and influx of neutrophils in normal 
subjects (Thomas, Yates et al. 1995) and patients with mild asthma (Thomas and 
Heywood 2002).   
 
Further studies reveal the correlation between the expression of TNF-α to the 
severity of asthma. The level of TNF-α mRNA and protein is greater in the airways of 
patients with refractory asthma than those of normal subjects and patients with mild 
asthma. (Howarth, Babu et al. 2005). In addition, as compared with patients with 
mild-to-moderate asthma and controls, patients with refractory asthma have 
increased expression of membrane-bound TNF-α, TNF-α receptor 1, and TACE by 
peripheral-blood monocytes  (Berry, Hargadon et al. 2006). Moreover, administration 
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of etanercept, a soluble TNF-α receptor-IgG1Fc fusion protein, in patients with 
refractory asthma improves airway measures, symptom scores and airway hyper-
responsiveness (Howarth, Babu et al. 2005; Berry, Hargadon et al. 2006).  
Figure 1.6. The normal airway and the effects of TNF-α on the asthmatic airway. 
Multiple actions of TNF-α contribute to asthma pathogenesis. Preformed TNF-α 
alone with histamine is immediately released from mast cells during allergic reponse. 
Through paracrine and autocrine effects, TNF-α perpetuates and amplifies 
inflammation by up-regulating adhesion molecules, which increase migration of 
activated leukocytes. TNF-α also induces epithelial cells to secrete mucin and 
fibroblasts, increasing production of glycoproteins. Independent of its pro-
inflammatory effects, TNF-α increases response of smooth muscles to contractile 
agents (Erzurum 2006). 
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1.3.2 Interferon-gamma (IFN-γ) 
The IFNs were originally discovered in 1957 as agents that interfere with viral 
replication (Isaacs and Lindenmann 1957). Initially, they were classified by the 
secreting cell type but now classified into type I and type II according to receptor 
specificity and sequence homology. The type I IFNs, in human, are comprised of 
multiple IFN-α subtyptes (depending on species), IFN-β, IFN-ε, IFN-κ and IFN-ω 
(Platanias 2005). By contrast, IFN-γ is the sole type II IFN.  While all IFNs have anti-
proliferative, anti-viral, and immunomodulatory effects, IFN-α and IFN-β 
predominantly contain the first two effects, whereas IFN-γ is predominantly an 
immunomodulatory mediator (Peters 1996).   
 
The observation that viral infection, the common inducer of IFNs, is a well-known 
trigger for asthma supports the concept that IFNs could play a negative role in the 
disease (Gern 2000). Typically, viral syndromes are characterised by intense 
inflammatory responses in the airways, with marked leukocyte trafficking and 
production of Th1-type cytokines such as IFNs. The subsequent interaction of IFNs 
with airway resident cells could initiate asthma exacerbations via multiple 
mechanisms, including production of cytokines/chemokines, or recruitment of 
different inflammatory cells (Proud and Chow 2006).  
 
IFN-γ is structurally unrelated to type I IFNs, binds to a different receptor, and is 
encoded by a separate chromosomal locus. Increased levels of IFN-γ have been 
detected in asthmatic airways (Cembrzynska-Nowak, Szklarz et al. 1993), and IFN-γ 
expression, assessed by immonostaining, is greater in subepithelium of patients with 
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severe asthma compared to those with moderate asthma (Shannon, Ernst et al. 
2008). Nevertheless, the immunopathogenic role of the IFN-associated pathways in 
asthma is still controversial. Previous in vivo evidence shows that IFN-γ could have 
suppressive activities against key features of allergic responses including IgE 
production, airway hyper-responsiveness and eosinophilic influx (Chung and Barnes 
1999). In contrast, recent evidence shows that IFNs could be detrimental to the 
pathogenesis of asthma. A chronic model of allergic asthma, by using blocking 
antibodies, reveals that IFN-γ is a major player in mediating ovalbumin-induced 
airway hyper-responsiveness to methacholine  (Kumar, Herbert et al. 2004). Another 
study targets expression of IFN-γ in the airways of IFN-kockout mice significantly 
increases allergen-induced responses including IL-5 and IL-13 expression and BAL 
eosinophilia (Koch, Witzenrath et al. 2006). Furthermore, an elegant study shows a 
critical role of IFN-γ and pulmonary dendritic cells in enhancing Th-2 dependent 
allergic responses after viral infection (Dahl, Dabbagh et al. 2004). 
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1.4 Chemokines 
Leukocyte recruitment represents a refinement of a fundamental property of a motile 
cell to detect a chemical gradient, orient itself, and move along the gradient. This 
process, known as chemotaxis, has been elegantly described and analysed in 
primitive single-celled organisms and is an essential property of cells at different 
stages of their life history in multicellular organisms. In higher animals, this property 
has been adapted to trap specific leukocyte types on the inner surface of small blood 
vessels and induce migration through the vessel wall into the tissues. Pivotal to the 
process of chemoattraction of leukocytes are the chemokines. 
 
Chemokines are small chemoattractant cytokines (8-14 kDa) with diverse effects on 
cellular recruitment, activation and differentiation. Chemokines are classified into four 
subfamilies, C, CC, CXC and CX3C on the basis of their sequence homology and 
the position of conserved cysteine residues within the protein (Zlotnik and Yoshie 
2000) (Fig. 1.7). Most of the known chemokines belong to CC chemokine (28 in 
number) and CXC chemokine (16 members) families. In both families, the first 
cysteine forms a disulphide bond with the third, and the second with the fourth 
cysteine. CC chemokines act upon the majority of leukocytes, but generally have 
little activity on neutrophils. In contrast, CXC chemokines are characteristically 
chemotactic for neutrophils and lymphocytes. CXC chemokines are further 
subdivided into two groups according to the presence or absence of a glutamate-
leucine-arginine (ELR) motif immediately before the first cysteine. Members of the 
former, such as CXCL1 (growth regulated oncogene-alpha, GRO-α), CXCL5 
(epithelial neutrophil activating protein, ENA-78), CXCL6 (granulocyte chemotactic 
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peptide-2, GCP-2), CXCL7 (neutrophilic activating protein-2, NAP-2) and CXCL8 (IL-
8), specifically induce migration of neutrophils into inflamed tissue (Bizzarri, Beccari 
et al. 2006), while those lacking the ELR motif, such as CXCL9 (monokine induced 
by IFN-γ; MIG), CXCL10 (IP-10), and CXCL11 (IP-9), are typically inducible by IFN-γ 
(Strieter, Belperio et al. 2002). There are some non-conforming chemokines: XC 
chemokine family has only one pair of cysteines and a single disulphide bond, and 
CX3C family has a CXXXC motif at the N-terminus. 
Figure 1.7. Classification and structure of chemokines. Based on conserved 
cysteine residue patterns, chemokines are classified into (A) CXC family (CXCL1 
through CXCL216), (B) CC family (CCL1 through CCL28), (C) C family (XCL1 and 
XCL2) and (D) CX3C family (CX3CL1) (Rostene, Kitabgi et al. 2007). 
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Chemokines are thought to bind to presenting molecules on the luminal surface of 
the vascular endothelium, such as glycosaminoglycans, where the chemokines 
engage their receptors on the leukocyte surface. Leukocytes typically roll on the 
endothelium through low affinity intermolecular interactions mediated by selectins. 
Stimulation of chemokine receptors induces the upregulation of adhesion molecules 
on the leukocyte surface and cytoskeletal changes necessary for firm attachment, 
followed by emigration. Chemokines can recruit and activate a range of leukocyte 
subtypes, which include eosinophils, Th2 lymphocytes, neutrophils and mast cells to 
the bronchi (Lukacs, Hogaboam et al. 2005). Chemokines can also activate or 
modulate the phenotype of structural cells within the airways. 
 
Following stimulation with inflammatory mediators, ASMC release a wide variety of 
chemokines. These include the CC chemokines CCL2 (monocyte chemotactic 
protein-1, MCP-1), CCL8 (MCP-2), CCL7 (MCP-3) (Pype, Dupont et al. 1999), CCL5 
(Regulated upon Activation, Normal T-cell Expressed, and Secreted, RANTES) 
(John, Hirst et al. 1997), CCL11 (eotaxin) (Chung, Patel et al. 1999), CCL17 (thymus 
and activation regulated chemokine, TARC) (Faffe, Whitehead et al. 2003) and 
CCL19 (macrophage inflammatory protein-3 beta, MIP-3β) (Kaur, Saunders et al. 
2006); the CXC chemokines CXCL1 (GRO-α), CXCL2 (GRO-β), CXCL3 (GRO-γ) 
(Jarai, Sukkar et al. 2004), CXCL8 (IL-8) (Pang and Knox 1998), CXCL10 (IFNγ-
induced protein 10, IP-10) (Hardaker, Bacon et al. 2004); and the CX3C chemokine 
CX3CL1 (fractalkine) (Sukkar, Issa et al. 2004). 
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1.4.1 CCL11 (Eotaxin) 
CCL11 is a highly potent chemoattractant for eosinophils (Jose, Griffiths-Johnson et 
al. 1994) acting via a single chemokine receptor, CCR3, which is highly expressed 
on eosinophils (Ponath, Qin et al. 1996).  
 
Animal studies have highlighted the production of both CCL11 mRNA and protein in 
the lung during early response to allergen exposure (Jose, Adcock et al. 1994; 
Ganzalo, Jia et al. 1996). In both animal and human studies of allergic airway 
disease, airway epithelium, microvascular endothelium, tissue macrophages, and 
sputum cells are shown to express increased CCL11, which is associated with 
airway hyper-responsiveness (Ying, Robinson et al. 1997; Ying, Meng et al. 1999; 
Zeibecoglou, Macfarlane et al. 1999). Furthermore, mice deficient in CCL11 show a 
reduction in ovalbumin-induced lung eosinophilia (Rothenberg, MacLean et al. 1997). 
These studies suggest a ubiquitous and essential role of CCL11 in the pathogenesis 
of asthma. 
 
CCL11 is released from ASMC constitutively and increased by TNF-α, IL-1β (Chung, 
Patel et al. 1999; Ghaffar, Hamid et al. 1999), IL-4 and IL-13 (Hirst, Hallsworth et al. 
2002; Moore, Church et al. 2002). The human CCL11 promoter contains 
CAAT/enhancer binding protein (C/EBP), activated protein-1 (AP-1), signal 
transducer and activator of transcription 6 (STAT6) and NF-κB binding sites. 
Induction of CCL11 by the Th2 cytokines IL-4 and IL-13 is mediated via STAT6 
activation, whereas TNFα-induced transcription is dependent on the NF-κB pathway 
(Clifford, Coward et al. 2011). In addition, histone H4 acetylation following TNF-α 
stimulation is a key event in regulating binding of NF-κB to the CCL11 promoter and 
subsequent transcription of CCL11 (Clarke, Sutcliffe et al. 2008).  
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1.4.2 CXCL8 (IL-8) 
CXCL8, a member of the ELR+ CXC chemokines, binds to G protein-coupled 
serpentine receptors CXCR1 and CXCR2 (Li, Zhang et al. 2002) on surface 
membrane of the target cells. CXCL8 is a potent chemoattractant for neutrophils.  
 
The level of CXCL8 in the sputum is increased in patients with asthma, with the 
highest levels in severe asthma (Jatakanon, Uasuf et al. 1999). In addition, CXCL8 
expression, detected by immunostain, is increased in both airway epithelium and 
subepithelium (Shannon, Ernst et al. 2008), as well as in the smooth muscle (Pepe, 
Foley et al. 2005), in patients with severe asthma compared to those with moderate 
asthma. Similarly, there are more neutrophils in the epithelium and subepithelium, 
along with more CXCL8 mRNA-positive cells in the subepithelium of patients with 
severe exacerbation of asthma (Qiu, Zhu et al. 2007).  
 
ASMC release CXCL8 in large quantities after stimulation by TNF-α, IL-1β (Watson, 
Grix et al. 1998), TGF-β (Fong, Pang et al. 2000) and bradykinin (Zhu, Bradbury et al. 
2003). The CXCL8 promoter contains binding motifs for the transcription factors NF-
κB, AP-1, and C/EBP (Mukaida, Okamoto et al. 1994). In ASMC, NF-κB is the major 
transcription factor involved in TNFα or bradykinin–induced CXCL8 gene 
transcription although AP-1 and C/EBP also contribute to maximal activation of the 
promoter  (Clifford, Coward et al. 2011). In addition, baseline and TNFα-induced 
CXCL8 release and mRNA expression is increased in ASMC of patients with asthma. 
Although there is no global increase of NF-κB activity, there is increased recruitment 
of p65 and C/EBPβ as well as RNA polymerase II to the promoter of CXCL8 in 
ASMC of patients with asthma  (John, Zhu et al. 2009). 
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1.4.3 CXCL10 (IP-10) 
CXCL10, a member of the ELR- CXC chemokines, elicits its effects by binding to 
CXCR3 (Loetscher, Pellegrino et al. 2001) on the surface of the target cell. As a 
chemoattractant, CXCL10 attracts several cell types including 
monocytes/macrophages, T cells, natural killer (NK) cells, mast cells and dendritic 
cells (Groom and Luster 2011). 
 
The observation of increased airway hyper-responsiveness and Th2 inflammatory 
rseponse in the airways of CXCL10 transgenic mice and an opposite effect after 
deletion of CXCL10 in a mouse model of asthma suggests the role for this cytokine 
in the pathogenesis of asthma (Medoff, Sauty et al. 2002). In human studies, 
CXCL10 is preferentially expressed in ASMC of patients with asthma and is elevated 
in the BAL and airway mucosa of patients with asthma compared to healthy subjects 
(Brightling, Ammit et al. 2005). In addition, this chemokine in BAL is increased in 
patients with asthma following segmental allergen challenge (Bochner, Hudson et al. 
2003). Furthermore, migration of human lung mast cell migration to asthmatic ASMC 
can be mediated by the CXCL10/CXCR3 axis (Brightling, Ammit et al. 2005). 
CXCL10 may also play a role in virus-induced asthma exacerbation. In patients with 
acute clinical asthma, serum CXCL10 is elevated in those with virus-induced than 
non-virus attack. In addition, increased serum CXCL10 levels are predictive of virus-
induced asthma and strongly associated with more severe airway obstruction (Wark, 
Bucchieri et al. 2007).  
 
In ASMC, CXCL10 is induced by TNF-α and IL-1β, mediated by NF-κB activation 
(Alrashdan, Alkhouri et al. 2012), and IFN-γ, through activation of the JAK2/STAT1 
pathway (Clarke, Clifford et al. 2010) .  
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1.4.4 CX3CL1 (fractalkine) 
CX3CL1 is a unique member of the CX3C chemokine and exists in two forms, a 
membrane bound and a soluble form, each mediating distinct biological actions. It is 
synthesised as a membrane-spanning adhesion molecule with the chemokine 
domain presented on a mucin-like stalk and serve as an adhesion protein promoting 
the retention of monocytes and T-cells. Soluble CX3CL1 can be released by 
proteolysis at a membrane-proximal region by TACE (A Disintegrin And 
Metalloproteinase 17; ADAM17) and ADAM10, and this soluble form resembles 
more a conventional chemokine which exhibits efficient chemotactic activity for 
monocyte, NK cells and T lymphocytes (Bazan, Bacon et al. 1997). Constitutive 
shedding occurs primarily via ADAM10, while increased shedding under 
inflammatory and excitotoxic conditions is mediated primarily by ADAM17 (Ludwig, 
Hundhausen et al. 2005). Both chemotaxis and adhesion are mediated by a highly 
selective G-protein-coupled receptor CX3CR1 (Imai, Hieshima et al. 1997) (Fig. 1.8). 
 
 In the airways, CX3CL1 is expressed in epithelial cells (Lucas, Chadwick et al. 
2001), endothelial cells (Rimaniol, Till et al. 2003) and ASMC (Sukkar, Issa et al. 
2004). CX3CL1 is involved in the pathogenesis of chronic inflammatory airway 
diseases such as asthma (Bisset and Schmid-Grendelmeier 2005) and chronic 
obstructive pulmonary disease (COPD) (Zhang and Patel 2010). CX3CL1 expression 
is increased in the epithelium, submucosa, and airway smooth muscle in patients 
with asthma, which contributes to recruitment of mast cells to the smooth muscle 
layer (El-Shazly, Berger et al. 2006). Compared with healthy subjects, patients with 
asthma have increased circulating CX3CL1 levels, and in the BAL fluid of these 
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patients, soluble CX3CL1 concentration is increased after segmental allergen 
challenge (Rimaniol, Till et al. 2003). 
Figure 1.8. Role of membrane bound and soluble CX3CL1 and the receptor 
CX3CR1. The membrane-anchored CX3CL1 functions as an adhesion molecule. 
The soluble CX3CL1, released by proteolysis at a membrane-proximal region by 
ADMA17, is chemotactic for monocytes, dendritic cells (DC) and T cells, which 
expresses CX3CR1 on their cell surface (Zhang and Patel 2010). 
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1.5 Nuclear factor-κB (NF-κB) 
Chronic inflammation in asthma is due to increased expression of multiple 
inflammatory proteins (cytokines, enzymes, receptors, adhesion molecules). In many 
cases these inflammatory proteins are induced by transcription factors, DNA-binding 
factors that mediate the transcription of selected target genes. Transcription factors 
bind to DNA-regulatory sequences (enhancers and silencers), usually localised in 
the 5’-upstream region of target genes, to modulate the rate of gene transcription, 
protein synthesis, and subsequent altered cellular function. Transcription factor 
activation is complex and may involve multiple intracellular signal transduction 
pathways, including protein kinase A (PKA), PKC, mitogen-activated protein kinases 
(MAPK) and Janus kinase (JAK), stimulated by cell-surface receptors (Clifford, 
Coward et al. 2011). They may also be directly activated by ligands such as 
glucocorticoids and vitamin A and D. Although numerous transcription factors are 
activated during the inflammatory response, NF-κB is regarded of paramount 
importance in asthmatic inflammation because it is activated by all the stimuli 
considered important in the inflammatory response to allergen exposure (Adcock, Ito 
et al. 2004).  
 
NF-κB is activated in response to a number of stimuli, such as physical and chemical 
stress, LPS, double-stranded RNA, T and B cell mitogens and pro-inflammatory 
cytokines. NFκB-induced gene expression is controlled by a complex series of 
enzymatic signalling events at multiple levels. A multitude of studies in ASMC 
implicate a role of NF-κB in regulation of inflammatory cytokines, chemokines and 
adhesion molecules (Clarke, Damera et al. 2009).  
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1.5.1 NF-κB Structure 
NF-κB is made up of a hetero- or homodimer of members of the DNA-binding Rel 
family of proteins which contains five known mammalian members: p50 (NF-κB1, 
precursor of which is p105), p65 (Rel A, NF-κB3), p52 (NF-κB2, precursor of which is 
p100), c-Rel and Rel B. While p52, c-Rel and Rel B are restricted to specific 
differentiated cell types (Siebenlist, Franzoso et al. 1994), the p65 and p50 subunits 
are ubiquitously expressed and have been extensively investigated, of which p50 
increases DNA binding and p65 confers transcriptional regulation (Hayden and 
Ghosh 2008). 
 
1.5.2 NF-KB activation 
In resting cells, the majority of NF-κB is bound to the inhibitor of NF-κB (IκB). IκB 
associates via its ankyrin repeats domain with NF-κB, which thus masks the nuclear 
localisation signals (NLS) of both NF-κB and IκB and holding NF-κB in the cytoplasm. 
Upon cellular stimulation, IκB is phosphorylated, ubiquinated, and degraded by the 
proteosomal pathway. With IκB removed, NF-κB translocates to the nucleus and 
mediates gene transcription. An overview of the NF-κB cascades is depicted in 
Fig.1.9. 
 
IκB phosphorylation and activation of Rel proteins can occur via the classical 
(canonical) or non-classical (non-canonical) pathway. In the classical pathway, a 
critical phosphorylation of IκB is performed by the IκB kinase (IKK) complex, which 
consists of at least three subunits, including two catalytic subunits IKK-α and β, also 
known as IKK-1 and 2, and one regulatory subunit IKK-γ, known as NF-κB essential 
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modulator (NEMO). Of the two catalytic subunits, IKK-β is 20-fold more active than 
IKK-α in the phosphorylation of IκB and is critical for NF-κB activation. Stimuli of the 
classical pathway include the TLR/IL-1R family members, ligation of the T-cell 
receptor (TCR), and TNFR signalling. 
Figure 1.9. NF-κB signalling pathways. The canonical pathways signal through i) 
TLR/IL-1 receptors, leading to IRAK activation and IKK-β phosphorylation; ii) 
intracellular viral receptors including RNA helicases and PKR, which activate IKK-β 
and iii) the TCR pathway, leading to IKK-α/β activation; TNFR pathway, which 
signals via TRAAD to activate IKK-β. The alternative pathway is induced by CD40-
CD40L activation, lymphotoxin-β or RANKL, which leads to activation of NIK and 
IKK-α. IRAK: IL-1 receptor-associated kinase, PKR: dsRNA-dependent protein 
kinase R, TNFR: TNF receptor, TRADD:  TNFR-1 associated death domain, RANKL: 
receptor activator of NF-κB ligand, NIK: NFkB-inducible kinase (Edwards, Bartlett et 
al. 2009). 
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In addition to the classical pathway, an alternative non-coninical pathway is 
described mainly in B cells. This latter pathway can be activated by different stimuli, 
including lymphotoxin β, CD40 ligand, and receptor activator of NF-κB ligand. The 
alternative pathway is characterised by the inducible phosphorylation and processing 
of p100-p52, and subsequent nuclear translocation of the heterodimer p52:rel B, 
which is independent of  IKK-γ or IKK-β but only requires the IKK-α subunit. This 
pathway is believed to play key roles in adaptive immunity (Clarke, Damera et al. 
2009). 
 
1.5.3 Post-translational modifications of NF-κB 
Subsequent to the activation process, NF-κB activity is substantially modulated by 
various post-translational modifications, including acetylation, SUMOylation, and 
phosphorylation. The intracellular control of NF-κB transactivation, subcellular 
localisation, DNA binding affinity and the interaction with cofactors and IκB via post-
translational modifications forms the intricate web for NF-κB regulation (Beck, 
Vanden Berghe et al. 2009). For example, phosphorylation of p65 enhances 
transcription, yet phosphorylation of p105 reduces its processing into p50 and hence 
reduces activation (Naumann and Scheidereit 1994). Acetylation of the Rel proteins 
also modulates the function of NF-κB (Spange, Wagner et al. 2009; Ghizzoni, 
Haisma et al. 2011). Additionally, covalent modification of the chromatin environment, 
which regulates the access of transcription factors to gene promoters, also alters 
NFκB-dependent transcription. This control is achieved by recruitment of protein 
complexes that alter chromatin structure via enzymatic modifications of histone tails 
and/or nucleosome remodelling. NF-κB activation requires several cofactor histone 
acetyltransferases (HAT), including CREB-binding protein (CBP), p300, p300/CBP 
activating factor (pCAF) and steroid receptor coactivator (SRC)-1. 
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1.6 Mitogen-activated protein kinases (MAPK) 
Many external inflammatory signals important in the inflammatory response seen in 
asthma, such as viral and bacterial infection, allergen, cytokines and growth factors, 
can activate intracellular kinases following binding to transmembrane receptors on 
responsive cells. The rapid amplification of the initiating signal is due to the number 
of enzymes involved in each kinase cascade. Protein kinases are classified as either 
tyrosine or serine/threonine kinases although dual kinases also exist. All kinases 
transfer the γ-phosphate of ATP to hydroxyl acceptor groups of the residues of target 
protein (Adcock, Chung et al. 2006). 
 
Mitogen-activated protein kinases (MAPK) are a family of serine/threonine kinases 
that transduce extracellular signals to the nucleus. The pathways are organised as 
parallel kinase cascades, consisting of MAPK, MAPK kinases (MAPKK, or MKK), 
and MAPK kinase kinases (MAPKKK, or MKKK) (Fig. 1.10). Activation of MAPK 
requires dual phosphorylation of threonine and tyrosine by upstream kinases and 
occurs in response to different stimuli. Once activated, MAPK phosphorylate 
selected intracellular proteins including transcription factors. The resulting changes 
in gene expression affect fundamental cellular processes such as proliferation, 
differentiation, survival and inflammation. In mammalian cells, there are five distinct 
subfamilies including p38 MAPK, c-Jun N-terminal kinase (JNK), extracellular signal-
regulated kinase (ERK), EKK 3/4 and ERK 5. Among the five distinctive MAPK 
pathways, p38 MAPK, JNK and ERK have been best characterised in ASMC (Clarke, 
Damera et al. 2009). 
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Figure 1.10. MAPK cascades (Cited from http://www.cellsignal.com/pathways/map-
kinase.jsp). Each group of cascades is composed of a set of three evolutionarily 
conserved, sequentially acting kinases: a MAPK, a MAPKK and a MAPKKK. 
MAPKKK activation leads to the phosphorylation and activation of a MAPKK, which 
then stimulates MAPK activity through dual phosphorylation on threonine and 
tyrosine residues. 
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1.6.1 p38 MAPK 
p38 MAPK signalling is activated in response to physical and chemical challenges, 
such as oxidative stress, ultraviolet irradiation, hypoxia, ischemia, as well as various 
cytokines. The downstream effectors of this cascade are transcription factors such 
as E26-like kinase 1 (Elk-1), serum response factor accessory protein (SAP)-1, 
activating transcription factor (ATF)-2, cAMP response element-binding (CREB), 
C/EBP homologous protein (CHOP), and myc-associated factor X (Max) (Fig. 1.11).  
 
There are four members of the p38 kinase family: α, β, γ and δ. All isoenzymes are 
activated by the same upstream MAPK kinases MKK3 or MKK6 but differ in their 
tissue distribution, regulation of kinase activation and subsequent phosphorylation of 
downstream substrates (Adcock, Chung et al. 2006). The α and β isoforms are 
effective in activating kinases downstream of p38 MAPK, such as MAPK activated 
protein kinase (MAPKAPK2/3) and mitogen and stress-activated protein kinase 
(MSK) 1 and 2. The substrates of p38 α and β include transcription factors, other 
protein kinases that in turn phosphorylate transcription factors, cytoskeletal proteins 
and translational components. In contrast, the γ and δ isozymes preferentially target 
transcription factors such as ATF-2, Elk-1, and SAP-1 (Chung 2011). 
 
In ASMC, p38 MAPK is involved in regulation of contractile response, proliferation, 
as well as inflammatory responses. For instance, p38 contributes to maximal 
acetylcholine-induced isometric contractile responses and in the increased 
contractile response of murine intrapulmonary airways after ozone exposure (Li, 
Zhang et al. 2011). In addition, p38 mediates proliferation of ASMC induced by basic 
fibroblast growth factor (bFGF) (Fernandes, Ravenhall et al. 2004) or IL-1β (Zhai, 
Eynott et al. 2004). Importantly, p38 mediates expression of many inflammatory 
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genes in response to multiple stimuli. For example, p38 mediates IL17A-induced IL-6, 
CXCL8 and CCL11 as well as bradykinin-induced IL-6 secretion and expression. p38 
also regulates expression of IL-5R in response to IL1-β, TNF-α and IFN-γ. p38 
appears to have both positive and negative regulatory effects on cytokine-induced 
inflammatory response: while it augments TNFα-induced IL-6 and CCL5 and IL1β-
induced CCL11 release, this kinase inhibits TNFα-induced ICAM-1 expression and 
IL1β-induced granulocyte macrophage-colony stimulating factor (GM-CSF) (Clarke, 
Damera et al. 2009). This suggests a gene specific role for p38 MAPK in regulating 
specific transcriptional outcomes.  
Figure 1.11. Schematic overview of MAPK pathways regulating ASMC 
functions. Various external stimuli activate immune cells or airway epithelial cells to 
release a variety of biological mediators. These mediators transduce their effects 
through p38, JNK or ERK signalling cascades, leading to expression of genes that 
modulate the contractile, proliferative and secretory responses of airway smooth 
muscles (Clarke, Damera et al. 2009). 
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1.6.2 c-Jun N-terminal kinase (JNK) 
JNK signalling is activated by environmental stress, pro-inflammatory cytokines and 
genotoxic agents. JNK consists of three isoforms, encoded by three different genes, 
of which JNK1 and 2 isoforms are widely distributed, while JNK3 is expressed only in 
neurons, cardiac myocytes and testes (Bennett 2006). JNK are phosphorylated and 
activated by the dual specificity MAPK kinases MKK4 and MKK7. Following 
activation, JNK enhances the transcriptional activity of AP-1 by phosphorylation of 
the AP-1 component c-Jun and thereby increasing AP-1 association with the basal 
transcriptional complex. These transcriptional factors modulate gene expression 
responsible for many biological responses, including migration, proliferation, 
differentiation and cell death. (Adcock, Chung et al. 2006). 
 
In murine studies, administration of the JNK inhibitor SP600125 after allergen 
challenge prevents T cell and eosinophil-mediated airway inflammation and ASMC 
proliferation, indicating a role for JNK signalling in allergic airway inflammation and 
remodelling (Eynott, Nath et al. 2003; Nath, Eynott et al. 2005).  
 
JNK activation is involved in expression of inflammatory mediators in human ASMC, 
as shown by the increased phosphorylation of JNK and c-Jun following TNF, IL-1β or 
IL-4/IL-13 stimulation, and the inhibition of GM-CSF, CCL5 (Oltmanns, Issa et al. 
2003), CXCL1 (Issa, Xie et al. 2006), CXCL10 (Alrashdan, Alkhouri et al. 2012) and 
CX3CL1 (Sukkar, Issa et al. 2004) expression after treatment with the JNK inhibitor 
SP600125. 
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1.6.3 Extracellular signal-regulated kinase (ERK) 
ERK signalling induces downstream activation of different intracellular transcription 
factors such as Elk-1, c-fos, c-myc, Sap-1 and Tal (Fig. 1.11), and consequently 
modulates regulation of meiosis, mitosis and post-mitotic functions in differentiated 
cells, in response to a variety of stimuli including growth factors, cytokines, virus 
infection, ligands for heterotrimeric G protein-coupled receptors, transforming agents 
and carcinogens (Shaul and Seger 2007). Activation of Raf leads to the activation of 
the MAPK kinases MEK1 and MEK2, which in turn activate ERK1/2. 
 
In ASMC, activation of ERK signalling is elicited by various stimuli, such as PDGF, 
epidermal growth factor (EGF), thrombin, oncostatin M, leukemia inhibitory factor 
(LIF), insulin-like growth factor-1 (IGF-1), and 5-hydroxy-tryptamine (Clarke, Damera 
et al. 2009). Cytokines are also important activators of ERK signalling. IL1β-activated 
phosphorylation of ERK1/2 leads to production of eosinophil-activating cytokines 
including PGE2, CCL5, CCL11 and GM-CSF (Hallsworth, Moir et al. 2001). ERK is 
also involved in mediating release of CCL11 and CXCL8 in response to Th2 
cytokines IL-4, IL9 and IL13, and the Th17 cytokine IL-17 (Clarke, Damera et al. 
2009).  
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1.7 Corticosteroids and glucocorticoid receptor 
1.7.1 Corticosteroids in treatment of asthma 
Corticosteroids are primary stress hormones that function to maintain homeostasis. 
They are synthesised and released by the adrenal cortex following stress-induced 
activation of the hypothalamic-pituitary-adrenal axis and affect nearly every organ 
and tissue in the body. Corticosteroids regulate a plethora of biological processes, 
including immune function, skeletal growth, reproduction, cognition, behaviour, cell 
proliferation and survival. Because of their powerful anti-inflammatory and 
immunosuppressive actions, synthetic corticosteroids are widely prescribed for the 
treatment of acute and chronic inflammatory diseases, autoimmune diseases, organ 
transplant rejection, and malignancies of the lymphoid system (Oakley and Cidlowski 
2011). 
 
Corticosteroids are by far the most effective controllers used in the treatment of 
asthma and the only drugs that can effectively suppress the characteristic 
inflammation in asthmatic airways.  They improve asthma control with a reduction in 
the need for reliever medications, such as a short-acting β2-adrenergic agonist, and 
lung function measurements, such as peak expiratory flow rate or FEV1. 
Corticosteroids also consistently reduce airway hyper-responsiveness in asthma to 
both direct and indirect challenges including histamine, cholinergic agonists, 
allergens, exercise and cold air and reduce numbers of exacerbations, prevent 
irreversible airway changes and decrease mortality (Chung, Gibeon et al. 2011). 
Inhaled corticosteroids are now recommended as first-line therapy for all patients 
with persistent symptoms and the need to use a β2-agonist inhaler for symptom 
control more than three times weekly (GINA 2011). 
66 
1.7.2 Cellular effects of corticosteroids 
At the cellular level, corticosteroids reduce the numbers of inflammatory cells in the 
airways, including eosinophils, T-lymphocytes, mast cells, and dendritic cells. These 
effects are produced through inhibition of inflammatory cell recruitment into the 
airway by suppressing the production of chemotactic mediators and adhesion 
molecules and by reducing the survival of the inflammatory cells in the airways. 
Structurally, corticosteroids reverse the shedding of epithelial cells, globlet cell 
hyperplasia and basement membrane thickening in the asthmatic airway. They also 
reduce the increased airway wall vascularity and mucosal blood flow, as well as the 
increased thickness of the sub-basement membrane representing deposition of the 
extracellular matrix, which are present in patients with asthma  (Chung, Gibeon et al. 
2011) (Fig. 1.12). The suppression of mucosal inflammation is relatively rapid with a 
significant reduction in eosinophils detectable within six hours (Gibson, Saltos et al. 
2001). Reversal of airway hyper-responsiveness may take several months to reach a 
plateau, probably reflecting recovery of structural changes in the airway (Juniper, 
Kline et al. 1990). 
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Figure 1.12. Cellular effects of corticosteroids in the airway. Corticosteroids 
inhibit the recruitment of inflammatory cells into the airway by suppressing 
production of chemotactic mediators and adhesion molecules and by inhibiting 
survival of inflammatory cells in the airway. Corticosteroids also inhibit cytokine 
release from airway structural cells such as epithelial cells and ASMC, reduce 
permeability of endothelial cells, and decrease mucus secretion from the mucus 
gland (Barnes 2006). 
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1.7.3 Glucocorticoid receptor (GR) 
Most anti-inflammatory effects of glucocorticoids are mediated via an intracellular 
protein, the glucocorticoid receptor (GR). GR belongs to the steroid/thyroid/retinoic 
acid nuclear receptor superfamily of transcription factor proteins and functions as a 
ligand-depedent transcription factor (Nicolaides, Galata et al. 2010) which 
suppresses expression of inflammatory genes through several mechanisms. 
 
Transactivation occurs via direct binding of activated GR to a DNA sequence termed 
the glucocorticoid-responsive element (GRE), which is present on the promoter of 
anti-inflammatory genes. In contrast, transrepression defines an interaction of 
activated GR with different transcription factors, such as NF-κB and AP-1, thus 
repressing expression of pro-inflammatory genes. Furthermore, cis-repression 
occurs when GR binds negative GRE, leading to gene suppression. There are few 
well documented examples of the last category, but some are relevant to side effects 
of corticosteroids, such as genes that regulate the hypopthalamic-pituitary axis 
(proopiomelanocortin and corticotrophin releasing factor), bone metabolism 
(osteocalcin) and skin structure (keratin) (Barnes 2006) (Fig. 1.13). 
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Figure 1.13. Overview of mechanisms of glucocorticoid-GR regulation of gene 
expression. In the nucleus, ligand-bound GR dimerises and binds to positive or 
negative GRE, leading to an increase or decrease in gene transcription (trans-
activation or cis-repression), respectively. In contrast, activated GR, as a monomer, 
also suppresses inflammatory genes (trans-repression) via interaction with 
transcription factors (Barnes 2011). 
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1.7.3.1 Ligand binding and nuclear translocation 
Liphophilic in nature, glucocorticoids exert their effects by freely diffusing across the 
plasma membrane of cells and binding to a ubiquitously expressed GR that is 
localised in the cytoplasm of target cells. In the absence of the hormone, GR is 
retained in the cytoplasm in an inactive state as part of a large multi-protein complex 
that includes the chaperone protein heat shock protein (hsp) 90. The association 
with hsp90 appears to maintain the receptor in a conformation that favours high-
affinity hormone binding. Binding of the hormone induces a conformational change in 
the receptor, resulting in dissociation of hsp90 and exposure of the nuclear 
localisation signals. This allows nuclear translocation of the activated glucocorticoid-
GR complex utilising selective importins (Bhavsar and Adcock 2008).  
 
1.7.3.2 Transactivation 
One of the major ways in which the GR elicits its genomic effects is by direct binding 
to DNA. Within the nucleus, GR homodimerises and binds to GRE in the regulatory 
regions of glucocorticoid-responsive genes. The consensus GRE sequence 
GGTACAnnnTGTTCT consists of two palindromic half-sites separated by a three-
base-pair spacer and is most often found in the promoter regions of target genes. 
The GR homodimer binds the GRE and undergoes additional conformational 
changes, resulting in the recruitment of coactivators such as SRC, CBP and pCAF. 
These coactivators induce remodelling of chromatin structure and unwinding of DNA 
by their intrinsic histone acetyltransferase and methyltransferase activities. RNA 
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polymerase II and the basal transcription machinery are then recruited to the newly 
accessible promoter to stimulate transcription of the linked gene (Fig. 1.14).  
Figure 1.14. Corticosteroid activation of anti-inflammatory gene expression  
(transactivation). Corticosteroids bind to cytoplasmic GR that translocate into the 
nucleus, where they bind to GRE in the promoter region of steroid-sensitive genes 
and also directly or indirectly to coactivator molecules such as CBP, pCAP or SRC, 
which have intrinsic HAT activity, causing acetylation of lysines on histone H4, which 
leads to activation of genes encoding anti-inflammatory proteins (Barnes 2011).  
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1.7.3.3 Transrepression  
The activated GR can also regulate gene expression, as a monomer, physically 
associating with other transcription factors and modulating their activity on 
responsive genes. For example, GR interacts with the c-jun and c-fos components of 
AP-1 and represses its responsive genes. Similarly, the receptor inhibits the 
transcriptional activity of NF-κB by associating with the p65 subunit, which is 
mediated by the second zinc-finger in the DNA-binding domain of GR. GR may 
either prevent these transcription factors from binding to their cognate response 
element or tether to the DNA-bound proteins and interfere with chromatin 
remodelling and/or recruitment of basal transcription machinery (Bhavsar and 
Adcock 2008) (Fig. 1.15).  
Figure 1.15. Corticosteroid suppression of activated inflammatory genes 
expression (transrepression). NF-κB (p65-p50) activated by pro-inflammatoy 
stimuli translocates into the nucleus, binding to specific κB recognition sites and to 
coactivators which have intrinsic HAT activities. This results in acetylation of core 
histone H4, leading to increased expression of inflammatory genes. Activated GR 
translocates into the nucleus and binds to coactivators in order to inhibit HAT 
activities and recruit HDAC2, which reverses histone acetylation, leading to 
suppression of these induced inflammatory genes (Barnes 2011). 
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1.7.3.4 Destabilisation of inflammatory mRNA 
Glucocorticoids also exert anti-inflammatory actions that do not depend on the 
receptor’s ability to regulate transcription in the nucleus. Adenylate-uridylate-rich 
elements (ARE) in the three prime untranslated region (3’-UTR) of many 
inflammatory genes control the stability of mRNA. Binding of ARE-binding proteins to 
mRNA results in the formation of messenger ribonucleoprotein (mRNP) complexes 
which control mRNA decay. Several ARE-binding proteins have been reported and 
include tristetrapolin (TTP), which promotes mRNA decay, and HuR family members, 
which are associated with mRNA stability. Importantly, HuR binding to ARE is 
dependent upon p38 MAPK activation. Dexamethasone has been reported to 
regulate the levels of HuR and TTP, thereby reducing the levels of inflammatory 
gene mRNAs through a p38 MAPK-mediated pathway subsequent to induction of 
MAPK phosphatase (MKP)-1 (Barnes 2006) (Fig. 1.16).  
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Figure 1.16. Destabilisation of inflammatory mRNA by corticosteroids through 
suppression of p38 MAPK by induction of MKP-1. The stability of mRNA coding 
for several inflammatory proteins is controlled by AU-rich element in the 3’-UTR. p38 
MAPK activated by inflammatory stress phosphorylates MAPKAPK2, which activates 
ARE binding proteins (AREBP), thus stabilising the mRNA by binding to ARE. 
Corticosteroid induces expression of MKP-1, which inhibits p38 and thus prevents 
stabilisation of multiple inflammatory proteins (Barnes 2011). 
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1.7.3.5 Post-translational modification of GR: focus on phosphorylation 
GR is also a substrate for several types of post-translational modifications that 
regulate corticosteroid responsiveness by modulating the levels or transcriptional 
activity of the receptor. These modifications include phosphorylation, acetylation, 
nitrosylation, redox regulation, ubiquitination and SUMOylation (Fig.1.17). 
Figure 1.17. Structure and post-translational modifications of GR. (A) 
Phosphorylation sites for human (h), murine (m) and rat (r) GR. (B) Post-translation 
modifications of hGR, except from the phosphorylation sites. DBD: DNA-binding 
domain; LBD: ligand-binding domain; NTD: N-terminal domain; HR: hinge region; aa: 
amino acids; P: phosphorylation; SUMO: SUMOylation; Ub: ubiquitination; Ac: 
acetylation (Beck, Vanden Berghe et al. 2009). 
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GR is a phosphoprotein that becomes hyper-phosphorylated typically after binding 
glucocorticoids (Bodwell, Orti et al. 1991). At least six different serine residues are 
identified as sites of phosphorylation in the AF-1 region of its N-terminal domain: 
S113, S141, S203, S211, S226 and S404 (Oakley and Cidlowski 2011). The 
receptor displays a basal level of phosphorylation and becomes hyper-
phosphorylated upon binding of glucocorticoids, with the extent of phosphorylation 
dependent on the nature of the bound ligand. Altered GR phosphorylation status can 
affect the binding of GR and its ligand, hsp90 interactions, subcellular localisation, 
and nuclear-cytoplasmic shuttling. Phosphorylation can also enhance the 
transcriptional activity of GR in a promoter-specific fashion and regulates both the 
basal and glucocorticoid-induced turnover of the receptor (Nicolaides, Galata et al. 
2010). The major kinases that phosphorylate GR include MAPK, cyclin-dependent 
kinases (CDKs) and glycogen synthase kinase-3β (GSK-3β) (Oakley and Cidlowski 
2011). 
 
Of the six human phosphorylated serine residues of GR, S203, S211 and S226 have 
been more extensively investigated (Table 1.2). It has been proposed that 
phosphorylation of GR at S211 is correlated with its transcriptional activity (Oakley 
and Cidlowski 2011). In the absence of the ligand, basally phosphorylated GRs at 
S203 and S211 are both in the cytoplasm, while dexamethasone-induced S211 
phosphorylated GR is mainly nuclear, while S203 phosphorylated GR preferentially 
resides in the cytoplasm. In addition, although dexamethasone induces 
phosphorylation of GR at both S203 and S211, the antagonist RU486 reverses 
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phosphorylation only of the latter (Wang, Frederick et al. 2002). On the contrary, 
phosphorylation of GR at S226 impairs its signalling capability (Oakley and Cidlowski 
2011), and GR transactivation function is found to be at its peak when the relative 
phosphorylation of S211 surpasses that of S226 (Chen, Dang et al. 2008). 
Furthermore, in lung epithelial cells, the degree of S211 phosphorylation correlates 
with ligand bind, nuclear translocation and GR transactivation (Adcock and Barnes 
2008). 
Table 1.2. Summary of effects of GR phosphorylation at S201, S211 and S226 
(Galliher-Beckley and Cidlowski 2009). 
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1.7.4 Corticosteroid insensitivity in severe asthma 
Recently, endobronchial biopsy performed in patients with severe asthma has 
become feasible and provides an important contribution to the field, by enabling 
studies to investigate the involvement of more distal parts of the lung. Distinct 
inflammatory and structural features are demonstrated in the airways of patients with 
severe asthma when compared to patients with milder forms of the disease (Pepe, 
Foley et al. 2005). In addition, pathological studies have identified different patterns 
of inflammation in the airways of patients with severe asthma, demonstrating that 
different phenotypes of severe asthma exist (Wenzel, Schwartz et al. 1999).  
 
It has been demonstrated that the peripheral blood mononuclear cells (PBMC) (Hew, 
Bhavsar et al. 2006) and alveolar macrophages (Bhavsar, Hew et al. 2008) from 
patients with severe asthma show impaired response to dexamethasone in terms of 
suppressing LPS-induced inflammatory cytokines, compared with subjects with non-
severe asthma.  In addition, alveolar macrophages of patients with severe asthma 
release decreased lipoxin A4, an anti-inflammatory lipid product, but increased 
leukotriene B4, a pro-inflammatory 5-lipoxygenase product, compared with non-
severe asthmatic subjects. Similarly, there is impaired corticosteroid sensitivity to 
LPS-induced leukotriene B4 but not lipoxin A4 in macrophages of patients with 
severe asthma (Bhavsar, Levy et al. 2010). It is still uncertain whether airway 
structural cells, such as ASMC, display differential corticosteroid sensitivity in a 
similar manner. 
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1.8 Hypothesis and aims 
Rationale: 
The clinical feature of severe asthma is relatively decreased therapeutic effect of 
corticosteroids to control the disease, suggesting the presence of corticosteroid 
insensitivity in severe asthma. Impaired effect of corticosteroid in terms of 
suppressing inflammatory cytokines have been reported in PMBC and alveolar 
macrophages of patients with severe asthma compared with non-severe asthmatic 
subjects. It is still unclear whether ASMC display in a similar manner. 
 
Therefore I hypothesise that relative corticosteroid insensitivity exists in ASMC of 
patients with severe asthma. 
 
To test this hypothesis, I aim to investigate and compare: 
 
1. cytokine-induced chemokine release and mRNA expression, and 
2. effect of dexamethasone on regulation of induced chemokines 
 
in ASMC of healthy subjects and patients with non-severe or severe asthma. 
 
Then the possible mechanisms are explored, focusing on expression and activation 
of MAPK, NF- kB and GR pathways. 
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Chapter 2. Materials and Methods 
2.1 Materials 
2.1.1 General reagents 
General laboratory reagents were purchased from Sigma-Aldrich (Dorset, UK) 
unless otherwise stated. 
 
2.1.2 Cell culture 
Dulbecco’s Modified Eagle’s Medium (DMEM), Hank’s Balanced Salt Solution 
(HBSS), cell culture grade bovine serum albumin (BSA), non-essential amino-acid 
solution, L-glutamine, penicillin/streptomycin solution, trypsin-EDTA solution, 
amphotericin B, and cell freezing medium were purchased from Sigma-Aldrich 
(Dorset, UK). Foetal calf serum (FCS) was purchased from Biosera (East Sussex, 
UK). The details for different cell treatments used in this thesis are shown in table 2.1. 
 
Treatment Source Stock solution 
TNF-α R&D Systems 10 μg/mL in 0.1% BSA 
IFN-γ R&D Systems 50 μg/mL in 0.1% BSA 
Dexamethasone Sigma-Aldrich 10-3 M in water 
GW-856553 GlaxoSmithKline 10-2 M in DMSO 
SP600125 Sigma-Aldrich 10-2 M in DMSO 
U0126 Sigma-Aldrich 10-2 M in DMSO 
Table 2.1.  Cytokines and inhibitors used in the project. 
 
2.1.3 Cell viability assay 
Methylthiazolydiphenyl-tetrazolium bromide (MTT) and dimethyl sulphoxide (DMSO) 
were purchased from Sigma-Aldrich (Dorset, UK). 
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2.1.4 Enzyme linked immunosorbent assays (ELISA) 
DuoSet ELISA kits for CCL11, CXCL8, CXCL10 and CX3CL1 were purchased from 
R&D Systems (Abingdon, UK). Nunc MaxiSorp flat-bottom 96 well plates were 
purchased from Fisher Scientific (Leicestershire, UK). SpectraMax Plus absorbance 
microplate reader was manufactured by Molecular Devices (California, USA). 
 
2.1.5 RNA extraction, cDNA preparation and real-time quantitative PCR 
The RNeasy Mini Kit, QIAshredder spin columns, DNAse enzyme and SYBR Green 
PCR Master Mix Reagent were purchased from Qiagen (West Sussex, UK). The 
NanoDrop 1000 spectrophotometer was from Thermo Sientific (Massachusetts, 
USA). The dNTPs and nuclease-free water were from Bioline (London, UK). Avian 
myeloblastosis virus (AMV) reverse transcriptase reaction buffer and enzyme, 
random primers and recombinant RNasin ribonuclease inhibitor were from Promega 
(Southampton, UK). The MBS 0.5G thermal cycler was from Thermo Hybaid 
(Middlesex, UK). The Rotor Gene 6000 real-time cycler, capillary tubes, and the 
Rotor Gene 6000 Series software (version 1.7) were from Corbett Research 
(Cambridge, UK).  
 
2.1.6 Whole cell/cytoplasmic/nuclear protein extraction and sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS PAGE)/Western blotting 
Hypotonic buffer (10X) and detergent were purchased from Active Motif (Rixensart, 
Belgium). Radioimmunoprecipitation assay (RIPA) lysis buffer was from Santa Cruz 
(Heidelberg, Germany). The complete Mini protease inhibitor cocktail was from 
Roche Applied Science (West Sussex, UK) and a 25X stock solution was prepared 
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in tissue culture grade water. Phenylmethylsulphonyl fluoride (PMSF) was from 
Sigma-Aldrich (Dorset, UK); a 200 mM stock solution was prepared in isopropanol. 
Bicinchoninic acid (BCA) assay was from Pierce Biotechnology (Illinois, USA). 4-
12% Bis-Tris Novex precast mini gels, XCell SureLock electrophoresis cells, 
PowerEase 500 power supply, NuPAGE MOPS SDS running buffer (20X) and iBlot 
transfer system were from Invitrogen (Paisley, UK). The full-range rainbow molecular 
weight markers, enhanced chemiluminescence (ECL) and ECL Plus solution were 
from GE Healthcare Life Sciences (Buckinghamshire, UK). FUJIFILM medical X-ray 
film was from Genetic Research Instrumentation Ltd (Braintree, UK). Re-Blot Plus 
mild antibody stripping solutions (10X) were from Millipore (Watford, UK). The Gel 
Doc-It imaging system was from Ultra-Violet Products (California, USA). 
 
2.2 Methods 
2.2.1 Recruitment of healthy subjects and patients with non-severe and severe 
asthma 
12 healthy subjects and 10 each patients with non-severe or severe asthma, 
respectively, were recruited in this research. All healthy subjects were normal 
volunteers without any disease, aged between 18 and 65 years, and had a negative 
PC20 to methacholine, normal spirometry, physical examination and no history of 
significant medical problems. Severe asthma patients were defined as needing either 
continuous or near-continuous oral corticosteroids, or high-dose inhaled 
corticosteroids, or both to achieve a level of mild-to-moderate persistent asthma and 
by 2 or more minor criteria (ATS. 2000). Patients with non-severe asthma used 
inhaled beclomethasone (0-1000 μg/day or equivalent) with perfect control of their 
asthma. Current and ex-smokers of greater than 5 pack-years were excluded. All 
patients gave informed consent to participate in this study which was approved by 
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the local Ethics Committee. All the subjects were free from upper respiratory 
infections and acute exacerbations within three months preceding the bronchoscopy.  
 
Compared with those with non-severe asthma, the patients with severe asthma 
suffer from longer duration of the disease and use higher doses of inhaled 
corticosteroids, and half receive oral prednisolones. These patients also have worse 
pulmonary functions and greater airway hyper-responsiveness (Table 2.2). 
 
Non-asthma 
Non-severe 
Asthma 
Severe Asthma 
Numbers  12 10 10 
Age, years  46.1 ± 12.2  42.3 ± 17.2  46.2 ± 14.4  
Gender, F/M  7/5 4/6 5/5 
Duration of asthma, years  N/A  23.9 ± 12.3  35.6 ± 12.0 *  
Inhaled corticosteroid dose,  
μg BDP equivalent   
0 740 ± 353  1563 ± 272 ***  
Atopy (n)
 $
  3 7 5 
Receiving oral corticosteroids (n)  0 0   5 * 
FEV1, L  3.35 ± 0.81  2.88 ± 0.41  2.24 ± 0.36 **  
FEV1,% predicted  96.8.0 ±12.4  88.6 ± 11.1  74.9 ± 12.4 *  
FEV1/FVC, %  80.3 ± 12.0  77.9 ± 4.6  67.7 ± 10.0 **  
β-agonist reversibility
 #
, %  N/A  15.7 ± 5.7  22.8 ± 10.6 
PC20, mg/mL  > 16  2.91 ± 2.88  0.91 ± 0.72 * 
Table 2.2. Characteristics of studied subjects. BDP, beclomethasone 
dipropionate; FEV1, forced expiratory volume in 1s; FVC, forced vital capacity; PC20, 
provocative concentration of methacholine causing a 20% fall in FEV1; N/A: not 
available. $ Defined as positive skin prick tests to one or more common 
aeroallergens. # Measured as percent increase in FEV1 after 400 μg salbutamol.       
* p <0.05, ** p<0.01, *** p<0.001 vs non-severe asthma. Data shown as mean ± 
SEM. 
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2.2.2 Human ASMC isolation and culture 
The ASMC from healthy subjects and patients with non-severe and severe asthma 
were obtained from the biopsies of the right lower bronchus, taken by the 
bronchoscopists. Biopsies were separated by aseptic needles into small pieces with 
the size less than 1 mm2. Each piece of tissue was transferred to a 6-well culture 
plate for attachment and growth. When confluent, cells were harvested and split into 
25-cm2 and then 75-cm2 flasks at the next passage. Subsequently, they were split 
into 150-cm2 flasks in preparation for experiments or stored at -80 °C in the liquid 
nitrogen. 
 
The cells were cultured in DMEM medium supplemented with 10% FCS, 4 mM L-
glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2.5 μg/mL amphotericin 
B. The presence of ASMC was confirmed by identifying the characteristic “hill and 
valley” morphology, and immunofluorescence techniques for calponin, smooth 
muscle α-actin and myosin heavy chain revealed that more than 95% of the cells 
displayed the characteristics of smooth muscle cells in culture (Oltmanns, Walters et 
al. 2008). Cell stocks were kept in 150-cm2 flasks at 37°C, 5% CO2, and humidified 
atmosphere. Cells at passage 4 or 5 were used for experiments. At 90% confluence, 
the cells were serum deprived for 24 hours in DMEM medium supplemented with 4 
mL L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 2.5 μg/mL 
amphotericin B, 1% non-essential amino acids, and 0.1% BSA. 
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2.2.3 Cell viability assay 
ASMC were seeded in 48-well tissue culture plates and stimulated as indicated. At 
the end of the period of stimulation the supernatant was removed, and cells were 
incubated with 150 μL of 1 mg/ml MTT solution in serum-free DMEM at 37°C in 5% 
CO2/95% air (vol/vol) for 15 minutes. Staining of the cells was confirmed by 
observation under a light microscope, the MTT solution was removed, and the plate 
dried by blotting on clean paper towels. 300 μL of DMSO was then added to each 
well and thoroughly mixed. The resulting solution was then transferred into 96-well 
microtitre plates and the absorbance at 550 nm was measured with the absorbance 
microplate reader. The effect of a treatment on cell viability was determined as a fold 
change in absorbance compared to the unstimulated control. 
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2.2.4 ELISA 
Chemokine release was measured in supernatants from 90% confluent cells in 24-
well (mostly) or 6-well (when RNA was also required) cell culture plates. At the end 
of the stimulation period supernatants were collected and stored at -20°C or assayed 
directly. Chemokine concentrations in the supernatants were determined by using 
specific DuoSet ELISA kits according to the manufacturer’s instructions. The 
antibody working concentrations, standard concentrations and supernatant dilutions 
for each assay are summarised in Table 2.3.  
 
Chemokine 
Capture Antibody 
(working 
concentration) 
Detection Antibody 
(working 
concentration) 
Standard 
concentration 
range 
CCL11 
Mouse anti-human 
( 2 ug/mL) 
Biotinylated goat  
anti-human 
(100 ng/mL) 
15.63-1000 pg/mL 
CXCL8 
Mouse anti-human 
( 4 ug/mL) 
Biotinylated goat  
anti-human 
(20 ng/mL) 
31.25-2000 pg/mL 
CXCL10 
Mouse anti-human 
( 2 ug/mL) 
Biotinylated goat  
anti-human 
(50 ng/mL) 
31.25-2000 pg/mL 
CX3CL1 
Mouse anti-human 
( 4 ug/mL) 
Biotinylated mouse 
anti-human 
(250 ng/mL) 
31.25-2000 pg/mL 
Table 2.3. Conditions used for ELISA. 
 
Briefly, 96-well microtitre plates were coated by dispensing 100 μL of capture 
antibody solution at the working concentration in PBS and incubated overnight at 
room temperature. The capture antibody solution was aspirated, and the plate 
washed three times with 300 μL of wash buffer using an ELISA plate washer 
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(Skatron, Norway) and dried by blotting against paper towels. The plate was then 
blocked by dispensing 300 μL of Block Buffer (1% BSA and 0.05% NaN3 in PBS) into 
each well and incubated for one hour at room temperature, followed by another wash 
step as described above. Seven recombinant protein standards were then prepared 
by carrying out 2-fold serial dilutions of the stock protein standard in the reagent 
diluent (1% BSA in PBS). 100 μL of the standards and diluted supernatants were 
then dispensed in the plate and incubated for 2 hrs at room temperature. The plate 
was then washed, and 100 μL of detection antibody diluted to the working 
concentration in the reagent diluent and dispensed into each well and incubated for 2 
hrs at room temperature. The plate was then washed and 100 μL of streptavidin-
HRP solution, diluted in 1/200 in Reagent Diluent, were dispensed in each well and 
incubated for 20 mins at room temperature protected from light. After the final wash 
step, 50 μL of the substrate solution, prepared by mixing equal volumes of Colour 
Reagents A (H2O2) and B (tetramethylbenzidine), were dispensed into each well and 
incubated until a change of colour was observed. The substrate reaction was then 
stopped by adding 50 μL of Stop Solution (2 N H2SO4). The absorbance of each well 
was then measured at 450 nm with a 540 nm correction with the absorbance 
microplate reader, and a four-parameter logistic standard curve was automatically 
generated using the microplate reader software. The chemokine concentration of 
each sample was determined from the standard curve and corrected for the dilution 
by multiplying by the dilution factor. 
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2.2.5 Determination of mRNA expression by RT-qPCR 
2.2.5.1 RNA extraction 
ASMC were seeded in 6-well culture plates at an initial density of 80,000 cells/well. 
After treatment as indicated, cells were washed with 1 ml HBSS and then lysed by 
adding 350 μL/well of RLT buffer containing 1% β-mercaptoethanol for 5 minutes at 
room temperature. The lysates were stored at -80 °C or further processed for RNA 
extraction with the RNeasy Mini Kit according to the manufacturer’s instructions. 
Briefly, cell lysates were homogenised by centrifugation through QIAshredder spin 
columns in the MIKRO 22R microcentrifuge, with radius of 87 mm, (Hettich, 
Germany) at 12,000 rpm for 2 minutes. An equal amount (350 μL) of 70% ethanol 
was then mixed with the lysate, and the resulting solution was applied to the RNeasy 
Mini spin column by centrifugation at 10,000 rpm for 15 seconds, in order for total 
RNA to be retained on the silica-based membrane. The membrane bound RNA was 
washed using suitable buffers to remove contaminants and incubated with a DNAse 
enzyme for 15 minutes at room temperature to remove DNA contamination. RNA 
was eluted from the column by applying 30 μL H2O and centrifuging at 10,000 rpm 
for one minute. The concentration of RNA was measured by the spectrophotometer. 
RNA purity was determined by determining the ratio of absorbance at 260 nm over 
the absorbance at 280 nm (A260/A280). 
 
2.2.5.2 Reverse transcription 
0.5 μg of total RNA in a final volume of 10 μL was incubated for 5 min at 70°C on the 
thermal cycler in order to denature the RNA strands. At the end of the denaturation 
step, 10 μL of reverse-transcription reaction mix was added, with total volume of 20 
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μL containing 1mM dNTPs, 1X AMV reverse transcriptase reaction buffer, 25 ng/mL 
random primers, 40 U recombinant RNasin ribonuclease inhibitor and 10 U AMV 
reverse transcriptase. The mixture was incubated at 42°C for 60 minutes followed by 
incubation at 90°C for 4 min to inactivate the reverse transcriptase enzyme. The final 
cDNA product was then diluted 4-fold in nuclease-free water. 
 
2.2.5.3 Real-time PCR 
5 μL of cDNA was added to capillary tubes containing 15 μL of reaction mixture, 
which consists of SYBR Green PCR Master Mix Reagent  and gene specific primers. 
The PCR reaction was carried out in the real-time cycler, where the cycling 
conditions were 15 minutes at 95°C (enzyme activation) followed by 35-60 cycles of 
20 seconds at 94°C (denaturing step), 20 seconds at 60°C (annealing step) and 20 
seconds at 72°C (elongation step). Fluorescence emitted from DNA-bound SYBR 
Green was detected at 510 nm after excitation at 470 nm during the extension step. 
Data from the reaction were analysed using the Rotor-Gene 6000 Series Software 
(version 1.7). DNA was quantified by the standard curve method of relative 
quantification, created by serial dilution of a suitable sample. Relative quantitation of 
gene expression was normalized to 18S rRNA expression. Specific primers for 
CCL11, CXCL8, CX3CL1 and 18S (Table 2.4) were designed according to their 
published sequences using the GenScript online primer design software and 
synthesised by Sigma-Genosys (Haverhill, Suffolk, UK). Primer specificity was 
measured by using the online sequence analysis software BLAST 
(www.ncbi.nlm.nih.gov/BLAST/). Melting curve analysis and agarose gel 
electrophoresis were carried out in order to ensure the presence of one specific PCR 
product. 
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Gene Primer sequence 
CCL11 
Forward: 5'-AAG CTT ACG CCA AAG CAC ACA CCT-3' 
Reverse: 5'-GAA TCC TGG CTT TGG AGT TGG AGA T-3' 
CXCL8  
Forward: 5'-GCC AAC ACA GAA ATT ATT GTA AAG CTT-3' 
Reverse: 5'-CCT CTG CAC CCA GTT TTC CTT-3' 
CX3CL1 
Forward: 5'-CCT GTA GCT TTG CTC ATC CAC TCT C-3' 
Reverse: 5'-TCC AAG ATG ATT GCG CGT T-3' 
18S 
Forward: 5'-CTT AGA GGG ACA AGT GGC G-3' 
Reverse: 5'-AGC CTG AGC CAG TCA GTG TA-3' 
Table 2.4. Primers used for RT-qPCR. 
 
2.2.6 Chromatin immunoprecipitation (ChIP) assay 
2.2.6.1 Optimisation of sonication 
ChIP assays were performed using the ChIP assay kit supplied by Millipore and the 
protocol therein. Briefly, ASMC were seeded in 75-cm2 flasks; at 90% confluency 
(estimated 2 x 106 cells), they were serum deprived for 24 hours. After treatment the 
cells were fixed in 1% formaldehyde at room temperature for 10 minutes. After 
neutralization with 0.125 M of glycine, cells were scraped, pelleted, and lysed in 400 
μL of 1% SDS lysis buffer. The DNA was fragmented by sonication with Vibra Cell 
high intensity ultrasonic liquid processor (Sonics, USA), the conditions for which 
were determined by optimisation over a range of 15-second pulses (1-9 pulses). The 
sonicated samples were de-crosslinked, and DNA recovered as described below. 
The purified DNA was dissolved in 50 uL of nuclear free water, and 5 μL of samples 
(2 x 105 cell equivalent) was loaded in a 2% agarose gel in TBE (Tris/Borate/EDTA) 
buffer. Electrophoresis was performed at 100 V for 30 minutes; then the gel was 
soaked in 0.5 μL/mL of ethidium bromide for 10 minutes. After washing with TBE 
buffer at room temperature for 30 minutes, the gel was exposed under UV light and 
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scanned by GelDoc-It imaging system (UVP Ltd, UK). Five 15-second pulses of 
sonication were shown to be optimal for fragmenting DNA with the range 200 to 
1000 bp (Fig.2.1). 
 
Figure 2.1. Optimisation of sonication for ChIP assay. Following fixing with 1% 
formaldehyde, 2 x 106 ASMC lyzed in SDS lysis buffer were sonicated under 40% 
maximal power, 15 seconds per pulse. After reverse crosslinking and DNA 
purification, 2 x 105 cell equivalent was loaded into a 2% agarose gel for 
electrophoresis. The gel was fluorescent-tagged with ethidium bromide and exposed 
to UV light.  
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2.2.6.2 Chromatin immunoprecipitation 
After sonication, the supernatant was collected following centrifuge at 13,000 rpm at 
8°C for 10 minutes. After addition of 1.6 mL of ChIP dilution buffer, 100 μL of sample 
was saved as input. After the protein-chromatin complex solution was pre-cleared 
with 80 μL of protein A agarose/salmon sperm DNA (provided as a 50% gel slurry in 
10mM Tris-HCl, 1mM EDTA, pH 8.0 containing 0.05% sodium azide), 4 μg of anti-
p65 antibody was added, and the sample incubated at 4°C overnight. Antibody/DNA 
complexes were captured with protein 60 μL of protein A agarose/salmon sperm 
DNA, washed with 1mL of low salt (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM 
Tris-HCl, pH 8.1, 150mM NaCl), high salt (0.1% SDS, 1% Triton X-100, 2mM EDTA, 
20mM Tris-HCl, pH 8.1, 500mM NaCl), lithium chloride immune complex wash buffer 
(0.25M LiCl, 1% IGEPAL CA630, 1% deoxycholic acid (sodium salt), 1mM EDTA, 
10mM Tris, pH 8.1) once and TE buffer (10mM Tris-HCl, pH 8.0, 1mM EDTA) twice, 
respectively, eluted with 250 μL of freshly prepared 1% SDS containing 0.1M 
NaHCO3, and reverse cross-linked by adding 0.2 M NaCl and incubation at 65 °C 
overnight. Both the DNA and input fractions were purified by phenol/chloroform wash 
and ethanol precipitation. The precipitated DNA out of 2 x 106 cell equivalent was 
resuspended in 50 μL of nuclease-free water, and qPCR (as described in 2.2.5.3) 
was performed on 5 μL of sample. Sample DNA was normalized to input DNA. The 
primer sequences (Chang, Bhavsar et al. 2012) were listed in Table 2.5. 
Gene Primer sequence 
CCL11  
Forward: 5'-GCA AAT CAG GAA TCC CTT CAT CGT G-3' 
Reverse: 5'-GCT CCT CTG GCC CAT CTG CCY GCC-3' 
CXCL8  
Forward: 5'-AAC AGT GGC TGA ACC AGA G-3' 
Reverse: 5'-AGG AGG GCT TCA ATA GAG G-3' 
CX3CL1 
Forward: 5'-GGC ATG TTC CCA GCT TGT GGC AGG-3' 
Reverse: 5'-GTT GCC AAG GAA CCA AGC CGG C-3' 
Table 2.5. Primer sequences for ChIP assays.  
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2.2.7 Determination of protein expression by Western blotting 
2.2.7.1 Whole cell extraction 
ASMC were seeded in 75-cm2 flasks. After treatment, cells were washed once with 
ice cold PBS.  In experiments where the expression of phosphorylated proteins was 
to be determined, PBS contained phosphatase inhibitor cocktail. After scraping, the 
cell suspension was transferred into pre-chilled tubes and pelleted at 7,000 rpm at 
4°C for 5 minutes. The supernatant was then removed and the cell pellet was 
resuspended in 60 μL of RIPA buffer containing 1 mM PMSF and 1X complete mini 
protease inhibitor cocktail, vortexed for 10 seconds and incubated on the ice for 30 
minutes. The lysates were then centrifuged at 13,000 rpm for 15 minutes, and the 
supernatant transferred in new pre-chilled tubes and stored at -80°C. To prepare a 
standard protein to compare the abundance of target proteins between healthy and 
diseased groups between different Western Blots, 12 flasks of confluent ASMC were 
trypsinised, followed by centrifuge and resuspension with RIPA buffer in the same 
way, and finally were aliquoted and stored at -80°C. 
 
2.2.7.2 Cytoplasmic and nuclear extraction 
ASMC were seeded in 75-cm2 flasks. After treatment, cells were washed once with 
ice cold PBS. After scraping, the cell suspension was transferred into pre-chilled 
tubes and pelleted at 7,000 rpm at 4°C for 5 minutes. The supernatant was then 
removed and the cell pellet resuspended in 80 μL hypotonic buffer containing 
complete mini protease inhibitor cocktail and incubated in the ice for 15 munutes. 4 
μL of detergent was added, and each sample was vortexed for 10 second. After 
centrifuge at 10,000 rpm at 4°C for 1 minute, the supernatant was collected 
(cytoplasmic extract). 
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The pellet was then washed by resuspension with 40 μL hypotonic buffer and 
centrifuge at 10,000 rpm for 1 minute at 4°C. The supernatant was then removed, 
and the cell pellet resuspended in 40 μL RIPA buffer containing 1 mM PMSF and 1X 
complete mini protease inhibitor cocktail, vortexed for 10 seconds and incubated in 
the ice for 30 minutes. The lysates were then centrifuged at 13,000 rpm for 15 
minutes, and the supernatant (nuclear extract) was transferred in new pre-chilled 
tubes and stored at -80°C. 
 
2.2.7.3 Determination of protein concentration 
Protein concentration was determined by performing BCA assay in a 96-well plate 
according to the manufacturer’s instructions. Briefly, 2 uL of protein extract was 
diluted 5-fold by addition of 8 uL tissue culture grade water. BSA standards (0.125, 
0.25, 0.5, 1 and 2 mg/mL) were prepared by serial 2-fold dilutions with equal amount 
of cell culture grade water. 2 uL of hypotonic buffer (for cytoplasmic extracts) and 
RIPA buffer (for nuclear extracts or whole cell lysates) was then added into 8 uL of 
BSA standards to make final concentrations of 0.1, 0.2, 0.4, 0.8 and 1mg/mL, 
respectively. The BCA protein assay reaction mixture was then prepared by mixing 
reagent A (sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium 
tartrate in 0.1 M sodium hydroxide) and B (4% cupric sulphate) in a ratio of 50:1. 200 
μL of the mixture was added to the protein extracts and standards, mixed for 30 
seconds, and the reaction incubated at 37°C for 30 minutes. The absorbance of the 
product was measured at 562 nm by absorbance microplate reader (Molecular 
Devices, UK) and the protein concentrations were determined by comparison to the 
standard curve and corrected by the dilution factor. 
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2.2.7.4 Western blotting 
40 μg of protein extracts were aliquoted into tubes and the total volume was adjusted 
to 21 μL by adding hypotonic buffer (for cytoplasmic extracts) or RIPA buffer (for 
nuclear extracts or whole cell lysates). 7 μL of 4X NuPAGE LDS sample buffer 
(glycerol 10%, Tris base 141 mM, Tris HCl 106 mM, LDS 2%, EDTA 0.51 mM, 
SERVA Blue G250 0.22 mM, phenol red 0.175 mM, pH 8.5) containing 3.8% β-
mercaptoethanol were added to the protein extracts, and the samples were heated 
at 70°C for 10 minutes to denature the proteins. The samples were then loaded onto 
a 4-12% Bis-Tris Novex pre-cast mini-gel. The gels were placed in the 
electrophoresis cell connected to a power supply and were electophoresed at 200 V 
for 50 minutes in NuPAGE MOPS SDS running buffer (MOPS 50 mM, Tris base 50 
mM, SDS 0.1%, EDTA 1 mM, pH 7.7). The gel cassette was opened and the gel was 
trimmed to an appropriate size with a gel knife, proteins were transferred from the 
gel to a nitrocellulose membrane using the iBlot transfer system at 20 V for 7 
minutes. Visualisation of the proteins on the membrane was performed by incubation 
with Ponceau Red (0.2% Ponceau S in 3% trichloroacetic acid and 3% sulfosalicylic 
acid) for 5 minutes to confirm protein transfer.  
 
After Ponceau Red was washed off with TBS-Tween (0.1% Tween), the membrane 
was blocked by incubating into 5% BSA (for phosphorylated proteins) or 5% skim 
milk (for unphosphorylated proteins) in TBS-Tween at room temperature for 30 
minutes. The membrane was then incubated with a suitable dilution of the primary 
antibody (Table 2.6), at 4°C overnight. The membrane was then washed three times 
with TBS-Tween for 5 minutes and then incubated with a suitable secondary 
antibody (Table 2.6) for 45 minutes at room temperature. The membrane was 
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washed four times with TBS-Tween for 5 minutes and then covered with 2 mL of 
ECL or ECL Plus solution for 1 minute or 5 minutes, respectively, at room 
temperature. Excess solution was removed, and the membrane wrapped in plastic 
film and exposed to a medical X-ray film in a cassette. After the exposed films were 
developed, the relevant bands were scanned by GelDoc-It imaging system (UVP Ltd, 
UK), and the band intensities were quantified by Launch VisionWorksLS acquisition 
and analysis system (version 6.8).  
 
In the experiments for which phosphorylated proteins were to be probed, after the 
bands were quantified, the membrane was stripped by incubation in 1X ReBlot Plus 
mild antibody stripping solution for 15 minutes. Complete stripping was confirmed by 
showing the disappearance of the bands after re-incubation with ECL/ECL Plus 
solution and the X-ray film was exposed. After washing and incubation with 5% skim 
milk in TBS-Tween, the total proteins on the membrane were probed with a suitable 
dilution of the primary antibody at 4°C on a shaker overnight. The following 
procedures were the same as described above. 
 
2.2.8 Statistical analysis 
GraphPad Prism Version 5.03 was the software for statistical analysis. Repeated 
measures analysis of variance (ANOVA) with Dunnet multiple comparison test was 
used for intra-group analysis of i) the effect of cytokine compared to unstimulation 
and ii) the effect of IFN-γ, dexamethasone, or MAPK inhibitor compared to TNF-α 
alone. Kruskal-Wallis test with Dunn’s multiple comparison was used to compare 
results between the three groups. p<0.05 was taken as significant. 
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Antibody Type Source Dilution 
Primary antibodies 
Phospho-p38 Rabbit polyclonal 
Cell Signalling 
(#9211) 
1:1,000 
Total p38 Rabbit polyclonal 
Cell Signalling 
(#9212) 
1:1,000 
Phospho-JNK Rabbit polyclonal 
Cell Signalling 
(#9251) 
1:2,000 
Total JNK Rabbit polyclonal 
Cell Signalling 
(#9252) 
1:2,000 
Phosho-ERK Rabbit polyclonal 
Cell Signalling 
(#4370) 
1:50,000 
Total ERK Rabbit polyclonal 
Cell Signalling 
(#9102) 
1:2,000 
Phospho-GR 
(S211) 
Rabbit polyclonal 
Cell Signalling 
(#4161) 
1:2,000 
Total GR (E-20) Rabbit polyclonal 
Santa Cruz          
(sc-1003) 
1:1,000 (whole cell) 
1:2,000 (nuclear) 
p65 (C-20) Rabbit polyclonal 
Santa Cruz          
(sc-372) 
1:5,000 
β-actin Mouse polyclonal 
Santa Cruz          
(sc-130065) 
1:20,000 
TBP Mouse mclonal 
Abcam      
(ab51841) 
1:5,000 
α-tubulin (B-7) Mouse polyclonal 
Santa Cruz          
(sc-5286) 
1:5,000 
Secondary antibodies 
HRP-conjugated 
anti-rabbit IgG 
Goat polyclonal 
DAKO           
(P0448) 
1:2,000 
HRP-conjugated 
anti-mouse IgG 
Rabbit polyclonal 
DAKO           
(P0447) 
1:2,000 
 Table 2.6. Antibodies used for Western blot.  
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Chapter 3. Regulation of chemokines in ASMC: effect of TNF-α and IFN-γ 
3.1 Introduction 
Although both TNF-α and IFN-γ are Th1 cytokines, they are involved in pathogenesis 
of asthma(Barnes 2008). TNF-α is one of the cytokines that amplify the inflammatory 
response in asthma, while IFN-γ has important immunomodulating effects. 
 
The modulating effect of IFN-γ on TNFα-mediated chemokine expression is variable: 
depending on the targeted gene, IFN-γ may either suppress or potentiate TNFα-
induced inflammatory chemokines. Some chemokines, such as CX3CL1, are only 
induced, synergistically, by the combined cytokines. 
 
NF-κB activity is critically involved in regulation of the inflammation in asthma. 
Expression of CCL11, CXCL8, CXCL10 and CX3CL1 is dependent on the NF-κB 
pathway (Edwards, Bartlett et al. 2009). NF-κB binding sites in the promoters of 
these genes have been identified (Mukaida, Okamoto et al. 1994; Matsukura, 
Stellato et al. 1999). Importantly, recruitment of the p65 component of NF-κB to the 
promoters of CCL11 (Nie, Knox et al. 2005) and CXCL8 (John, Zhu et al. 2009) in 
ASMC and CX3CL1 (Bhavsar, Sukkar et al. 2008) in airway epithelial cells has been 
investigated. 
 
Despite observations of elevated expression of CCL11 (Chan, Burgess et al. 2006), 
CXCL8 (John, Zhu et al. 2009), CXCL10 (Brightling, Ammit et al. 2005) and CX3CL1 
(El-Shazly, Berger et al. 2006) in ASMC of patients with asthma, the difference in 
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chemokine release and mRNA expression in ASMC between patients with non-
severe and severe asthma has not yet  be investigated. 
 
In this chapter, the effects of TNF-α, IFN-γ, or the combination, on chemokine 
release in ASMC of healthy subjects are examined. The modulating effects of IFN-γ 
on TNFα-mediated chemokine expression are extensively investigated, in terms of 
protein release, mRNA expression and recruitment of the p65 component of NF-κB 
to the gene promoters. Cytokine-induced chemokines are compared between ASMC 
of healthy subjects and patients with non-severe and severe asthma. Finally, 
regulation of p65, in terms of expression, nuclear translocation, and recruitment to 
the gene promoters, is investigated and compared between groups. 
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3.2 Results 
3.2.1 Effect of TNF-α and IFN-γ on chemokine expression in ASMC 
3.2.1.1 Effect of TNF-α and IFN-γ on CCL11 release 
To investigate the regulatory effect of TNF-α and IFN-γ on CCL11 release, ASMC of 
healthy subjects were stimulated with TNF-α (1, 3, 10, 30, 100 ng/mL) or IFN-γ (1, 10, 
100 ng/mL) alone or in combination. Supernatants were collected 24 hours later, and 
CCL11 measured by ELISA. ASMC constitutively released CCL11 (266 ± 89 pg/mL); 
this was further induced by TNF-α in a concentration-dependent manner, with 
maximal induction of 2860 ± 542 pg/mL by TNF-α at 100 ng/mL (Fig. 3.1A; p<0.001 
vs unstimulated). In contrast, CCL11 release was induced to a lesser extent (548 ± 
144 pg/mL, p<0.05 vs unstimulated) by IFN-γ at 1 ng/mL, which was maintained at 
higher concentrations (Fig. 3.1B).  
 
The influence of IFN-γ on TNF-α induced CCL11 release was also investigated. The 
stimulatory effect of TNF-α was suppressed by IFN-γ in a concentration-dependent 
manner, with maximal inhibition of approximately 50% achieved by IFN-γ at 10 
ng/mL (p<0.05 at all concentrations of TNF-α) and maintained at 100 ng/mL (Fig. 
3.1C).
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Figure 3.1. Effect of TNF-α and IFN-γ on CCL11 release in ASMC. ASMC were 
stimulated with (A) TNF-α (1-100 ng/mL), (B) IFN-γ (1-100 ng/mL), or (C) both, for 24 
hours. CCL11 release was measured by ELISA. Bars and points represent mean ± 
SEM of ASMC from 3 healthy subjects. (A, B) * p<0.05, ** p<0.01 vs unstimulated. 
(C) * p<0.05 IFN-γ 100 ng/mL vs TNF-α alone, # p<0.05 IFN-γ 10 ng/mL vs TNF-α 
alone.  
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3.2.1.2 Effect of TNF-α and IFN-γ on CXCL8 release 
To investigate the regulatory effect of TNF-α and IFN-γ on CXCL8 release, ASMC of 
healthy subjects were stimulated with TNF-α (1, 3, 10, 30, 100 ng/mL) or IFN-γ (1, 10, 
100 ng/mL) alone or in combination. Supernatants were collected 24 hours later, and 
CXCL8 measured by ELISA. Baseline CXCL8 release was below the limit of 
detection of ELISA (< 31.25 pg/mL), while it was induced by TNF-α in a 
concentration-dependent manner, with maximal induction of 4502 ± 743 pg/mL by 
TNF-α at 100 ng/mL (Fig. 3.2A; p<0.01). In contrast, treatment with IFN-γ did not 
induce CXCL8 release (Fig. 3.2B).  
 
The influence of IFN-γ on TNF-α induced CXCL8 release was also investigated. The 
stimulatory effect of TNF-α was suppressed by IFN-γ in a concentration-dependent 
manner, with maximal inhibition of approximately 30% achieved with IFN-γ at 100 
ng/mL (Fig. 3.2C; p<0.01 vs TNF-α alone). 
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Figure 3.2. Effect of TNF-α and IFN-γ on CXCL8 release in ASMC. ASMC were 
stimulated with (A) TNF-α (1-100 ng/mL), (B) IFN-γ (1-100 ng/mL), or (C) both, for 24 
hours. CXCL8 release was measured by ELISA. Bars and points represent mean ± 
SEM of ASMC from 3 healthy subjects. (A) * p<0.05, ** p<0.01 vs unstimulated. (C) 
** p<0.01 vs TNF-α alone. 
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3.2.1.3 Effect of TNF-α and IFN-γ on CXCL10 release 
To investigate the regulatory effect of TNF-α and IFN-γ on CXCL10 release, ASMC 
of healthy subjects were stimulated with TNF-α (1, 3, 10, 30, 100 ng/mL) or IFN-γ (1, 
10, 100 ng/mL) alone or in combination. Supernatants were collected after 24 hours, 
and CXCL10 was measured by ELISA. CXCL10 release was below the limit of 
detection (<31.25 pg/mL) at baseline but was induced by TNF-α in a concentration-
dependent manner, with maximal release reached at 10 ng/mL (6.3 ± 1.5 ng/mL; 
p<0.001 vs unstimulated) and maintained at higher concentrations (Fig. 3.3A). In 
contrast, CXCL10 was induced to a lesser extent by IFN-γ in a concentration-
dependent manner, maximally 2.0 ± 0.7 ng/mL with IFN-γ at 100 ng/mL (Fig. 3.3B; 
p<0.05 vs unstimulated).  
 
The influence of IFN-γ on TNFα-induced CXCL10 release was also investigated. In 
contrast to the effect seen in terms of regulating CCL11 and CXCL8 release, the 
stimulatory effect of TNF-α on CXCL10 was potentiated by IFN-γ in a concentration-
dependent manner, with approximately 18-fold potentiation by IFN-γ at 100 ng/mL 
(Fig. 3.3C). 
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Figure 3.3. Effect of TNF-α and IFN-γ on CXCL10 release in ASMC. ASMC were 
stimulated with (A) TNF-α (1-100 ng/mL), (B) IFN-γ (1-100 ng/mL), or (C) both, for 24 
hours. CXCL10 release was measured by ELISA. Bars and points represent mean ± 
SEM of ASMC from 3 healthy subjects. (A, B) * p<0.05, ** p<0.01, *** p<0.001 vs 
unstimulated. (C) * p<0.05, ** p<0.01, *** p<0.001 vs TNF-α alone. 
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3.2.1.4 Effect of TNF-α and IFN-γ on CX3CL1 release 
To investigate the regulatory effect of TNF-α and IFN-γ on CX3CL1 release, ASMC 
of healthy subjects were stimulated with TNF-α (1, 3, 10, 30, 100 ng/mL) or IFN-γ (1, 
10, 100 ng/mL) alone or in combination. Supernatants were collected after 24 hours, 
and CX3CL1 measured by ELISA. In contrast to the effect seen in terms of 
regulation of CCL11, CXCL8 and CXCL10 release, neither TNF-α nor IFN-γ induced 
CX3CL1 (Fig. 3.4A and B).  However, under combination of TNF-α and IFN-γ there 
was a concentration-dependent increase in CX3CL1 release, with a maximum of 
1508 ± 357 pg/mL induced by TNF-α and IFN-γ at 10 ng/mL each (Fig. 3.4C; p<0.01 
vs unstimulated), suggesting that TNF-α and IFN-γ synergistically induce CX3CL1 
release. 
 
This synergy was better displayed by a concentration response curve. CX3CL1 was 
not induced by TNF-α alone. In the presence of IFN-γ, TNF-α induced CX3CL1 
release in a concentration-dependent manner; the synergistic effect of IFN-γ was 
also concentration-dependent (Fig. 3.4D; p<0.05 and p<0.01 at IFN-γ 10 ng/mL and 
100 ng/mL, respectively). 
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Figure 3.4. Effect of TNF-α and IFN-γ on CX3CL1 release in ASMC. Cells were 
stimulated with (A) TNF-α (1-100 ng/mL), (B) IFN-γ (1-100 ng/mL), or (C, D) both, for 
24 hours. CX3CL1 release was measured by ELISA. Bars and points represent 
mean ± SEM of ASMC from 3 healthy subjects. (C) ** p<0.01 vs unstimulated. (D)    
* p<0.05, ** p<0.01 vs TNF-α alone. 
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3.2.1.5 Effect of IFN-γ on TNFα-induced CCL11 in ASMC of healthy subjects 
and patients with non-severe and severe asthma 
Having shown that IFN-γ inhibits TNFα-induced CCL11 (3.3.1.1), an investigation 
was undertaken to determine whether this suppressive effect occurs at the level of 
mRNA and in ASMC of patients with asthma. ASMC were stimulated with TNF-α (10 
ng/mL) or IFN-γ (10 ng/mL) alone or in combination for 24 hours. CCL11 release in 
supernatants and mRNA extracted from cell lysates were measured by ELISA and 
RT-qPCR, respectively. TNFα induced CCL11 release was suppressed by over 50% 
by IFN-γ. This effect was observed in ASMC of healthy subjects (Fig. 3.5A) as well 
as patients with non-severe (Fig. 3.5B) and severe asthma (Fig. 3.5C). RT-qPCR 
revealed a more pronounced suppressive effect of IFN-γ on TNFα-induced CCL11 
mRNA, in ASMC, by over 80%, of healthy subjects (Fig. 3.6A) and patients with non-
severe (Fig. 3.6B) and severe asthma (Fig. 3.6C). 
 
3.2.1.6 Effect of IFN-γ on TNFα-induced CXCL8 in ASMC of healthy subjects 
and patients with non-severe and severe asthma 
ASMC were stimulated with TNF-α (10 ng/mL) or IFN-γ (10 ng/mL) alone or in 
combination for 24 hours. CXCL8 release in supernatants and mRNA extracted from 
cell lysates were measured by ELISA and RT-qPCR, respectively. CXCL8 release 
induced by TNF-α was not altered by IFN-γ at 10 ng/mL. This effect was consistent 
in ASMC of the healthy (Fig. 3.7A) and patients with non-severe (Fig. 3.7B) and 
severe asthma (Fig. 3.7C). RT-qPCR also revealed that induced CXCL8 mRNA was 
not influenced by IFN-γ in ASMC of healthy subjects (Fig. 3.8A) and patients with 
non-severe (Fig. 3.8B) and severe asthma (Fig. 3.8C). 
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Figure 3.5. Effect of IFN-γ on TNFα-induced CCL11 release in ASMC of healthy 
subjects and patients with non-severe and severe asthma. Cells were stimulated 
with TNF-α (10 ng/mL) and/or IFN-γ (10 ng/mL) for 24 hours. CCL11 release from 
ASMC of the (A) healthy and patients with (B) non-severe and (C) severe asthma 
was measured by ELISA. Bars represent mean ± SEM. * p<0.05, *** p<0.001. 
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Figure 3.6. Effect of IFN-γ on TNFα-induced CCL11 mRNA expression in ASMC 
of healthy subjects and patients with non-severe and severe asthma. Cells 
were stimulated with TNF-α (10 ng/mL) and/or IFN-γ (10 ng/mL) for 24 hours. CCL11 
mRNA and 18S from ASMC of the (A) healthy subjects and patients with (B) non-
severe  and (C) severe asthma were measured by RT-qPCR. Bars represent mean ± 
SEM. * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 3.7. Effect of IFN-γ on TNFα-induced CXCL8 release in ASMC of healthy 
subjects and patients with non-severe and severe asthma. Cells were stimulated 
with TNF-α (10 ng/mL) and/or IFN-γ (10 ng/mL) for 24 hours. CXCL8 release from 
ASMC of the (A) healthy and patients with (B) non-severe and (C) severe asthma 
was measured by ELISA. Bars represent mean ± SEM. ** p<0.01, *** p<0.001. 
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Figure 3.8. Effect of IFN-γ on TNFα-induced CXCL8 mRNA expression in ASMC 
of healthy subjects and patients with non-severe and severe asthma. Cells 
were stimulated with TNF-α (10 ng/mL) and/or IFN-γ (10 ng/mL) for 24 hours. 
CXCL8 mRNA and 18S from ASMC of the (A) healthy and patients with (B) non-
severe and (C) severe asthma were measured by RT-qPCR. Bars represent mean ± 
SEM. *** p<0.001. 
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3.2.1.7 Effect of IFN-γ on TNFα-induced CXCL10 in ASMC of the healthy 
subjects and patients with non-severe and severe asthma 
Having shown that either TNF-α or IFN-γ alone induces CXCL10 release in ASMC of 
healthy subjects, and that the combination has a synergistic effect (3.3.1.3), an 
investigation was undertaken to determine whether this effect is present in ASMC of 
patients with asthma. Cells were stimulated with TNF-α (10 ng/mL) or IFN-γ (10 
ng/mL) alone or in combination. Supernatants were collected after 24 hours, and 
CXCL10 measured by ELISA. TNF-α and IFN-γ, to a lesser extent, induced CXCL10 
release, while in combination there was nearly 10-fold greater induction compared to 
TNF-α alone. This effect was observed in ASMC of healthy subjects (Fig. 3.9A) and 
patients with non-severe (Fig. 3.9B) and severe asthma (Fig. 3.9C). 
 
3.2.1.8 Effect of TNF-α and IFN-γ on CX3CL1 in ASMC of the healthy subjects 
and patients with non-severe and severe asthma 
Having shown that TNF-α and IFN-γ synergistically induce CX3CL1 release in ASMC 
of healthy subjects, an investigated was undertaken to determine whether this effect 
also occurs at the mRNA level and in ASMC of asthmatic subjects. Cells were 
stimulated with TNF-α (10 ng/mL) or IFN-γ (10 ng/mL) alone or in combination for 24 
hours. CX3CL1 release in supernatants and mRNA extracted from cell lysates were 
measured by ELISA and RT-qPCR, respectively. Neither TNF-α nor IFN-γ alone 
significantly induced CX3CL1 release. The induction was only seen with a 
combination of these cytokines. This effect was consistent in ASMC of healthy 
subjects (Fig. 3.10A) and patients with non-severe (Fig. 3.10B) and severe asthma 
(Fig. 3.10C). RT-qPCR revealed a similar effect in ASMC of healthy subjects (Fig. 
3.11A) and patients with non-severe (Fig. 3.11B) and severe asthma (Fig. 3.11C). 
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Figure 3.9. Effect of IFN-γ on TNFα-induced CXCL10 release in ASMC of 
healthy subjects and patients with non-severe and severe asthma. Cells were 
stimulated with TNF-α (10 ng/mL) and/or IFN-γ (10 ng/mL) for 24 hours. CXCL10 
release from ASMC of the (A) healthy and patients with (B) non-severe and (C) 
severe asthma was measured by ELISA. Bars represent mean ± SEM. * p<0.05,     
** p<0.01 *** p<0.001 vs unstimulated. 
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Figure 3.10. Effect of TNF-α and IFN-γ on CX3CL1 release in ASMC of healthy 
subjects and patients with non-severe and severe asthma. Cells were stimulated 
with TNF-α (10 ng/mL) and/or IFN-γ (10 ng/mL) for 24 hours. CX3CL1 release from 
ASMC of the (A) healthy and patients with (B) non-severe and (C) severe asthma 
was measured by ELISA. Bars represent mean ± SEM. ** p<0.01, *** p<0.001. 
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Figure 3.11. Effect of TNF-α and IFN-γ on CX3CL1 mRNA expression in ASMC 
of healthy subjects and patients with non-severe and severe asthma. Cells 
were stimulated with TNF-α (10 ng/mL) and/or IFN-γ (10 ng/mL) for 24 hours. 
CX3CL1 mRNA and 18S from ASMC of the (A) healthy (A) and patients with (B) 
non-severe and (C) severe asthma were measured by RT-qPCR. Bars represent 
mean ± SEM. ** p<0.01, *** p<0.001. 
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3.2.1.9 Effect of TNF-α on recruitment of NF-κB (p65) to the promoter of CCL11 
in ASMC 
As TNFα-induced CCL11 expression is NFκB-dependent, which includes recruitment 
of the p65 component of NF-κB to the gene promoter (described in 3.1), a time-
course effect of TNF-α on p65 recruitment was examined before comparison 
between groups was undertaken. ASMC of healthy subjects were stimulated with 
TNF-α (10 ng/mL) for 30-240 minutes. p65 binding to the promoter of CCL11 was 
measured by ChIP assay. TNF-α induced recruitment of p65 to the CCL11 promoter 
in a time-dependent manner, with a maximal 13-fold increase over baseline 
occurring at 60 minutes, which then decreased over time (Fig. 3.12). 
Figure 3.12. Effect TNF-α on p65 NF-κB recruitment to the CCL11 promoter in 
ASMC. Cells were stimulated with TNF-α (10 ng/mL) for time indicated. p65 
recruitment to CCL11 promoter was measured by ChIP assay. Bars represent mean 
of ASMC from 2 healthy subjects.  
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3.2.1.10 Effect of TNF-α on recruitment of NF-κB (p65) to the promoter of 
CXCL8 in ASMC 
As TNFα-induced CXCL8 expression is NFκB-dependent through recruitment of the 
p65 to the gene promoter (described in 3.1), a time-course effect of TNF-α on p65 
recruitment to the CXCL8 promoter was examined before comparison between 
groups was undertaken. ASMC of healthy subjects were stimulated with TNF-α (10 
ng/mL) for 30-240 minutes. p65 binding to the promoter of CXCL8 was measured by 
ChIP assay. TNF-α induced p65 recruitment to the CXCL8 promoter in a time-
dependent manner, with a maximal 6.2-fold increase over baseline occurring at 60 
minutes, which then decreased over time (Fig. 3.13).   
Figure 3.13. Effect TNF-α on p65 NF-κB recruitment to the CXCL8 promoter in 
ASMC.  Cells were stimulated with TNF-α (10 ng/mL) for time indicated. p65 
recruitment to CXCL8 promoter was measured by ChIP assay. Bars represent mean 
of ASMC from 2 healthy subjects.  
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3.2.1.11 Effect of TNF-α and IFN-γ on recruitment of NF-κB (p65) to the 
promoter of CX3CL1 in ASMC 
To investigate the effect of TNF-α and IFN-γ on recruitment of p65 to the CX3CL1 
promoter, ASMC of healthy subjects were stimulated with TNF-α alone or in 
combination with IFN-γ (10 ng/mL each) for 30-120 minutes. p65 binding to the 
promoters of CX3CL1 was measured by ChIP assay. TNF-α induced p65 recruitment 
to the CX3CL1 promoter in a time-dependent manner, with a maximal increase of 
3.4-fold increase over baseline occurring at 60 minutes, which then decreased over 
time. IFN-γ did not modulate p65 recruitment induced by TNF-α (Fig. 3.14).  
 
Figure 3.14. Effect TNF-α and IFN-γ on p65 NF-κB recruitment to the CX3CL1 
promoter in ASMC. Cells were stimulated with TNF-α (10 ng/mL) or combined TNF-
α and IFN-γ (10 ng/mL each) for indicated time. p65 recruitment to the CX3CL1 
promoter was measured by ChIP assay. Bars represent mean of ASMC from 2 
healthy subjects. 
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3.2.1.12 Effect of IFN-γ on TNFα-induced p65 recruitment to the CCL11 
promoter in ASMC of healthy subjects and patients and non-severe and severe 
asthma 
Given the observation that IFN-γ inhibited CCL11 release and mRNA expression 
induced by TNF-α (3.3.1.1 and 3.3.1.5), an investigation into the effect of IFN-γ on 
TNFα-induced p65 recruitment to the CCL11 promoter was undertaken. ASMC were 
stimulated with TNF-α (10 ng/mL) or IFN-γ (10 ng/mL) alone or in combination for 
one hour. p65 recruitment to the CCL11 promoter was measured by ChIP assay. 
TNF-α, but not IFN-γ, induced p65 recruitment to the CCL11 promoter, and this 
induction was partially suppressed by IFN-γ. These effects were consistent in ASMC 
of the healthy (Fig. 3.15A) as well as patients with non-severe (Fig. 3.15B) and 
severe asthma (Fig. 3.15C). 
 
3.2.1.13 Effect of IFN-γ on TNFα-induced p65 recruitment to the CXCL8 
promoter in ASMC of healthy subjects and patients and non-severe and severe 
asthma 
Given the observation that IFN-γ inhibited CXCL8 release induced by TNF-α 
(3.3.1.2), the effect of IFN-γ on TNFα-induced p65 recruitment to the CXCL8 
promoter was investigated. ASMC were stimulated with TNF-α (10 ng/mL) or IFN-γ 
(10 ng/mL) alone or in combination for one hour. p65 recruitment to the CXCL8 
promoter was measured by ChIP assay. TNF-α but not IFN-γ induced p65 
recruitment to the CXCL8 promoter, and this induction was partially inhibited by IFN-
γ. These effects were consistent in ASMC of the healthy (Fig. 3.16A) as well as 
patients with non-severe (Fig. 3.16B) and severe asthma (Fig. 3.16C). 
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Figure 3.15. Effect of IFN-γ on TNFα-induced p65 recruitment to the CCL11 
promoter in ASMC. Cells were stimulated with TNF-α (10 ng/mL), IFN-γ (10 ng/mL), 
or both for one hour. p65 recruitment to CCL11 promoter in ASMC of the (A) healthy 
and patient with (B) non-severe and (C) severe asthma was measured by ChIP 
assay. Bars represent mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 3.16. Effect of IFN-γ on TNFα-induced p65 recruitment to the CXCL8 
promoter in ASMC. Cells were stimulated with TNF-α (10 ng/mL), IFN-γ (10 ng/mL), 
or both for one hour. p65 recruitment to the CXCL8 promoter in ASMC of the (A) 
healthy and patients with (B) non-severe and (C) severe asthma was measured by 
ChIP assay. Bars represent mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001. 
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3.2.1.14 Effect of IFN-γ on TNFα-induced p65 recruitment to CX3CL1 promoter 
in ASMC of healthy subjects and patients and non-severe and severe asthma 
Given the observation that TNF-α and IFN-γ synergistically induced CX3CL1 release 
and mRNA expression, the effect of IFN-γ on TNFα-induced p65 recruitment to the 
CX3CL1 promoter was investigated. ASMC were stimulated with TNF-α (10 ng/mL), 
IFN-γ (10 ng/mL), alone or in combination, for one hour. p65 recruitment to the 
CX3CL1 promoter was measured by ChIP assay. TNF-α, but not IFN-γ, induced p65 
recruitment to the CX3CL1 promoter, and IFN-γ did not modulate TNFα-induced p65 
recruitment. These effects were consistent in ASMC of the healthy (Fig. 3.17A) as 
well as patients with non-severe (Fig. 3.17B) and severe asthma (Fig. 3.17C). 
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Figure 3.17. Effect of IFN-γ on TNFα-induced p65 recruitment to the CX3CL1 
promoter in ASMC. Cells were stimulated with TNF-α (10 ng/mL), IFN-γ (10 ng/mL), 
or both for one hour. p65 recruitment to the CX3CL1 promoter in ASMC of the 
healthy (A) and patients with non-severe (B) and severe asthma (C) was measured 
by ChIP assay. Bars represent mean ± SEM. *** p<0.001. 
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3.2.2 Comparison of cytokine-induced chemokine release and mRNA 
expression in ASMC of healthy subjects and patients with non-severe and 
severe asthma 
3.2.2.1 Comparison of TNFα-induced CCL11 in ASMC of healthy subjects and 
patients with non-severe and severe asthma 
Baseline and induced CCL11 release and mRNA expression from ASMC of the 
healthy and patients with non-severe and severe asthma were compared. Cells were 
stimulated with TNF-α (10 ng/mL) for 24 hours. CCL11 release and mRNA 
expression was measured by ELISA and RT-qPCR, respectively. Baseline CCL11 
release from ASMC of patients with non-severe asthma was 4.4-fold greater than 
that of healthy subjects (p<0.01) and 6.6-fold greater than that of patients with 
severe asthma (p<0.01). In addition, TNFα-induced CCL11 release from ASMC of 
patients with non-severe asthma was 2.5-fold greater than that of healthy subjects 
(p<0.01) and 3.1-fold greater than that of patients with severe asthma. There was no 
significant difference in either baseline or induced CCL11 release between the 
healthy and severe asthmatics (Fig.18A).  
 
RT-qPCR revealed a similar effect: both baseline and induced CCL11 mRNA 
expression from ASMC of non-severe asthma was greater than that of healthy 
subjects and patients with severe asthma. No significant difference in either baseline 
or induced CCL11 mRNA was observed between the healthy and patients with 
severe asthma (Fig.18B).  
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Figure 3.18. Comparison of TNFα-induced CCL11 in ASMC of healthy subjects 
and patients with non-severe and severe asthma. ASMC were stimulated with 
TNF-α (10 ng/mL) for 24 hours. CCL11 (A) release and (B) mRNA expression were 
measured by ELISA and RT-qPCR, respectively. Horizontal lines represent median. 
## p<0.01, ### p<0.001 vs unstimulated (US). * p<0.05, ** p<0.01, *** p<0.01. 
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3.2.2.2 Comparison of TNFα-induced CXCL8 in ASMC of healthy subjects and 
patients with non-severe and severe asthma 
Baseline and induced CXCL8 release and mRNA expression from ASMC of the 
healthy and patients with non-severe and severe asthma were compared. Cells were 
stimulated with TNF-α (10 ng/mL) for 24 hours. CXCL8 release and mRNA 
expression was measured by ELISA and RT-qPCR, respectively. While CXCL8 was 
induced by TNF-α in ASMC, neither baseline nor induced CXCL8 release differed 
between three groups (Fig. 3.19A). RT-qPCR revealed a similar effect, with no 
significant difference of baseline or induced CXCL8 mRNA between all groups (Fig. 
3.18B). 
 
3.2.2.3 Comparison of cytokine-induced CXCL10 release in ASMC of healthy 
subjects and patients with non-severe and severe asthma 
Baseline and cytokine-induced CXCL10 release and mRNA expression from ASMC 
of the healthy and patients with non-severe and severe asthma were compared. 
Cells were stimulated with TNF-α (10 ng/mL) or IFN-γ (10 ng/mL) alone or the 
combination (10 ng/mL) for 24 hours. CXCL10 release was measured by ELISA. The 
levels of baseline CXCL10 release were not significantly different between the 
groups. While CXCL10 was induced by either cytokine alone or in combination in all 
the three groups, IFNγ-induced CXCL10 was almost two-fold greater in ASMC of 
patients with severe asthma (1135.0 pg/mL) than those of both healthy subjects 
(556.3 pg/mL) and non-severe asthma (592.6 pg/mL) (p<0.05, respectively) (Fig. 
3.20B). In contrast, there was no difference of CXCL10 release induced by TNF-α 
alone or in combination with IFN-γ in ASMC between the groups (Fig. 3.20 A and C). 
130 
Figure 3.19. Comparison of TNFα-induced CXCL8 in ASMC of healthy subjects 
and patients with non-severe and severe asthma. ASMC were stimulated with 
TNF-α (10 ng/mL) for 24 hours. CXCL8 (A) release and (B) mRNA expression were 
measured by ELISA and RT-qPCR, respectively. Horizontal lines represent median. 
** p<0.01, *** p<0.001 vs unstimulated. 
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Figure 3.20. Comparison of cytokine-induced CXCL10 in ASMC of healthy 
subjects and patients with non-severe and severe asthma. ASMC were 
stimulated with (A) TNF-α (10 ng/mL), (B) IFN-γ (10 ng/mL) alone or (C) in 
combination for 24 hours. CXCL10 release was measured by ELISA. Horizontal lines 
represent median. # p<0.05 ## p<0.01 vs unstimulated. * p<0.05. 
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3.2.2.4 Comparison of TNFα and IFNγ -induced CX3CL1 in ASMC of healthy 
subjects and patients with non-severe and severe asthma 
Baseline and induced CX3CL1 release and mRNA expression from ASMC of the 
healthy and patients with non-severe and severe asthma were compared. Cells were 
stimulated with TNF-α and IFN-γ (10 ng/mL each) for 24 hours. CX3CL1 release and 
mRNA expression was measured by ELISA and RT-qPCR, respectively. While 
CX3CL1 was induced by TNF-α and IFN-γ in combination, neither baseline nor 
induced CX3CL1 release differed between three groups (Fig. 3.21A). q-RT PCR 
revealed a similar effect, with no significant difference of baseline or induced 
CX3CL1 mRNA between all groups   (Fig. 3.21B). 
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Figure 3.21. Comparison of TNFα and IFNγ -induced CX3CL1 in ASMC of 
healthy subjects and patients with non-severe and severe asthma. ASMC were 
stimulated with TNF-α and IFN-γ (10 ng/mL each) for 24 hours. CX3CL1 (A) release 
and (B) mRNA expression were measured by ELISA and RT-qPCR, respectively. 
Horizontal lines represent median. * p<0.05, ** p<0.01, *** p<0.001 vs unstimulated. 
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3.2.3 Investigation and comparison of NF-κB (p65) regulation in ASMC 
3.2.3.1 Comparison of TNFα-induced p65 protein and mRNA expression in 
ASMC of the healthy subjects and patients with non-severe and severe asthma 
To compare p65 expression in response to TNF-α, ASMC of healthy subjects and 
patients with non-severe and severe asthma were stimulated with TNF-α (10 ng/mL) 
for 24 hours. p65 protein in whole cell lysates and mRNA were measured by 
Western Blot and RT-qPCR, respectively. In ASMC of healthy subjects, TNF-α 
slightly, but consistently, induced p65 protein expression by approximately 1.2-fold, 
and there was a trend towards greater p65 induction in cells of patients with severe 
asthma (Fig. 3.22A). This difference was greater at the level of mRNA abundance: in 
ASMC of healthy subjects, p65 mRNA was induced by TNF-α by 2.3-fold, while there 
was a 5.6-fold induction in cells of patients with severe asthma (Fig. 3.22B; p<0.05). 
Figure 3.22. Comparison of induced p65 protein and mRNA expression in 
ASMC of healthy subjects and patients with non-severe and severe asthma. 
Cells were stimulated with TNF-α (10 ng/mL) for 24 hours. p65 (A) protein and (B) 
mRNA expression was measured by Western Blot and RT-qPCR, respectively. 
Horizontal lines represent median. * p<0.05. 
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3.2.3.2 Effect of TNF-α on nuclear translocation of p65 in ASMC 
To determine the effect of TNF-α on p65 nuclear translocation in ASMC, cells of 
healthy subjects were stimulated with TNF-α (10 ng/mL) over a time course (30 
minutes to 2 hours). p65, TBP (TATA box-binding protein) and α-tubulin in the both 
nuclear and cytoplasmic extracts were measured by Western Blot. TNF-α increased 
nuclear abundance of p65 at 30 minutes, which was maintained at one hour and 
decreased slightly at 2 hour post-stimulation (Fig. 3.23A). In contrast, cytoplasmic 
p65 revealed a reciprocal change (Fig. 3.23B). These results confirm that TNF-α 
induces p65 nuclear translocation in ASMC. 
Figure 3.23. Effect of TNF-α on p65 NF-κB nuclear translocation in ASMC. Cells 
were stimulated with TNF-α (10 ng/mL) for time indicated. p65 and TBP in (A) 
nuclear and (B) cytoplasmic extracts were measured by Western Blot. A 
representative blot of ASMC from 2 healthy subjects is shown. 
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3.2.3.3 Comparison of baseline nuclear p65 abundance in ASMC of healthy 
subjects and patients with non-severe and severe asthma 
Baseline nuclear abundance of p65 in ASMC between the three groups was 
compared. After serum starvation for 24 hours, nuclear extracts were collected. p65 
and TBP were measured by Western Blot and normalised to the standard protein 
(described in 2.2.7.1). The quantity of nuclear p65 was consistent between three 
groups (Fig. 3.24). 
Figure 3.24. Comparison of baseline abundance of nuclear p65 in ASMC of 
healthy subjects and patients with non-severe (NSA) and severe asthma (SA). 
Cells were serum starved for 24 hours. p65 and TBP in nuclear extracts were 
measured by Western Blot. A representative is shown. Horizontal lines represent 
median. STD: standard protein. 
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3.2.3.4 Comparison of nuclear translocation of p65 induced by TNF-α in ASMC 
of healthy subjects and patients with non-severe and severe asthma 
To compare nuclear translocation of p65 induced by TNF-α in ASMC, cells were 
stimulated by TNF-α (10 ng/mL) over a time course (30 minutes to 2 hours). p65 and 
TBP in the nuclear extracts were measured by Western Blot. In ASMC of healthy 
subjects, nuclear abundance of p65 was increased by TNF-α compared to baseline 
by approximately 2.5-fold after 30 minutes, sustained at one hour, and decreased 
slightly at 2 hours post-stimulation. This effect was similar in ASMC of patients with 
non-severe and severe asthma (Fig. 3.25). 
Figure 3.25. Comparison of TNFα-induced p65 nuclear translocation in ASMC 
of healthy subjects and patients with non-severe and severe asthma. Cells 
were stimulated with TNF-α (10 ng/mL) for time indicated. p65 and TBP in the 
nuclear extracts were measured by Western Blot. Points represent mean ± SEM. 
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3.2.3.5 Comparison of cytokine-induced p65 recruitment to chemokine 
promoters in ASMC of healthy subjects and patients with non-severe and 
severe asthma 
Given the observation of differential CCL11 expression in ASMC of patients with 
non-severe asthma compared to those of healthy subjects and patients with severe 
asthma (3.3.2.1), p65 recruitment to chemokine promoters was compared. Cells 
were stimulated with either TNF-α (10 ng/mL) for CCL11 and CXCL8 or combined 
TNF-α and IFN-γ (10 ng/mL each) for CX3CL1 for one hour. p65 recruitment to 
chemokine promoters was measured by ChIP assay. Recruitment of p65 to 
promoters of CCL11, CXCL8, or CX3CL1 was not different between three groups 
(Fig. 3.26). 
139 
Figure 3.26. Comparison of cytokine-induced p65 NF-κB recruitment to 
chemokine promoters in ASMC of healthy subjects and patients with non-
severe and severe asthma. ASMC were stimulated with TNF-α (10 ng/mL) for 
CCL11 (A) and CXCL8 (B) or combined TNF-α and IFN-γ (10 ng/mL each) for 
CX3CL1 (C) for one hour. Recruitment of p65 to promoters of chemokines were 
measured by ChIP assay. Horizontal lines represent median.    
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3.3 Discussion 
Summary of results: 
The release of CCL11, CXCL8 and CX3CL10 was induced by TNF-α. IFN-γ 
suppressed the former two TNFα-induced chemokines but potentiated the latter one. 
In contrast, while CX3CL1 was induced by neither TNF-α or IFN-γ alone, it was 
synergistically induced by combination of the two cytokines. These supressing 
effects of IFN-γ were associated with inhibition of the p65 component of NF-κB which 
is recruitmented to the targeted chemokine gene promoters. Additionally, both 
baseline and TNFα-induced CCL11 was greater in ASMC of patients with non-
severe asthma, while CXCL10 induced by IFN-γ, rather than TNF-α alone or in 
combination with IFN-γ, was heightened in those of severe asthma. The p65 
component of NF-κB expression was heightened in ASMC of patients with severe 
asthma, while its nuclear translocation and recruitment to gene promoters were not 
different between groups. 
   
3.3.1 Modulating effect of IFN-γ on TNFα-induced inflammation 
The observations of suppression of TNFα-induced CCL11 and CXCL8 by IFN-γ in 
ASMC (3.3.1.1 and 3.3.1.2) are consistent with literature (Keslacy, Tliba et al. 2007). 
This consistent effect is further confirmed in ASMC of patients with non-severe and 
severe asthma (3.3.1.5). Other reported TNFα-induced inflammatory genes 
suppressed by IFN-γ in ASMC include IL-6 (Keslacy, Tliba et al. 2007), IL-17 
receptor (Lajoie-Kadoch, Joubert et al. 2006), and TLR3 (Sukkar, Xie et al. 2006).  
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It is reported that IFN-γ is an inhibitor of TNFα-induced NF-κB transcriptional activitiy 
in ASMC: IFN-γ suppresses TNFα-induced NF-κB reported activity, and increased 
acetylation of the p65 subunit of NF-κB after TNF-α exposure is attenuated by IFN-γ. 
In addition, trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, partially 
reverses the inhibitory effect of IFN-γ on TNFα-induced genes which are NF-κB 
dependent. (Keslacy, Tliba et al. 2007). As p65 acetylation contributes to NF-κB 
activity (Ishinaga, Jono et al. 2007; Barroso, Eyre et al. 2011), these findings suggest 
that IFN-γ suppresses the expression of some of the TNFα-induced pro-inflammatory 
genes by interfering with NF-κB transcriptional activity, possibly through reducing 
acetylation levels of key regulatory proteins.  
 
TNF-α induces p65 recruitment to the promoters of CCL11 and CXCL8; in addition, 
these recruitments are suppressed by IFN-γ (3.3.1.12 and 3.3.1.13). These 
observations suggest that the suppressive effect of IFN-γ on TNFα-induced 
inflammatory gene expression is at least partially through inhibition of NF-κB 
recruitment to the gene promoters. Of interest, it is reported that TNFα-induced p65 
recruitment of CCL11 in ASMC is also inhibited by fluticasone in association with 
reduced recruitment of acetylated histone H4 (Nie, Knox et al. 2005). Given that the 
anti-inflammatory effect exerted by glucocorticoids is through reversal of histone 
acetylation mediated by HDAC (Barnes 2006), and that the suppressive of IFN-γ on 
TNFα-induced, NF-κB dependent genes is prevented by the HDAC inhibitor (Keslacy, 
Tliba et al. 2007), it is possible that the suppressive effect of IFN-γ and glucocorticoid 
on TNFα-induced CCL11 is through similar mechanisms, such as induction of HDAC 
activity. 
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TNFα-induced CXCL8 release and mRNA expression are not suppressed by IFN-γ 
at 10 ng/mL (3.3.1.6) as the concentration optimisation experiment shows the 
inhibition occurs only with IFN-γ at 100 ng/mL (3.3.1.2). Intriguingly, IFN-γ at 10 
ng/mL still partially inhibits TNFα-induced p65 recruitment to the CXCL8 promoter 
(3.3.1.13). Perhaps this partial suppressive effect of p65 recruitment by IFN-γ at this 
concentration is not sufficient to cause a change at the level of gene transcription.   
 
The synergistic effects of TNF-α and IFN-γ on induction of CXCL10 and CX3CL1 
(3.3.1.3 and 3.3.1.4) in ASMC are consistent with literature (Hardaker, Bacon et al. 
2004; Sukkar, Issa et al. 2004). These effects are further confirmed, extending from 
ASMC of healthy subjects to those of non-severe and severe asthma (3.3.1.7 and 
3.3.1.8). Other pro-inflammatory genes reported which are synergistically induced by 
TNF-α and IFN-γ in ASMC include CCL5 (John, Hirst et al. 1997), CD38 (Tliba, 
Panettieri et al. 2004), or TLR2 and TLR3 (Sukkar, Xie et al. 2006).  
 
The synergistic effect of combined TNF-α and IFN-γ treatment on CXCL10 in ASMC 
is not regulated at the level of NF-κB activation, STAT-1 phosphorylation or in vivo 
recruitment of these transcription factors to the gene promoter. Instead, the synergy 
results from increased recruitment of CBP to the CXCL10 promoter, which is 
associated with increased RNA polymerase II recruitment (Clarke, Clifford et al. 
2010). In contrast, the mechanism of the synergy on CX3CL1 is still not clear and 
need further investigation. 
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In other cell types, TNF-α and IFN-γ collaborate at the gene level by increasing 
promoter activation through a synergistic interaction between NF-κB and STATs 
activated by TNF-α and IFN-γ, respectively. A functional cooperation has been 
demonstrated between NF-κB and STAT1 in the regulation of genes activated by 
these cytokines, including ICAM-1 (Jahnke and Johnson 1995), CCL5 (Ohmori, 
Schreiber et al. 1997), and caspase 11 (Schauvliege, Vanrobaeys et al. 2002). Other 
mechanisms which may account for the synergistic effect of TNF-α and IFN-γ include 
IFNγ-induced up-regulation of TNF-α receptors (Ruggiero, Tavernier et al. 1986; 
Tsujimoto and Vilcek 1986; Kost, Mutch et al. 1999) or vice versa (Sanceau, Merlin 
et al. 1992; Krakauer and Oppenheim 1993). Intriguingly, in ASMC, whereas TNF-α 
induces p65 recruitment to the CX3CL1 promoter, this recruitment is not modulated 
by IFN-γ (3.3.1.11 and 3.3.1.14). This suggests that the synergistic induction of 
CX3CL1 by TNF-α and IFN-γ in ASMC is through mechanism(s) other than the NF-
κB pathway. 
 
In summary, depending on the inflammatory milieu, IFN-γ can antagonize or 
synergize TNFα-induced inflammatory actions in ASMC. The suppressive effect of 
IFN-γ is through inhibition of TNFα-induced p65 to the promoters of specific 
inflammatory genes. Further studies investigating whether STAT1 or CBP plays a 
role in the synergy between these two cytokines will provide further mechanistic 
insights. 
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3.3.2 Differential expression of inflammatory chemokines in ASMC 
CCL11 release and mRNA expression both at baseline and post-stimulation by TNF-
α are elevated in ASMC of patients with non-severe asthma (3.3.2.1). Similarly, 
increased expression of CCL11 induced by IL-1β and IL-13 in ASMC of patients with 
asthma is reported, which is in part mediated by enriched extracellular matrix 
substrates such as fibronectin (Chan, Burgess et al. 2006). Intriguingly, the greater 
CCL11 expression exists in ASMC of patients with non-severe but not severe 
asthma (3.3.2.1). CCL11 is a potent chmoattractant for eosinophils and hence 
contributes to eosinophilic inflammation in diseased tissue. Investigation into 
differential inflammatory phenotypes of the airways of severe asthma has been 
inconclusive. One study reports a higher concentration of eosinophils in BAL fluid in 
the patients with moderate asthma, while there is very little difference between 
normal controls and patients with severe asthma (Wenzel, Szefler et al. 1997). My 
results suggest a possible mechanism accounting for this differential eosinophil 
count between groups.   
 
The results showing no difference in CXCL8 expression in any of the groups (3.2.2.2) 
are not consistent with the literature, which demonstrates elevated CXCL8 
expression in ASMC of patients with asthma compared to those of healthy subjects 
(John, Zhu et al. 2009). The induced CXCL8 release from healthy and asthmatic 
subjects described by John et al is 10,000 and 40,000 pg/mL, respectively, which is 
2.5-10 fold greater levels compared to my results when the cells are treated with 
TNF-α at the same concentration and duration. Possible explanations include 
different manipulation or different passages of the cells for experiment. 
145 
 
It has been recognised that neutrophilic inflammation in the airway is a feature of 
severe asthma (Wenzel, Szefler et al. 1997; Shannon, Ernst et al. 2008) although 
the neutrophil count is not different in the bronchial biopsies of patients with non-
severe or severe asthma (Macedo, Hew et al. 2009). Given that CXCL8 is a potent 
chemoattractant for neutrophils, it is rational to suggest that this chemokine release 
may be increased from ASMC of patients with severe asthma. However, the reuslts 
reveal no difference in CXCL8 release or mRNA expression in ASMC between the 
groups (3.2.2.2). This indicates that in contrast to epithelial and subepithelial cells, 
where higher CXCL8 is expressed (Shannon, Ernst et al. 2008), ASMC may not be 
the cells which contribute to neutrophilic inflammation in severe asthma. 
 
Comparison of cytokine-induced CXCL10 in ASMC of healthy subjects and patients 
with asthma in literature is inconsistent: while increased CXCL10 release induced by 
Cytomix (combination of TNF-α, IL-1β and IFN-γ) is displayed in ASMC of patients 
with asthma (Brightling, Ammit et al. 2005), conflicting results of release and mRNA 
expression of CXCL10 induced by each of these cytokines individually are reported 
(Alrashdan, Alkhouri et al. 2012). My results reveal ASMC of patients with severe 
asthma release greater CXCL10 after exposure to IFN-γ, rather than TNF-α alone or 
in combination with IFN-γ, compared to those of healthy subjects and non-severe 
asthma (3.2.2.3). Increased serum CXCL10 levels are predictive of virus-induced 
asthma and strongly associated with more severe airway obstruction (Wark, 
Bucchieri et al. 2007), and the CXCL10/CXCR3 axis mediates mast cell migration to 
ASMC of patients with asthma (Brightling, Ammit et al. 2005), which is a major 
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determinant of asthma. Hence, in severe asthma, perhaps especially in response to 
viral infection, the interaction between ASMC-derived CXCL10 and mast cell–
expressing CXCR3 may be an important pathway facilitating the migration of mast 
cells into the airway smooth muscle bundles. 
 
Although immunohistochemistry in airways in literature reveals increased staining of 
CX3CL1 in airway smooth muscle of asthma patients compared to that of healthy 
subjects (El-Shazly, Berger et al. 2006), there is no difference in TNFα and IFNγ -
induced CX3CL1 release from ASMC between healthy subjects and patients with 
non-severe or severe asthma. This suggests the greater expression of membrane-
bound CX3CL1 does not result in increased release of cytokine-induced of this 
chemokine in the soluble form. 
 
3.3.3 Regulation and differential expression of NF-κB (p65) in ASMC 
There have been several lines of evidence to indicate enhanced NF-κB signalling in 
tissues of asthma, especially of severe asthma (Edwards, Bartlett et al. 2009). For 
example, PBMC of adult severe uncontrolled asthma display higher expression of 
p65 and IKK-β proteins and greater p65-DNA binding affinity than normal individuals 
(Gagliardo, Chanez et al. 2003).  Nevertheless, expression of each NFκB-mediated 
gene is differentially regulated, depending on the intracellular milieu and related 
signalling pathways, and may not be influenced equally by overall heightened NF-κB 
activity in diseased cells or tissue. Hence, investigation of targeted inflammatory 
genes individually, by techniques such as ChIP assay, which examines the 
recruitment of transcription factors to the specific gene promoter, is necessary.  
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The observations of increased p65 protein and mRNA in ASMC of patients with 
severe asthma (3.2.3.1) are an extension of increased NF-κB expression in other 
human cells, such as PBMC (Gagliardo, Chanez et al. 2003) and peripheral 
(Abdulamir, Kadhim et al. 2009) and BAL lymphocytes (Abdulamir, Hafidh et al. 
2009). Whereas CXCL10 release induced by IFN-γ is increased in ASMC of severe 
asthma (3.2.2.3), this is less likely to be attributed to greater p65 expression as IFN-γ 
only causes transient nuclear translocation of p65 and does not induce p65 
recruitment to the CXCL10 promoter (Clarke, Clifford et al. 2010). In addition, despite 
increased p65 expression in severe asthma, the nuclear abundance of this protein 
was not different between groups (3.2.3.3) and TNF-α induced p65 nuclear 
translocation was similar in ASMC of healthy subjects and patients with non-severe 
and severe asthma (3.2.3.4). This is in contrast to the findings of increased or rapid 
nuclear translocation of p65 in human PBMC (Tomari, Matsuse et al. 2003) or 
murine bronchial epithelium of asthma (Poynter, Irvin et al. 2002), respectively. 
Therefore, the differential regulation of NF-κB signalling pathway in healthy and 
asthmatic subjects may be organism or cell –specific. 
  
Although the release and mRNA expression of CCL11 is increased in ASMC of 
patients with non-severe asthma (3.2.2.1), there is no difference in p65 recruitment 
to the CCL11 promoter between the groups. Therefore, the mechanism which 
underlies differential expression of CCL11 is uncertain and needs further 
investigation. Post-translational modification of transcription factors, by 
phosphorylation, methylation or acetylation may affect catalytic activity, stability, 
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trafficking and protein-protein interactions such as co-factor recruitment (Shen, 
Kirmani et al. 2011). For example, serine 276 on p65 is a substrate for p38α (Ji, Liu 
et al. 2010), and phosphorylation of serine 276, while not interfering with 
translocation or DNA-binding affinity, may be essential for transcriptional activity 
(Okazaki, Sakon et al. 2003). Thus, it could be the phosphorylation status of p65 
bound to each promoter that influences the ability of this transcription factor to 
induce gene transcription.   
 
In summary, depending on the inflammatory milieu, there is differential expression of 
inflammatory chemokines in ASMC of patients with asthma. This is not attributed to 
differential expression of p65 or altered recruitment to the gene promoters. Further 
investigation is required to determine the underlying mechanism. 
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Chapter 4. Corticosteroid responsiveness of ASMC of healthy subjects and 
patients with non-severe and severe asthma 
4.1 Introduction 
Corticosteroids are the mainstay treatment of asthma. They are effective in 
improving asthma symptoms, pulmonary function and result in reduction of the need 
for short-acting β2-agonist as well as airway hyper-responsiveness (Barnes 2006). 
However, patients with severe asthma are either barely maintained or even not well 
controlled despite administration of high-dose corticosteroids (Bousquet, 
Mantzouranis et al. 2010). The clinical feature of these patients is relatively reduced 
effect of corticosteroids to control the symptoms of their asthma, suggestive of the 
presence of corticosteroid insensitivity in severe asthma. 
 
In PBMC (Hew, Bhavsar et al. 2006) and alveolar macrophages (Bhavsar, Hew et al. 
2008), the effect of corticosteroids is impaired in terms of suppressing induced 
cytokines in patients with severe asthma compared to those with non-severe asthma. 
It is unclear whether ASMC display a similar phenotype. It is also unknown if the 
response to corticosteroids is different in ASMC between healthy subjects and 
patients with asthma in terms of suppressing or potentiating inflammatory 
chemokines. 
 
IFN-γ acts a pleiotropic cytokine in ASMC. In addition to its ability to induce 
chemokines such as CXCL10, IFN-γ modulates, in terms of either suppression or 
potentiation, the cytokine-induced chemokines, as shown in the previous chapter. 
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Furthermore, IFN-γ influences the effect of corticosteroids. In ASMC, IFN-γ impairs 
the suppressive effect of corticosteroids on TNFα-induced pro-asthmatic genes, such 
as CD38 (Tliba, Cidlowski et al. 2006), CCL5 and CXCL10 (Banerjee, Damera et al. 
2008). It is uncertain how this cytokine impacts on other asthma-related chemokines, 
such as CCL11 and CXCL8, and whether there is any difference in the modulating 
effects of IFN-γ in ASMC between healthy and asthmatic subjects. 
 
In this chapter, the effects of dexamethasone on suppression (CCL11, CXCL8 and 
CXCL10) or potentiation (CX3CL1) of chemokine expression are compared between 
ASMC of healthy subjects and patients with non-severe and severe asthma, at the 
level of both protein release and mRNA expression. The effects of IFN-γ on the 
suppressive effect of dexamethasone on the former chemokines are investigated, 
followed by comparison of the effects between groups.  
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4.2 Results 
4.2.1 Effect of dexamethasone on cell number and viability of ASMC 
To investigate whether the effect of dexamethasone on chemokine modulation in 
ASMC is confounded by altered cell numbers, cells were pretreated with 
dexamethasone at 10-10-10-6 M for 2 hours and subsequently stimulated with TNF-α 
and/or  IFN-γ (10 ng/mL each) for 24 hours. Cell numbers were unchanged with 
exposure to different concentrations of dexamethasone (10-8 or 10-6 M) in the 
absence or presence of TNF-α and IFN-γ (Fig. 4.1A). 
 
Cell viability was also determined by MTT assay. Compared to its absence, 
dexamethasone at different concentrations (10-10–10-6 M) did not significantly 
influence the MTT signal, regardless of treatment with TNF-α 10 ng/mL or combined 
TNF-α and IFN-γ at 10 ng/mL each (Fig. 4.1B). 
Figure 4.1. Effect of dexamethasone, TNF-α, and IFN-γ on cell number and 
viability of ASMC. (A) ASMC were pretreated with dexamethasone (10-8 or 10-6 M) 
for 2 hrs and stimulated with combined TNF-α and IFN-γ (10 ng/mL each) for 24 hrs. 
(B) ASMC were pretreated with dexamethasone (10-10-10-6 M) for 2 hrs and 
stimulated with TNF-α (10 ng/mL) or combined TNF-α and IFN-γ (T+I; 10 ng/mL 
each) for 24 hrs. Bars represent mean ± SEM of ASMC from 3 healthy subjects. 
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4.2.2 Comparison of the corticosteroid response in ASMC of healthy subjects 
and patients with non-severe and severe asthma 
4.2.2.1 Comparison of the suppressive effect of dexamethasone on CCL11 
release 
To compare the effect of corticosteroid in terms of suppressing CCL11 release, 
ASMC were pretreated with dexamethasone (10-10-10-6 M) for 2 hours, followed by 
stimulation with TNF-α (10 ng/mL) for 24 hours. CCL11 was measured by ELISA. In 
ASMC of the healthy and patients with non-severe asthma, dexamethasone inhibited 
induced CCL11 release in a concentration-dependent manner, with maximal 
dexamethasone mediated-suppression of CCL11 at 10-6 M by 45.2% and 49.56%, 
respectively. In contrast, the concentration response curve for dexamethasone in 
ASMC of patients with severe asthma was less marked, where dexamethasone at 
10-6 M suppressed induced CCL11 release by merely 20.31%. The suppressive 
effect of dexamethasone at 10-7 and 10-6 M in patients with severe asthma was 
significantly less than observed in the healthy and patients with non-severe 
asthmatics (Fig. 4.2; p<0.05, respectively). 
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Figure 4.2. Comparison of the suppressive effect of dexamethasone on CCL11 
release in ASMC of healthy subjects and patients with non-severe and severe 
asthma. ASMC were pretreated with dexamethasone (10-10-10-6 M) for 2 hours and 
stimulated with TNF-α (10 ng/mL) for 24 hours. CCL11 release was measured by 
ELISA. Points represent mean ± SEM. * p<0.05 vs healthy subjects. # p<0.05 vs 
patients with non-severe asthma. 
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4.2.2.2 Comparison of the suppressive effect of dexamethasone on CXCL8 
release 
To compare the effect of corticosteroid in terms of suppressing CXCL8 release, 
ASMC were pretreated with dexamethasone (10-10-10-6 M) for 2 hours, followed by 
stimulation with TNF-α (10 ng/mL) for 24 hours. CXCL8 was measured by ELISA.  In 
ASMC of healthy subjects, dexamethasone at 10-6 M suppressed TNFα-induced 
CXCL8 release by 49.8%. At this concentration, dexamethasone inhibited induced 
CXCL8 release in ASMC of patients with non-severe and severe asthma by, to a 
lesser extent, 39.9% and 25.7%, respectively. The difference in dexamethasone 
response between the cells of the healthy subjects and patients with severe asthma 
was statistically significant over a range of dexamethasone concentrations (Fig. 4.3; 
p<0.05 at 10-8 and 10-7 M, p<0.01 at 10-6 M, respectively). 
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Figure 4.3. Comparison of the suppressive effect of dexamethasone on CXCL8 
release in ASMC of healthy subjects and patients with non-severe and severe 
asthma. ASMC were pretreated with dexamethasone (10-10-10-6 M) for 2 hours and 
stimulated with TNF-α (10 ng/mL) for 24 hours. CXCL8 release was measured by 
ELISA. Points represent mean ± SEM. * p<0.05, ** p<0.01 vs healthy subjects. 
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4.2.2.3 Comparison of the suppressive effect of dexamethasone on CXCL10 
release 
To compare the effect of corticosteroid in terms of suppressing CX3CL1 release, 
ASMC were pretreated with dexamethasone (10-10-10-6 M) for 2 hours, followed by 
stimulation with TNF-α (10 ng/mL) for 24 hours. CXCL10 was measured by ELISA. 
CXCL10 release induced by TNF-α was suppressed by dexamethasone in a 
concentration-dependent manner, with statistical significance achieved at 10-9-10-6 M. 
In contrast to CCL11 and CXCL8 release, the suppression of which by 
dexamethasone was impaired in ASMC of patients with severe asthma, the induced 
CXCL10 was not dissimilar in those of healthy subjects and patients with non-severe 
and severe asthma (Fig. 4.4).  
 
4.2.2.4 Comparison of the potentiating effect of dexamethasone on CX3CL1 
release  
To compare the effect of corticosteroid in terms of potentiating CX3CL1 release, 
ASMC were pretreated with dexamethasone (10-10-10-6 M) for 2 hours, followed by 
stimulation with combined TNF-α and IFN-γ (10 ng/mL each) for 24 hours. CX3CL1 
was measured by ELISA. CX3CL1 release induced by TNF-α and IFN-γ was 
potentiated, rather than suppressed, by dexamethasone in a concentration-
dependent manner, with statistical significance reached at 10-9-10-6 M. There was no 
difference in the potentiating effect of dexamethasone on induced CX3CL1 release 
in ASMC of the healthy and patients with non-severe and severe asthma (Fig. 4.5). 
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Figure 4.4. Comparison of the suppressive effect of dexamethasone on 
CXCL10 release in ASMC of healthy subjects and patients with non-severe and 
severe asthma. ASMC were pretreated with dexamethasone (10-10-10-6 M) for 2 
hours and stimulated with TNF-α (10 ng/mL) for 24 hours. CXCL10 release was 
measured by ELISA. Points represent mean ± SEM.  
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Figure 4.5. Comparison of the potentiating effect of dexamethasone on 
CX3CL1 release in ASMC of healthy subjects and patients with non-severe and 
severe asthma. ASMC were pretreated with dexamethasone (10-10-10-6 M) for 2 
hours and stimulated with TNF-α and IFN-γ (10 ng/mL each) for 24 hours. CX3CL1 
release was measured by ELISA. Points represent mean ± SEM.  
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4.2.2.5 Comparison of the suppressive effect of dexamethasone on CCL11 
mRNA expression 
To determine the optimal concentration of dexamethasone in ASMC for investigation 
of the suppressive effect on induced CCL11 mRNA, cells of healthy subjects were 
pretreated with dexamethasone at 10-10-10-6 M for 2 hours, followed by stimulation 
with TNF-α at 10 ng/mL for 24 hours. CCL11 mRNA and 18S rRNA were measured 
by RT-qPCR. TNFα-induced CCL11 mRNA was inhibited by dexamethasone in a 
concentration dependent manner, with maximal suppression of 51.6% at 10-7 M 
(p<0.01); this was maintained at a higher concentration (Fig. 4.6). 
Figure 4.6. Effect of dexamethasone on induced CCL11 mRNA expression in 
ASMC. Cells were pretreated with dexamethasone (10-10-10-6 M) for 2 hours and 
stimulated with TNF-α (10 ng/mL) for 24 hours. CCL11 mRNA and 18S rRNA were 
measured by RT-qPCR. Bars and points represent mean ± SEM of ASMC from 3 
healthy subjects. * p<0.05, ** p<0.01 vs TNF-α alone. 
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To compare the suppressive effect of dexamethasone on induced CCL11 mRNA 
expression in ASMC between different groups, cells were pretreated with 
dexamethasone (10-7 M) for 2 hours and then stimulated with TNF-α (10 ng/mL) for 
24 hours. In ASMC of healthy subjects and patients with non-severe asthma, TNFα-
induced CCL11 mRNA was inhibited by dexamethasone by 60.5% (Fig. 4.7A; 
p<0.001) and 72.1% (Fig. 7B; p<0.001), respectively. In contrast, in those of severe 
asthma, there was no dexamethasone-mediated suppression of CCL11 mRNA (Fig. 
4.7C). 
Figure 4.7. Comparison of the suppressive effect of dexamethasone on CCL11 
mRNA expression. ASMC were pretreated with dexamethasone (10-7 M) for 2 
hours and stimulated with TNF-α (10 ng/mL) for 24 hours. CCL11 mRNA and 18S 
rRNA from ASMC of (A) healthy subjects and patients with (B) non-severe and (A) 
severe asthma (C) were measured by RT-qPCR. Bars represent mean ± SEM.        
*** p<0.01.  
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4.2.2.6 Comparison of the suppressive effect of dexamethasone on CXCL8 
mRNA expression 
To determine the optimal concentration of dexamethasone in ASMC to investigate  
its suppressive effect on induced CXCL8 mRNA, cells of healthy subjects were 
pretreated with dexamethasone at 10-10-10-6 M for 2 hours, followed by stimulation 
with TNF-α at 10 ng/mL for 24 hours. CXCL8 mRNA and 18S rRNA were measured 
by RT-qPCR. TNFα-induced CXCL8 mRNA was inhibited by dexamethasone in a 
concentration dependent manner, with maximal suppression of 43.5% at 10-7 M 
(Fig.4.8; p<0.05). 
Figure 4.8. Effect of dexamethasone on induced CXCL8 mRNA expression in 
ASMC. Cells were pretreated with dexamethasone (10-10-10-6 M) for 2 hours and 
stimulated with TNF-α (10 ng/mL) for 24 hours. CXCL8 mRNA and 18S rRNA were 
measured by RT-qPCR. Bars and points represent mean ± SEM of ASMC from 4 
healthy subjects. * p<0.05 vs TNF-α alone. 
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To compare the suppressive effect of dexamethasone on induced CXCL8 mRNA 
expression in ASMC between different groups, cells were pretreated with 
dexamethasone (10-7 M) for 2 hours and then stimulated with TNF-α (10 ng/mL) for 
24 hours. In ASMC of healthy subjects and patients with non-severe asthma, TNFα-
induced CXCL8 mRNA was inhibited by dexamethasone by 58.8% (Fig. 4.9A; 
p<0.001) and 42.2% (Fig. 4.9B; p<0.05), respectively. In contrast, in cells of patients 
with severe asthma, there was no dexamethasone-mediated suppression of CCL11 
mRNA (Fig. 4.9C). 
Figure 4.9. Comparison of the suppressive effect of dexamethasone on CXCL8 
mRNA expression. ASMC were pretreated with dexamethasone (10-7 M) for 2 
hours and stimulated with TNF-α (10 ng/mL) for 24 hours. CXCL8 mRNA and 18S 
rRNA from ASMC of (A) healthy subjects and patients with (B) non-severe and (C) 
severe asthma were measured by RT-qPCR. Bars represent mean ± SEM. * p<0.01, 
*** p<0.001.  
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4.2.2.7 Comparison of the potentiating effect of dexamethasone on CX3CL1 
mRNA expression 
To determine the optimal concentration of dexamethasone in ASMC to investigate its  
potentiating effect on induced CX3CL1 mRNA, cells of healthy subjects were 
pretreated with dexamethasone at 10-10-10-6 M for 2 hours, followed by stimulation 
with TNF-α and IFN-γ at 10 ng/mL each for 24 hours. CX3CL1 mRNA and 18S rRNA 
were measured by RT-qPCR. TNFα and IFNγ–induced CX3CL1 mRNA was 
potentiated by dexamethasone in a concentration-dependent manner, with a 
maximal 3.1-fold potentiation at 10-7 M, which was maintained at a higher 
concentration (Fig. 4.10). 
Figure 4.10. Effect of dexamethasone on induced CX3CL1 mRNA expression in 
ASMC. Cells were pretreated with dexamethasone (10-10-10-6 M) for 2 hours and 
stimulated with TNF-α and IFN-γ (T+I; 10 ng/mL each) for 24 hours. CX3CL1 mRNA 
and 18S rRNA were measured by RT-qPCR. Bars and points represent mean ± 
SEM of ASMC from 4 healthy subjects. ** p<0.01, *** p<0.001 vs T+I alone. 
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To compare the potentiating effect of dexamethasone on induced CX3CL1 mRNA 
expression in ASMC between different groups, cells were pretreated with 
dexamethasone (10-7 M) for 2 hours and then stimulated with TNF-α and IFN-γ (10 
ng/mL each) for 24 hours. Dexamethasone potentiated induced CX3CL1 mRNA 
expression in to a similar degree (3.5-4.3 fold) in ASMC of healthy subjects (Fig. 
4.11A; p<0.01) and patients with non-severe (Fig. 4.11B; p<0.001) and severe 
asthma (Fig. 4.11C; p<0.001). 
Figure 4.11. Comparison of the potentiating effect of dexamethasone on 
CX3CL1 mRNA expression. ASMC were pretreated with dexamethasone (10-7 M) 
for 2 hours and stimulated with TNF-α and IFN-γ (10 ng/mL each) for 24 hours. 
CX3CL1 mRNA and 18S rRNA from ASMC of (A) healthy subjects and patients with 
(B) non-severe and (C) severe asthma were measured by RT-qPCR. Bars represent 
mean ± SEM. ** p<0.01, *** p<0.001.  
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4.2.3 Effect of IFN-γ on the suppressive effect of dexamethasone in ASMC of 
healthy subjects and patients with non-severe and severe asthma 
4.2.3.1 Effect of IFN-γ on suppressive effect of TNFα-induced CXCL10 release 
in ASMC  
To investigate and compare the effect of IFN-γ on the suppressive effect of 
dexamethasone on induced CXCL10 release, ASMC were pretreated with 
dexamethasone (10-10-10-6 M) for 2 hours and subsequently stimulated with TNF-α 
(10 ng/mL) or IFN-γ (10 ng/mL) alone or in combination for 24 hours. CXCL10 
release was measured by ELISA. In ASMC of healthy subjects, TNFα-induced 
CXCL10 was inhibited by dexamethasone in a concentration-dependent manner, 
with maximal suppression of 95% at 10-7 and 10-6 M (Fig. 4.12A; p<0.01), 
respectively. In contrast, CXCL10 release was suppressed by dexamethasone at 10-
6 M by 27% and minimally (1%) when induced by IFN-γ alone and in combination 
with TNF-α, respectively. The suppressive effects of dexamethasone on CXCL10 
were significantly less on exposure to IFN-γ alone (p<0.01) or combined with TNF-α 
(p<0.001) than TNF-α alone, over a range of concentrations (10-8-10-6 M). The 
differences in dexamethasone inhibition of CXCL10 induced by IFN-γ alone and in 
combination with TNF-γ almost reached statistical significance (Fig. 4.14A; p=0.052-
0.058 at 10-8-10-6 M). 
 
Similarly, in ASMC of patients with non-severe (Fig. 4.12B) and severe asthma (Fig. 
4.12C), TNFα-induced CXCL10 release was nearly completely inhibited by 
dexamethasone at both 10-7 and 10-6 M, while this chemokine was not supressed in 
the presence of IFN-γ. The suppressive effects of dexamethasone on CXCL10 
induced by TNF-α alone and in combination with IFN-γ were significantly different 
over a range of concentrations (p<0.001 at 10-9-10-6 M). 
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Figure 4.12. Effect of IFN-γ on suppression of TNFα-induced CXCL10 release 
by dexamethasone in ASMC. Cells were pretreated with dexamethasone (10-10 - 
10-6 M) for 2 hours and stimulated with TNF-α (10 ng/mL), IFN-γ (10 ng/mL), or both, 
for 24 hours. CXCL10 release in ASMC of (A) healthy subjects and patients with (B) 
non-severe and (C) severe asthma was measured by ELISA. Points represent mean 
± SEM. ** p<0.01, ** p<0.01 vs TNF-α. 
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4.2.3.2 Effect of IFN-γ on the suppressive effect of dexamethasone on TNFα-
induced CCL11 release in ASMC  
To investigate and compare the effect of IFN-γ on the suppressive effect of 
dexamethasone on induced CCL11 release, ASMC were pretreated with 
dexamethasone (10-10-10-6 M) for 2 hours and subsequently stimulated with TNF-α 
(10 ng/mL) or IFN-γ (10 ng/mL) alone or in combination for 24 hours. CCL11 release 
was measured by ELISA. In ASMC of healthy subjects, constitutive CCL11 release 
was inhibited by dexamethasone in a concentration-dependent manner, with 
maximal suppression of 65.5% at 10-7 M, which was maintained at higher 
concentration. In the presence of IFN-γ, dexamethasone at the same concentration 
suppressed CCL11 by only 41.7% (Fig. 4.13A; p<0.01). The suppressive effects of 
dexamethasone on CCL11 at baseline and post-stimulation with IFN-γ were 
significantly different over a range of concentrations (p<0.05 at 10-8 M and p<0.01 at 
10-7 and 10-6 M, respectively). This impairment in dexamethasone suppression by 
IFN-γ was more distinct when cells were exposed to TNF-α: suppression of TNFα-
induced CCL11 release by maximally 62.9% was achieved with dexamethasone at 
10-6 M. With addition of IFN-γ, dexamethasone at the same concentration only 
minimally suppressed induced CCL11 by 7.7% (Fig. 4.12B). The differences in 
suppressive effects of dexamethasone were significant over a range of 
concentrations (p<0.01 at 10-8 M- 10-6 M). 
 
In ASMC of patients with non-severe asthma, significant differences in the 
suppressive effect of dexamethasone were observed at 10-9-10-7 M. However, the 
slope of the concentration response curve was less distinct between cells stimulated 
with TNF-α alone and combined TNF-α and IFN-γ (Fig. 4.13C). Furthermore, in 
ASMC of patients with severe asthma, there was no modulation of the suppressive 
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effect of dexamethasone by IFN-γ: the concentration response curves of the two 
overlapped (Fig. 4.13D). 
Figure 4.13. Effect of IFN-γ on the suppressive effect of TNFα-induced CCL11 
release by dexamethasone in ASMC. ASMC were pretreated with dexamethasone 
(10-10-10-6 M) for 2 hours and stimulated with TNF-α (10 ng/mL) or IFN-γ (10 ng/mL 
each) alone or in combination for 24 hours. CCL11 release in ASMC of (A, B) 
healthy subjects and patients with (C) non-severe and (D) severe asthma was 
measured by ELISA. Points represent mean ± SEM. # p<0.05, ## p<0.01 vs no 
cytokiine.* p<0.05, ** p<0.01 vs TNF-α. 
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4.2.3.3 Effect of IFN-γ on suppressive effect of TNFα-induced CXCL8 release in 
ASMC 
To investigate and compare the effect of IFN-γ on the suppressive effect of 
dexamethasone on induced CXCL8 release, ASMC were pretreated with 
dexamethasone (10-10-10-6 M) for 2 hours and subsequently stimulated with TNF-α 
(10 ng/mL) in the presence or absence of IFN-γ (10 ng/mL) for 24 hours. CXCL8 
release was measured by ELISA. In ASMC of healthy subjects, TNFα-induced 
CXCL8 was suppressed by dexamethasone in a concentration-dependent manner. 
With the addition of IFN-γ, there was a reduction in the suppressive effect of 
dexamethasone on induced CXCL8 release. Dexamethasone at 10-7 M suppressed 
TNFα-induced CXCL8 by 52.6%, while the suppression of TNFα and IFNγ–induced 
CXCL8 was reduced to 24.6% (p<0.05).  At 10-8 M, dexamethasone suppressed 
TNFα–induced CXCL8 by 31.2% but did not suppress TNFα and IFNγ–induced 
CXCL8 at all. Intriguingly, TNFα and IFNγ -induced CXCL8 was paradoxically 
increased by 30.3% (p<0.01) by dexamethasone at 10-9 M (Fig. 4.14A). 
 
Similarly, in cells of patients with non-severe asthma, with dexamethasone at 10-8 M, 
CXCL8 release was significantly higher in response to TNF-α and IFN-γ than to TNF-
α alone (p<0.05).  Again, TNFα and IFNγ –combined CXCL8 was potentiated by 
25.4% (p<0.01) by dexamethasone at 10-9 M (Fig. 4.14B). 
 
In ASMC of patients with severe asthma, as also shown in 4.2.2.2, the suppressive 
effect of dexamethasone was reduced in terms of inhibiting TNFα-induced CXCL8. In 
the presence of IFN-γ, the suppressive effect was further impaired. At 10-7 M, 
dexamethasone inhibited TNFα-induced CXCL8 by 19.2% but minimally (2.2%) 
following TNF-α and IFN-γ (p<0.05). In addition, dexamethasone potentiated TNFα 
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and IFNγ-induced CXCL8 release at 10-9 and 10-8 M by 43.1% (p<0.01) and 36.8% 
(p<0.01), respectively (Fig 4.14C).  
Figure 4.14. Effect of IFN-γ on the suppression of TNFα-induced CXCL8 
release by dexamethasone in ASMC. ASMC were pretreated with dexamethasone 
(10-10-10-6 M) for 2 hours and stimulated with TNF-α (10 ng/mL) or combined TNF-α 
and IFN-γ (10 ng/mL each) for 24 hours. CXCL8 release in ASMC of (A) healthy 
subjects and patients with (B) non-severe and (C) severe asthma was measured by 
ELISA. Points represent mean ± SEM. * p<0.05, ** p<0.01,*** p<0.001 vs TNF-α.   
## p<0.01 vs T+I alone. 
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4.3 Discussion 
Summary of results: 
The effects of dexamethasone in terms of suppressing release and mRNA 
expression of TNFα-induced CCL11 and CXCL8, but not CXCL10, were impaired in 
ASMC of patients with severe asthma, while the potentiating effect on TNFα and 
IFNγ–induced CX3CL1 was not different between groups. IFN-γ impaired the 
suppressive effects of dexamethasone on induced CXCL10, CCL11 and CXCL8 
release in ASMC of healthy subjects and those of non-severe asthma. This 
modulating effect on dexamethasone suppression of CXCL10 was consistent in all 
groups but was minimal or absent on that of CCL11 and CXCL8 in cells of patients 
with severe asthma. Intriguingly, in the presence of TNF-α and IFN-γ, 
dexamethasone at lower concentration paradoxically increased induced CXCL8 
release in ASMC of all groups. 
 
4.3.1 Relative corticosteroid insensitivity in ASMC of patients with severe 
asthma  
Whereas the pharmacological effects of corticosteroids have been largely 
investigated, the modulatory actions on inflammatory genes in ASMC remain 
complex and not fully characterised. Depending on the genes targeted, 
corticosteroids have either both anti-inflammatory or pro-inflammatory effect on 
chemokines. For instance, while corticosteroids antagonise cytokine-induced CCL11 
(Pang and Knox 2001), CXCL8 (John, Au et al. 1998) and CXCL10 (Banerjee, 
Damera et al. 2008), they augment induced CX3CL1 (Sukkar, Issa et al. 2004; 
Banerjee, Damera et al. 2008). 
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The observation of reduced suppressive effect of dexamethasone on TNFα-induced 
release and mRNA of CCL11 (4.2.2.1 and 4.2.2.5) and CXCL8 (4.2.2.2 and 4.2.2.6) 
in ASMC of patients with severe asthma extend the impaired corticosteroid 
suppression of serum-induced ASMC proliferation in asthma (Roth, Johnson et al. 
2004) as well as corticosteroid insensitivity in terms of suppressing induced 
cytokines in both PBMC (Hew, Bhavsar et al. 2006) and alveolar macrophages 
(Bhavsar, Hew et al. 2008) of patients with severe asthma. Noteworthy, the effects of 
dexamethasone on modulating cytokine-induced CXCL10 (4.2.2.3) and CX3CL1 
(4.2.2.4 and 4.2.2.7) are not different in any of the groups, indicating that not all 
responses to corticosteroids are compromised in severe asthma. This is consistent 
with the findings in other cell types (Hew, Bhavsar et al. 2006; Bhavsar, Hew et al. 
2008) of severe asthmatic subjects and supported by the clinical manifestation that 
patients with severe asthma suffer from side effects attributed to long term use of 
corticosteroids (Bousquet, Mantzouranis et al. 2010) and display different clinical 
features than subjects with generalized glucocorticoid resistance (Charmandari, Kino 
et al. 2008). 
 
In ASMC, CX3CL1 induced by TNF-α and IFN-γ is potentiated by dexamethasone 
(4.2.2.5 and 4.2.2.6). Since CX3CL1 has pro-inflammatory properties, not all the 
effects of corticosteroids are considered to be anti-inflammatory. The potentiating 
effect of dexamethasone on CX3CL1 expression is likely through a transactivation 
mechanism with the binding of activated GR to its positive GRE site on the gene 
promoter (Garin, Pellet et al. 2002). Interestingly, this chemokine induced by the 
same cytokines is suppressed by dexamethasone in human airway epithelial cell line 
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A549 (Bhavsar, Sukkar et al. 2008). The mechanisms underlying the cell-specific 
opposite regulatory effects of corticosteroids on CX3CL1 expression are unknown 
and need further investigation. The fact that the potentiating effect of 
dexamethasone on CX3CL1 release and mRNA expression is similar in the three 
groups (4.2.2.5 and 4.2.2.6) implicates that there is likely to be no differential effects 
of dexamethasone on GRE binding. 
 
4.3.2 Impaired suppressive effect of dexamethasone by IFN-γ in ASMC 
Respiratory virus infection is the most common cause of asthma exacerbation, and 
IFN-γ is a major cytokine in response to viral infection (Wark and Gibson 2006). The 
IFNγ-mediated impairment of dexamethasone suppression of induced pro-asthmatic 
chemokines may explain why the current treatment of virus-induced exacerbation of 
asthma, i.e. high-dose inhaled or oral corticosteroids, is only partially effective 
(Message and Johnston 2001).  
 
The suppressive effects of corticosteroid on inflammatory mediators in ASMC are 
stimuli-specific (Tliba and Amrani 2008). For example, while several steroids 
considerably inhibit IL1β-induced GM-CSF, they only partially suppress this cytokine 
induced by thrombin (Tran, Fernandes et al. 2005). This may account for the 
observation of poorer dexamethasone suppression of CXCL10 release induced by 
IFN-γ than by TNF-α (4.2.3.1). In addition, the specific combination of TNF-α with 
IFN-γ, but not IL-1β or IL-13, impairs corticosteroid suppression of several pro-
asthmatic genes such as CCL5, CXCL10 (Banerjee, Damera et al. 2008) and CD38 
(Tliba, Cidlowski et al. 2006). Such an effect of IFN-γ on corticosteroid suppression 
175 
of CXCL10 is further confirmed in ASMC of patients with non-severe and severe 
asthma (4.2.3.1). Similar modulating effects of IFN-γ are also demonstrated in 
regulation of TNFα-induced CCL11 (4.2.3.2) and CXCL8 (4.2.3.3) release in ASMC 
of healthy and non-severe asthmatic subjects.  
 
In ASMC, the combination of TNF-α and IFN-γ inhibits GRα-DNA binding activity and 
GRE-dependent gene transcription through up-regulation of GR-β expression (Tliba, 
Cidlowski et al. 2006), which is increased in airways of patients with severe asthma 
(Bergeron, Fukakusa et al. 2006) and correlates with corticosteroid-resistant asthma 
(Leung, Hamid et al. 1997), perhaps through suppression of HDAC2 expression by 
inhibiting glucocorticoid response elements in its promoter (Li, Leung et al. 2010). 
Another possible mechanism contributing to IFNγ-induced corticosteroid resistance 
involves over-induction of interferon regulatory factor-1 (IRF-1). In ASMC, IFN-γ, but 
not TNF-α, induces recruitment of IRF-1 to the CD38 promoter, which makes this 
gene resistant to corticosteroid suppression. Exogenous expression of IRF-1 dose-
dependently inhibits glucocorticoid-induced GRE reporter activity, and silencing IRF-
1 expression consistently restores GRE reporter activity in TNFα- and IFN-γ treated 
cells (Tliba, Damera et al. 2008). Furthermore, a recent study suggests a role for 
serine/threonine protein phosphatase 5 in corticosteroid resistance induced by TNF-
α and IFN-γ,  possibly through down-regulation of phosphorylated GR at serine 211 
(Bouazza, Krytska et al. 2012) 
 
The chemokines CCL11 (4.2.2.1 and 4.2.2.5) and CXCL8 (4.2.2.2 and 4.2.2.6), 
which are less supressed by dexamethasone in ASMC of patients with severe 
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asthma, are resistant to dexamethasone in the presence of IFN-γ (4.2.3.2 and 
4.2.3.3), a cytokine which is highly expressed in the inflammatory cells of the airways 
of severe asthma (Shannon, Ernst et al. 2008). This implicates the possibility of IFN-
γ being involved in the mechanisms underlying corticosteroid insensitivity in severe 
asthma. However, the fact that CXCL10, another chemokine which is resistant to 
corticosteroid inhibition in the presence of IFN-γ (4.2.3.1), is not insensitive to the 
suppressive effect of dexamethasone in ASMC of severe asthmatic subjects (4.2.2.3) 
argues against this deduction. Furthermore, while addition of IFN-γ impairs 
dexamethasone suppression of both baseline and TNFα-induced CCL11 release, 
combination of TNF-α and IFN-γ results in a poorer response to dexamethasone 
than IFN-γ alone (4.2.3.2). This suggests that not only IFN-γ but also TNF-α may 
have impact on the suppressive effect of corticosteroids. 
 
Interestingly, whereas IFN-γ impairs the suppressive effects of dexamethasone on 
TNFα-induced CCL11, CXCL8 and CXCl10 in ASMC of health subjects, this cytokine 
differentially modulate the effects of dexamethasone in ASMC of patients with 
asthma, depending on the chemokine targeted. In contrast to a consistent IFNγ-
induced corticosteroid resistance in terms of suppressing CXCL10 in all groups 
(4.2.3.1), IFN-γ impairs the suppressive effect of dexamethasone on TNFα-induced 
CCL11 in ASMC of healthy subjects but has less influence in those of non-severe 
asthma. Furthermore, in ASMC of patients with severe asthma, where corticosteroid 
insensitivity exists, IFN-γ does not further modulate the response to dexamethasone 
in terms of suppressing CCL11 release (4.2.3.2). On the other hand, surprisingly, 
dexamethasone at lower concentration (i.e. 10-9 M) consistently increases TNFα and 
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IFNγ–induced CXCL8 release (4.2.3.3). This potentiating effect of dexamethasone at 
a specific concentration on induced CXCL8 is in contrast to the concentration-
dependent potentiation of induced CX3CL1 release (4.2.2.4) and mRNA expression 
(4.2.2.7). The mechanism underlying the differential modulating effects of IFN-γ on 
corticosteroid response is unclear. 
 
In summary, relative corticosteroid insensitivity exists in ASMC of patients with 
severe asthma in terms of suppressing CCL11 and CXCL8. IFN-γ induces 
corticosteroid resistance in terms of CCL11, CXCL8 and CXCL10 in ASMC of 
healthy patients but has differing modulating effects on corticosteroid, depending on 
the chemokine targeted. Further investigation is required to establish the role of IFN-
γ in corticosteroid insensitivity in severe asthma. 
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Chapter 5. 
Role of MAPK in corticosteroid insensitivity in 
ASMC of patients with severe asthma 
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Chapter 5. Role of MAPK in corticosteroid insensitivity in ASMC of patients 
with severe asthma 
5.1 Introduction 
Several distinct molecular mechanisms (Table 5.1) contributing to decreased anti-
inflammatory effects of corticosteroids have been identified. There is heterogeneity 
of mechanisms even within a single disease; meanwhile, similar molecular 
mechanisms are also identified in different inflammatory diseases (Barnes 2010).  
Table 5.1. Possible molecular mechanisms of corticosteroid insensitivity 
(Barnes 2010). 
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The MAPK p38, JNK and ERK have been implicated in mechanisms of corticosteroid 
insensitivity. For example, IL-2 and IL-4, which are increased in the airways of 
patients with steroid resistant asthma, impair the suppressive effect of corticosteroid 
in T-cells through induction of p38 MAPK activity (Irusen, Matthews et al. 2002). 
Elevated JNK activity is observed in dermal inflammation of patients with 
corticosteroid resistant asthma, and this activity is not supressed by oral 
prednisolone (Sousa, Lane et al. 1999), and microbial superantigen induces 
corticosteroid resistance in T-cell through ERK activation (Li, Goleva et al. 2004). 
Notably, relative corticosteroid insensitivity in alveolar macrophages of patients with 
severe asthma is associated with elevated p38 MAPK activity, and the degree of p38 
phosphorylation correlates inversely to the suppressive effects of dexamethasone on 
inflammatory chemokines (Bhavsar, Hew et al. 2008). 
 
Increased activation of MAPK has been demonstrated in the airway cells of patients 
with asthma (Liu, Liang et al. 2008; Robins, Roussel et al. 2011). However, the role 
of MAPK in corticosteroid insensitivity in ASMC of severe asthma has not been 
investigated. In this study, activation of MAPK p38, JNK and ERK, as measured by 
phosphorylation of the kinases, is compared in ASMC of healthy subjects and 
patients with non-severe and severe asthma. Then the possible role for MPAK 
activation in corticosteroid responsiveness is investigated. 
181 
5.2 Results 
5.2.1 Effect of TNF-α on MAPK activation in ASMC—Optimisation studies 
To investigate the effect of TNF-α on MAPK activation in ASMC, cells of healthy 
subjects were stimulated with TNF-α (10 ng/mL) over a time course (5 minutes to 2 
hours). Phosphorylated and total p38, JNK and ERK were measured by Western 
Blot. p38 phosphorylation was induced by TNF-α at 5 minutes, peaked at 15 minutes, 
and declined over time (Fig. 5.1A). In contrast, induced JNK and EKR 
phosphorylation peaked between 15-30 minutes and rapidly declined by one hour 
(Fig. 5.2B and C). 15 minute was chosen as the treatment duration for further 
experiments. 
Figure 5.1. Regulation of MAPK in ASMC. Cells were stimulated with TNF-α (10 
ng/mL) for indicated time. Phosphorylated and total (A) p38, (B) JNK and (C) ERK  
were measured by Western Blot. Bars represent mean ± SEM of ASMC from 3 
healthy subjects. * p<0.05, ** p<0.01, *** p<0.001 vs unstimulated.  
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5.2.2 Comparison of TNFα-induced p38 MAPK activation in ASMC of healthy 
subjects and patients with non-severe and severe asthma 
To compare induced p38 activity between the three groups, ASMC were stimulated 
with TNF-α (10 ng/mL) for 15 minutes. Phosphorylated and total p38 expression was 
measured by Western Blot. TNF-α induced p38 phosphorylation by 2.2 and 2.5–fold, 
over baseline, in ASMC of the healthy and patients with non-severe asthma, 
respectively. In contrast, in ASMC of severe asthmatics, phosphorylation of p38 was 
induced by 10.0-fold, which is significantly greater than that observed in cells of 
healthy subjects (p<0.01) and patients with non-severe asthma (p<0.05) (Fig. 5.2). 
Figure 5.2. Comparison of induced p38 MAPK phosphorylation in ASMC of 
healthy subjects and patients with non-severe and severe asthma. ASMC were 
stimulated with TNF-α (10 ng/mL) for 15 minutes. Phosphorylated and total p38 were 
measured by Western Blot. Horizontal lines represent median. * p<0.05, ** p<0.01. 
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5.2.3 Comparison of TNFα-induced JNK activation in ASMC of healthy subjects 
and patients with non-severe and severe asthma 
To compare induced JNK activity between the three groups, ASMC were stimulated 
with TNF-α (10 ng/mL) for 15 minutes. Phosphorylated and total JNK expression was 
measured by Western Blot. TNF-α induced a 6.2-fold increase over baseline in JNK 
phosphorylation in ASMC of the healthy. Phosphorylated JNK was induced, to a 
greater extent, in cells of non-severe (9.1 fold, p<0.05) and severe asthma (13.6 fold, 
p<0.01) than in healthy subjects, while there was no significant difference between 
non-severe and severe asthmatics (Fig. 5.3).   
Figure 5.3. Comparison of induced JNK phosphorylation in ASMC of healthy 
non-severe and severe asthmatics. ASMC were stimulated with TNF-α (10 ng/mL) 
for 15 minutes. Phosphorylated and total JNK were measured by Western Blot. 
Horizontal lines represent median. * p<0.05, ** p<0.01. 
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5.2.4 Comparison of TNFα-induced ERK activation in ASMC of healthy 
subjects and patients with non-severe and severe asthma 
To compare induced ERK activity in the three groups, ASMC were stimulated with 
TNF-α (10 ng/mL) for 15 minutes. Phosphorylated and total ERK expression was 
measured by Western Blot. TNF-α increased ERK phosphorylation by 3.5-fold, over 
baseline, in ASMC of healthy subjects and by 8.1-fold in those of asthma (Fig. 5.4A; 
p<0.05). However, there was no significant difference between non-severe and 
severe asthma (Fig. 5.4B; p=0.63). 
Figure 5.4. Comparison of induced ERK phosphorylation in ASMC of healthy 
subjects and patients with non-severe and severe asthma. ASMC were 
stimulated with TNF-α (10 ng/mL) for 15 minutes. Phosphorylated and total ERK 
expression in ASMC of (A) healthy subjects and patients with (A, B) non-severe and 
severe asthma were measured by Western Blot. Horizontal lines represent median.  
* p<0.05. 
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5.2.5 Correlation between induced MAPK phosphorylation and suppressive 
effect of dexamethasone in ASMC 
It was observed that phosphorylation of all MAPK was increased in ASMC of patients 
with asthma, while only p38 phosphorylation was greater in ASMC of severe 
asthmatics compared to non-severe asthmatics (5.3.2-5.3.4). Data from healthy 
subjects and patients with non-severe and severe asthma were combined, and 
Spearman's rank-order correlation was performed to determine a correlation 
between MAPK activation and suppressive effect of dexamethasone on TNFα-
induced release of CCL11 or CXCL8. Induced p38 phosphorylation correlated 
inversely to the degree of suppression of both induced CCL11 (r=-0.50, p=0.007; Fig. 
5.5A) and CXCL8 (r=-0.45, p=0.018; Fig. 5.5B). In contrast, there was no significant 
correlation between either induced JNK (Fig. 5.6) or ERK (Fig. 5.7) phosphorylation 
and suppressive effect of dexamethasone on induced chemokines. 
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Figure 5.5. Correlation between suppression of induced (A) CCL11 and (B) 
CXCL8 release by dexamethasone and phosphorylation of p38 MAPK induced 
by TNF-α in ASMC.  
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Figure 5.6. Correlation between suppression of induced (A) CCL11 and (B) 
CXCL8 release by dexamethasone and phosphorylation of JNK induced by 
TNF-α in ASMC. 
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Figure 5.7. Correlation between suppression of induced (A) CCL11 and (B) 
CXCL8 release by dexamethasone and phosphorylation of ERK induced by 
TNF-α in ASMC.  
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5.2.6 Effect of p38 inhibition on chemokine release and suppressive effect of 
dexamethasone in ASMC of patients with severe asthma 
A selective p38α/β inhibitor, GW-856553, was used to investigate a role for p38 
MAPK activity in chemokine release and dexamethasone-mediated suppression. To 
determine the specificity of this inhibitor for p38 MAPK activity, ASMC of healthy 
subjects were pretreated by GW-856553 (10-10-10-6 M) for 2 hours and stimulated 
with TNF-α (10 ng/mL) for 15 minutes. Phosphorylated and total p38, JNK and ERK 
were measured by Western Blot. TNF-α induced a 2-fold increase in p38 
phosphorylation, which was suppressed by GW-856553 in a concentration-
dependent manner. Phosphorylation of p38 was reduced to its baseline level by the 
inhibitor at 10-6 M (Fig. 5.8A). In contrast, TNFα-induced JNK and ERK 
phosphorylation was not modulated by GW-856553 (Fig. 5.8 B and C). 
 
To investigate the role of p38 MAPK activation in chemokine release from ASMC of 
patients with severe asthma, cells were pretreated with GW-853556 (10-10-10-6 M) for 
2 hours and stimulated with TNF-α (10 ng/mL) for 24 hours. CCL11 and CXCL8 
release was measured by ELISA. TNFα-induced CCL11 was not significantly 
influenced by GW-856553 (Fig. 5.9A). In contrast, induced CXCL8 was partially 
inhibited in a concentration-dependent manner by GW-856553, with maximal 
suppression by 32% at 10-6 M (Fig. 5.9B; p<0.01). 
 
To determine a role for p38 MAPK activation in corticosteroid insensitivity in severe 
asthma, ASMC of severe asthmatics, were pretreated with GW-856553 (10-8 or 10-6 
M) and/or dexamethasone (10-9-10-6 M) for 2 hours and stimulated with TNF-α (10 
ng/mL) for 24 hours.  In the absence of the inhibitor, dexamethasone at 10-6 M 
suppressed induced CCL11 release by 11.9%, with GW-856553 at 10-6 M, 
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dexamethasone at the same concentration inhibited induced CCL11 by up to 55.0% 
(Fig. 5.10A; p<0.05 vs vehicle control). Similarly, with GW-856553 at 10-6 M, 
dexamethasone (10-6 M) suppression of induced CXCL8 release was improved from 
32.5% to 65.2% (Fig. 5.10B; p<0.01). 
Figure 5.8. Effect of GW-856553 on MAPK activaties in ASMC. Cells were 
pretreated with GW-856553 (1-10-10-6 M) for 2 hours and stimulated with TNF-α (10 
ng/mL) for 15 minutes. Phosphorylated and total (A) p38, (B) JNK and (C) ERK were 
measured by Western Blot. Bars represent mean of 2 ASMC from healthy subjects.
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Figure 5.9. Effect of p38 MAPK inhibitor on chemokine release in ASMC of 
patients with severe asthma. Cells were pretreated with GW-856553 (10-10-10-6 M) 
for 2 hours and stimulated with TNF-α (10 ng/mL) for 24 hours. (A) CCL11 and (B) 
CXCL8 release was measured by ELISA. Bars represent mean ± SEM of ASMC 
from 6 patients with asthma. # p<0.05, ## p<0.01 vs TNF-α alone. ** p<0.01,          
*** p<0.001.  
Figure 5.10. Effect of p38 MAPK inhibition on the response of dexamethasone 
in ASMC of patients with severe asthma. Cells were pretreated with GW-856553  
(10-8 or 10-6 M) and/or dexamethasone (10-9-10-6 M) for 2 hours and stimulated with 
TNF-α (10 ng/mL) for 24 hours. (A) CCL11 and (B) CXCL8 release was measured by 
ELISA. Points represent mean ± SEM of ASMC from 6 patients with severe asthma.  
* p<0.05, ** p<0.01, *** p<0.001 vs vehicle.  
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5.2.7 Effect of JNK inhibition on chemokine release and suppressive effect of 
dexamethasone in ASMC of patients with severe asthma 
To investigate a role for JNK activation in chemokine release from ASMC of patients 
with severe asthma, cells were pretreated with a selective JNK inhibitor, SP600125 
(10-10-10-6 M) for 2 hours and stimulated with TNF-α (10 ng/mL) for 24 hours. CCL11 
and CXCL8 release was measured by ELISA. CCL11 induced by TNF-α was not 
modulated by SP600125 (Fig. 5.11A), whereas TNFα-induced CXCL8 was slightly 
but significantly increased by the inhibitor at 10-6 M (Fig. 5.11B; p<0.01). 
 
To determine a role for JNK activation in corticosteroid insensitivity in ASMC of 
patients with severe asthma, cells were pretreated with SP600125 (10-10 or 10-8 M) 
and/or dexamethasone (10-9-10-6 M) for 2 hours and stimulated with TNF-α (10 
ng/mL) for 24 hours. The suppressive effect of dexamethasone on induced CCL11 
and CXCL8 was not affected by SP600125 (Fig. 5.12A and B). 
 
5.2.8 Effect of ERK inhibition on chemokine release and suppressive effect of 
dexamethasone in ASMC of patients with severe asthma 
To investigate a role for ERK activation in chemokine release, ASMC of patients with 
severe asthma were pretreated with a selective ERK inhibitor, U0126 (10-10-10-6 M) 
for 2 hours and stimulated with TNF-α (10 ng/mL) for 24 hours. CCL11 and CXCL8 
release was measured by ELISA. U0126 partially inhibited TNFα-induced CCL11 in 
a concentration-dependent manner, with maximal suppression of 37% at 10-6 M (Fig. 
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5.13A). In contrast, TNFα-induced CXCL8 was not suppressed by U0126 at lower 
concentrations but was paradoxically potentiated by 76% at 10-6 M (Fig. 5.13B). 
 
To determine a role for ERK activation in corticosteroid insensitivity in severe asthma, 
ASMC of patients with severe asthma were pretreated with U0126 (10-10 or 10-8 M) 
and/or dexamethasone (10-9-10-6 M) for 2 hours and stimulated with TNF-α (10 
ng/mL) for 24 hours. The suppressive effect of dexamethasone on induced CCL11 
(Fig. 5.14A) and CXCL8 (Fig. 5.14B) was not modulated by U0126. 
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Figure 5.11. Effect of JNK inhibitor on chemokine release in ASMC of patients 
with severe asthma. Cells were pretreated with SP600125 (10-10-10-6 M) for 2 hours 
and stimulated with TNF-α (10 ng/mL) for 24 hours. (A) CCL11 and (B) CXCL8 
release was measured by ELISA. Bars represent mean ± SEM of ASMC from 5-6 
patients with severe asthma. ## p<0.01 vs TNF-α alone. *** p<0.001.  
Figure 5.12. Effect of JNK inhibitor on the response of dexamethasone in 
ASMC of patients with severe asthma. Cells were pretreated with SP600125 (10-10 
or 10-8 M) and/or dexamethasone (10-9-10-6 M) for 2 hours and stimulated with TNF-
α (10 ng/mL) for 24 hours. (A) CCL11 and (B) CXCL8 release was measured by 
ELISA. Bars and points represent mean ± SEM of ASMC from 5-6 patients with 
severe asthma. 
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Figure 5.13. Effect of ERK inhibitor on chemokine release in ASMC of patients 
with severe asthma. Cells were pretreated with U0126 (10-10-10-6 M) for 2 hours 
and stimulated with TNF-α (10 ng/mL) for 24 hours. (A) CCL11 and (B) CXCL8 
release was measured by ELISA. Bars represent mean ± SEM of ASMC from 6 
patients with severe asthma # p<0.05 vs TNF-α alone. *** p<0.001.  
Figure 5.14. Effect of ERK inhibitor on chemokine release in ASMC of patient 
with severe asthma. Cells were pretreated with U0126 (10-10 or 10-8 M) and/or 
dexamethasone (10-9-10-6 M) for 2 hours and stimulated with TNF-α (10 ng/mL) for 
24 hours. CCL11 (C) and CXCL8 (D) release was measured by ELISA. Points 
represent mean ± SEM of ASMC from 6 patients with severe asthma. 
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5.2.9 Effect of IFN-γ on MAPK activity induced by TNF-α in ASMC 
Based on the observation that p38 phosphorylation was greater in ASMC of patients 
with severe asthma (5.3.2) and that p38α/β inhibition improved the suppressive 
effect of dexamethasone on induced CCL11 and CXCL8 release in those of severe 
asthmatics (5.3.6), a role for heightened p38 activity in corticosteroid insensitivity in 
ASMC of severe asthmatics was implicated. Given that IFN-γ impaired suppressive 
of dexamethasone on the same chemokines (4.2.3.2 and 4.2.3.3), the effect of IFN-γ 
on induced MAPK was also investigated. 
 
ASMC were stimulated with TNF-α and/or IFN-γ (10 ng/mL) for 15 minutes. 
Phosphorylated and total p38, JNK and ERK were measured by Western Blot. In 
ASMC of healthy subjects, phosphorylation of p38 was induced by TNF-α but not 
IFN-γ, and IFN-γ did not modulate TNFα-induced p38 phosphorylation (Fig. 5.15A). 
This effect was consistent also in cells of patients with non-severe and severe 
asthma (Fig. 5.15B and C). 
 
Similarly, in ASMC of healthy subjects, TNF-α but not IFN-γ induced phosphorylation 
of JNK and ERK, and this phosphorylation was not influenced by IFN-γ. ASMC of 
non-severe and severe asthmatics responded similarly to IFN-γ (Fig. 5.16 and 5.17). 
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Figure 5.15. Effect of IFN-γ on TNFα-induced p38 MAPK phosphorylation. 
ASMC of (A) healthy subjects and patients with (B) non-severe and (C) severe 
asthma were stimulated with TNF-α and/or IFN-γ (10 ng/mL each) for 15 minutes. 
Phosphorylated and total p38 were measured by Western Blot. Bars represent mean 
± SEM. * p<0.05, ** p<0.01. 
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Figure 5.16. Effect of IFN-γ on TNFα-induced JNK phosphorylation. ASMC of (A) 
healthy subjects and patients with (B) non-severe and (C) severe asthma were 
stimulated with TNF-α and/or IFN-γ (10 ng/mL each) for 15 minutes. Phosphorylated 
and total JNK were measured by Western Blot. Bars represent mean ± SEM.            
* p<0.05, ** p<0.01, *** p<0.001. 
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Figure 5.17. Effect of IFN-γ on TNFα-induced ERK phosphorylation. ASMC of (A) 
healthy subjects (A) and patients with (B) non-severe and (C) severe asthma were 
stimulated with TNF-α and/or IFN-γ (10 ng/mL each) for 15 minutes. Phosphorylated 
and total JNK were measured by Western Blot. Bars represent mean ± SEM.           
** p<0.01, *** p<0.001. 
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5.3 Discussion 
Summary of results: 
TNFα-induced p38 MAPK activation was heightened in ASMC of patient with severe 
asthma, which inversely correlated to dexamethasone suppression of inflammatory 
chemokines. In contrast, activation of JNK and ERK was increased in ASMC of 
patients with asthma, while there was no difference in those between non-severe 
and severe asthma. Furthermore, inhibition of p38 α/β activity improved the 
suppressive effect of dexamethasone in severe asthma. IFN-γ, which impairs the 
suppressive effect of dexamethasone in ASMC, did not modulate MAPK activities. 
 
Of the four isoforms of p38 MAPK, the α and β isoforms are highly effective at 
activating downstream kinases, such as MAPKAP 2/3 and MSK 1/2, and activate 
several transcription factors. In contrast, the γ and δ isoforms are less effective in 
activating downstream kinases (Adcock, Chung et al. 2006). Unlike the earlier 
compounds that caused undesirable liver toxicity, the second-generation of p38 
MAPK inhibitors have considerably reduced effect on cytochrome P450 and result in 
less side effects (Adams, Boehm et al. 1998). GW-856553 (losmapimod), a selective 
p38α/β inhibitor developed by GlaxoSmithKline (Aston, Bamborough et al. 2009), 
belongs to the nicotinamide class of p38 inhibitors. The therapeutic role of this drug 
has been extensively studied in clinical trials of several diseases including major 
depression, neuropathic pain, rheumatoid arthritis, myocardial infarction and airway 
diseases (Lomas, Lipson et al. 2012). In a phase II clinical trial, GW-856553 
improves hyperinflation and reduces plasma fibrinogen in patients with COPD 
(Lomas, Lipson et al. 2012).  
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GW-856553 has a pKi=8.1 and a pKi=7.6 for p38α and p38β, respectively, and 
demonstrates 100-fold greater selectivity for both the α and β isoforms against a 
panel of 67 human kinases (Goldstein, Kuglstatter et al. 2010). The specificity of this 
molecule is further confirmed by the observations that GW-856553 suppresses 
TNFα-induced p38 phosphorylation to a baseline level, while induced JNK and ERK 
phosphorylation is not modulated by the inhibitor (5.2.6). This effect is consistent 
with that reported in PBMC (Bhavsar, Khorasani et al. 2010) and supported by 
studies demonstrating that p38 inhibitors prevent auto-phosphorylation (Galan, 
Garcia-Bermejo et al. 2000; Matsuguchi, Musikacharoen et al. 2000; Ge, Gram et al. 
2002). 
  
Heightened p38 activity in severe asthma (5.2.2) is now extended from alveolar 
macrophages (Bhavsar, Hew et al. 2008) and airway epithelial cells (Liu, Liang et al. 
2008) to ASMC. A role for increased p38 activity in corticosteroid insensitivity in 
severe asthma is suggested by an inverse correlation between p38 phosphorylation 
and the suppressive effects of dexamethasone on inflammatory chemokines (5.2.5). 
This is further confirmed by the observations of improved dexamethasone 
suppression of CCL11 and CXCL8 release in ASMC of severe asthma (5.2.6) to a 
level which is achieved in those of non-severe asthma (4.2.2.1 and 4.2.2.2). These 
findings indicate that, in addition to p38γ (Mercado, To et al. 2011), p38 α/β inhibition 
restores corticosteroid sensitivity in severe asthma, and this effect extends from 
PMBC (Bhavsar, Khorasani et al. 2010) to ASMC.  
 
202 
In contrast to increased JNK phosphorylation in other human cell types and tissue in 
corticosteroid resistant severe asthma (Sousa, Lane et al. 1999; Kobayashi, 
Mercado et al. 2011), despite increased JNK activation in ASMC of both non-severe 
and severe asthma, there is no difference between the two groups (5.2.3). Similarly, 
while ERK activity is greater in cells of asthma, which is consistent with the literature 
(Jude, Solway et al. 2010; Robins, Roussel et al. 2011), there is no difference 
between non-severe and severe asthma (5.2.4). These observations would suggest 
that there may only be a limited role for JNK or ERK activation in corticosteroid 
insensitivity in ASMC of patients with severe asthma, which is further confirmed by 
an absence of correlation between JNK/ERK phosphorylation and dexamethasone 
suppression of chemokines (5.2.5) and lack of any modulatory effect by specific 
inhibitors of JNK/ERK on the suppressive effect of dexamethasone in cells of severe 
asthma (5.2.8 and 5.2.9). 
 
Whereas IFNγ impairs the suppressive effects of corticosteroid on several 
chemokines in ASMC (4.2.3.1-4.2.3.3), absence of its modulation on any of the 
MAPK activities (5.2.9) suggests that IFN-γ may contribute to corticosteroid 
resistance through signalling pathways which are not involved in severe asthma .  
 
In summary, there is heightened p38 MAPK activity in ASMC of patients with severe 
asthma, which contributes to corticosteroid insensitivity. p38 inhibition restores 
corticosteroid sensitivity in severe asthma and thus suggests the potential as a 
therapeutic target. 
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Chapter 6. Regulation of GR and NF-κB (p65) by corticosteroids in ASMC 
6.1 Introduction 
The anti-inflammatory effects of corticosteroids are mediated through GR, a ligand-
activated transcription factor that modulates inflammatory and anti-inflammatory 
gene expression through a variety of molecular signalling pathways. Briefly, following 
activation by ligand binding of a glucocorticoid, GR dissociates from chaperone 
proteins and rapidly translocates into the nucleus. Within the nucleus, GR either 
binds to specific GRE on DNA within the promoter region of corticosteroid-
responsive genes to enhance transcription of anti-inflammatory genes, or represses 
transcription of pro-inflammatory genes by interaction with inflammatory transcription 
factors, such as NF-κB and AP-1. Both of the processes involve modification of 
histones and alteration in chromatin structure (Bloom 2008). Insensitivity to 
corticosteroid may develop at multiple points in anti-inflammatory signalling 
pathways, including GR abnormalities (e.g. reduced GR number and ligand binding 
affinity), decreased translocation of GR from the cytoplasm to the nucleus, altered 
GR interactions with other transcription factors, and abnormalities of histone-
modifying enzymes (Fig. 6.1).  
 
GR is a phosphoprotein, and changes in its phosphorylation pattern may affect all 
aspects of its function (Weigel and Moore 2007). The phosphorylation of these sites 
can be ligand dependent or independent. GR phosphorylation of specific amino acid 
residues has been associated with modulation of ligand binding, nuclear 
translocation, DNA binding, receptor dimerization, and interaction with general 
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transcription factors (Duma, Jewell et al. 2006). Of the six serine residues which are 
characterised as phosphorylation targets in human GR, phosphorylation of GR at 
S211 may correlate to ligand binding, nuclear translocation and transcriptional 
activity and thus is a hallmark for the transactivation potential of GR (Weigel and 
Moore 2007; Oakley and Cidlowski 2011).  
Figure 6.1. Mechanisms of glucocorticoid action by GR and sites of regulation 
in corticosteroid insensitivity. The activation of kinase pathways by inflammatory 
mediators or T-cell receptor coactivation (CD3/CD28) attenuates GR function by 
reducing ligand binding and nuclear translocation, or by mutually 
suppressing/interacting with NF-κB and AP-1. Allergens and superantigens not only 
affect GR ligand binding but also, along with Th2 cytokines, induce GRβ. Cigarette 
smoke and reactive oxygen species (ROS) stress prevent GR nuclear translocation 
or reduce the activity of HDAC2, reducing the ability of GR to switch off inflammatory 
genes (Adcock and Barnes 2008). 
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Glucocorticoids have a major effect on ASMC function due to high expression of GR 
(Adcock, Gilbey et al. 1996). However, the mechanisms by which corticosteroids 
modulate inflammatory genes in ASMC are not fully understood. It is also unclear 
whether ASMC display differential regulations of GR signalling pathways between 
the healthy and diseased subjects. Given the observations of impaired corticosteroid 
suppression of inflammatory chemokine expression (4.2.2.1, 4.2.2.2, 4.2.2.5 and 
4.2.2.6), which correlates to heightened p38 activity (5.2.2, 5.2.5 and 5.2.6), in 
ASMC of patients with severe asthma, mechanisms of GR and NF-κB regulation in 
response to corticosteroids are investigated in this chapter, in terms of  expression, 
nuclear translocation and phosphorylation. The interaction between TNFα-induced 
p38 activity and nuclear translocation of GR are also explored. 
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6.2 Results 
6.2.1 Investigation and comparison of GR regulation in ASMC 
6.2.1.1 Comparison of GR abundance in ASMC of healthy subjects and 
patients with non-severe and severe asthma 
The abundance of GR in ASMC at baseline was compared. After serum starvation 
for 24 hours, whole cell lysates were collected. Total GR and β-actin were measured 
by Western Blot and normalised to the standard protein (described in 2.2.7.1). GR 
expression in ASMC of patients with asthma was 49% of that expressed in cells of 
healthy subjects (Fig. 6.2 A and B; p<0.01). However, there was no significant 
difference between patients with non-severe and severe asthma (Fig. 6.2 A and C). 
Figure 6.2. Comparison of baseline GR expression in ASMC of healthy 
subjects and patients with non-severe (NSA) and severe asthma (SA). GR and 
β-actin in the whole cell lysates were measured by Western Blot. (A) A 
representative blot with duplicates for each group. (B) Comparison of ASMC of 
healthy subjects and patients with asthma. (C) Comparison of ASMC of non-severe 
and severe asthmatics. Horizontal lines represent median. ** p<0.01. 
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6.2.1.2 Effect of dexamethasone on GR expression in ASMC 
To determine the effect of dexamethasone on total GR expression in ASMC, cells of 
healthy subjects were stimulated with dexamethasone (10-6 M) over a time course (5 
minutes to 24 hours). Total GR and β-actin expression in the whole cell lysates was 
measured by Western Blot. Dexamethasone did not influence GR expression up to 4 
hours post-stimulation. However, after 24 hours, the baseline abundance of total GR 
was suppressed by 57.5% (Fig. 6.3; p<0.01). 
Figure 6.3. Effect of dexamethasone on GR expression in ASMC. Cells were 
stimulated with dexamethasone (10-6 M) for time indicated. Total GR and β-actin in 
the whole cell lysates were measured by Western Blot. Bars represent mean ± SEM 
of ASMC from 3 healthy subjects. ** p<0.01 vs unstimulated. 
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6.2.1.3 Effect of dexamethasone on nuclear translocation of GR in ASMC 
To investigate the effect of dexamethasone on nuclear translocation of GR in ASMC, 
cells of healthy subjects were stimulated with dexamethasone (10-7 M) for 30 
minutes to 4 hours. GR, TBP and α-tubulin in both nuclear and cytoplasmic extracts 
were measured by Western Blot. Nuclear GR abundance was increased by 
dexamethasone at 30 minutes and was sustained for 4 hours, while cytoplasmic GR 
displayed a reciprocal effect (Fig. 6.4). These results confirm that nuclear 
translocation of GR is induced by dexamethasone in ASMC. 
Figure 6.4. Effect of dexamethasone on nuclear translocation of GR in ASMC. 
Cells were stimulated with dexamethasone (10-7 M) for time indicated. GR, TBP and 
α-tubulin in (A) nuclear and (B) cytoplasmic extracts were assessed by Western Blot. 
A representative blot of ASMC from 2 healthy subjects is shown. 
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6.2.1.4 Comparison of baseline nuclear abundance of GR in ASMC of healthy 
subjects and patients with non-severe and severe asthma 
Baseline nuclear GR abundance in ASMC at baseline was compared between the 
three groups. After serum starvation for 24 hours, nuclear extracts were collected. 
GR and TBP were measured by Western Blot and normalised to the standard protein 
(described in 2.2.7.1). The quantity of nuclear GR was similar among ASMC of 
healthy subjects and patients with non-severe and severe asthma (Fig. 6.5). 
Figure 6.5. Comparison of baseline abundance of nuclear GR in ASMC of 
healthy subjects and patient with non-severe (NSA) and severe asthma (SA). 
GR and TBP in the nuclear extracts were measured by Western Blot. A 
representative blot is shown. Horizontal lines represent median. STD: standard 
protein. 
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6.2.1.5 Comparison of nuclear translocation of GR induced by dexamethasone 
in ASMC of healthy subjects and patients with non-severe and severe asthma 
To compare nuclear translocation induced by dexamethasone in ASMC, cells were 
stimulated with dexamethasone (10-7 M) for 30 minutes to 4 hours. GR and TBP in 
the nuclear extracts were measured by Western Blot. In ASMC of healthy subjects 
and patients with non-severe asthma, dexamethasone induced approximately a 3-
fold increase in GR abundance at 30 minutes, which was maintained to one hour 
post-stimulation, followed by a gradual decrease. Of importance, in ASMC of 
patients with severe asthma, nuclear GR was induced by less than 2-fold; this was 
significantly decreased compared to those of healthy subjects and patients with non-
severe asthma at all time points (Fig. 6.6). 
Figure 6.6. Comparison of dexamethasone-induced GR nuclear translocation 
in ASMC of healthy subjects and patients with non-severe and severe asthma. 
ASMC were stimulated with dexamethasone (10-7 M) for time indicated. GR and TBP 
in the nuclear extracts were measured by Western Blot. Points represent mean ± 
SEM. * p<0.05 vs healthy subjects. # p<0.05, ## p<0.01 vs patients with non-severe 
asthma. 
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6.2.1.6 Effect of dexamethasone on phosphorylation of GR at S211 in ASMC 
To investigate the effect of dexamethasone on phosphorylation of GR at the serine 
residue 211 (S211), ASMC of healthy subjects were stimulated with dexamethasone 
(10-6 M) for 5 minutes to 4 hours. Phosphorylated and total GR in the whole cell 
lysates were measured by Western Blot. GR phosphorylation was significantly 
induced by dexamethasone at 30 minutes (p<0.01) post-stimulation, which was 
further increased (5.2-fold) at one hour and maintained for 4 hours (Fig. 6.7; 
p<0.001).  
Figure 6.7. Effect of dexamethasone on GR phosphorylation at S211 in ASMC. 
Cells were stimulated with dexamethasone (10-6 M) for time indicated. 
Phosphorylated and total GR in the whole cell lysates were measured by Western 
Blot. Bars represent mean ± SEM of ASMC from 3 healthy subjects. ** p<0.01,       
*** p<0.001 vs unstimulated (US).  
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6.2.1.7 Comparison of phosphorylation of GR at S211 induced by 
dexamethasone in ASMC of healthy subjects and patients with non-severe and 
severe asthma 
To compare phosphorylation of GR at S211 induced by dexamethasone in ASMC, 
cells were stimulated with dexamethasone (10-6 M) for 2 hours. Total and 
phosphorylated GR in the whole cell lysates were measured by Western Blot. In 
ASMC of healthy subjects, dexamethasone induced a 6-fold increase in GR 
phosphorylation at S211, and this induction was similar between the cells of the 
healthy and patients with asthma (Fig. 6.8). 
Figure 6.8. Comparison of dexamethasone-induced GR phosphorylation at 
S211 in ASMC of healthy subjects and patients with non-severe and severe 
asthma. Cells were stimulated with dexamethasone (10-6 M) for 2 hours. 
Phosphorylated and total GR in whole cell lysates were measured by Western Blot. 
Horizontal lines represent median.  
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6.2.2 Investigation of mechanisms of suppression of NF-κB activity by 
corticosteroid 
6.2.2.1 Comparison of the suppressive effect of dexamethasone on induced 
p65 protein and mRNA expression in ASMC of healthy subjects and patients 
with non-severe and severe asthma 
To compare the suppressive effect of dexamethasone on induced p65 protein 
expression, ASMC were pretreated with dexamethasone  (10-7 M) for 2 hours and 
then stimulated with TNF-α (10 ng/mL) for 24 hours. p65 and TBP in the whole cell 
lysates were measured by Western Blot. In ASMC of healthy subjects, p65 protein 
expression induced by TNF-α was suppressed by dexamethasone by 21.3% 
(p<0.05). This suppressive effect was similar in cells of patients with non-severe 
asthma (p<0.001) and was maintained in those of severe asthma (p<0.01) (Fig. 
6.9A). 
 
To compare the suppressive effect of dexamethasone on induced p65 mRNA 
expression, ASMC were pretreated with dexamethasone  (10-10-10-6 M) for 2 hours 
and then stimulated with TNF-α (10 ng/mL) for 24 hours.  p65 mRNA and 18S rRNA 
were measured by RT-qPCR. In ASMC of healthy subjects, TNFα-induced p65 
mRNA was inhibited in a concentration-dependent manner, with maximal 
suppression of approximately 50% by dexamethasone at 10-7 and 10-6 M (p<0.01, 
respectively). This suppressive effect was similar in cells of patients with non-severe 
asthma and was maintained in those of severe asthma (Fig. 6.9B).  
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Figure 6.9. Comparison of the suppressive effect of dexamethasone on 
induced p65 expression in ASMC of healthy subjects and patients with non-
severe and severe asthma. Cells were pretreated with dexamethasone (10-7 M for 
protein and 10-10-10-6 M for mRNA) for 2 hours and TNF-α (10 ng/mL) for 24 hours. 
p65 protein/TBP and p65 mRNA/18S were measured by Western Blot and RT-qPCR, 
respectively. Bars and points represent mean ± SEM. * p<0.05, ** p<0.01,              
*** p<0.001. 
216 
6.2.2.2 Effect of dexamethasone on TNFα-induced nuclear translocation of p65 
in ASMC of healthy subjects and patients with non-severe and severe asthma 
To investigate the effect of dexamethasone on nuclear translocation of p65 induced 
by TNF-α in ASMC, cells were stimulated with dexamethasone (10-7 M) or TNF-α (10 
ng/mL) alone or in combination for 30 minutes. p65 and TBP in nuclear extracts were 
measured by Western Blots. TNF-α increased nuclear abundance of p65, which was 
not affected by dexamethasone. This effect was similar in ASMC of healthy subjects 
and patients with non-severe and severe asthma (Fig. 6.10 A-C). 
Figure 6.10. Effect of dexamethasone on TNFα-induced nuclear translocation 
of p65 NF-κB in ASMC. Cells were stimulated with TNF-α (10 ng/mL) and/or 
dexamethasone (10-7 M) for 30 minutes. Nuclear p65 and TBP from ASMC of (A) 
healthy subjects and patients with (B) non-severe and (C) severe asthma were 
measured by Western Blot. Bars represent mean ± SEM. * p<0.05, *** p<0.001. 
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6.2.2.3 Effect of dexamethasone on p65 recruitment to the CCL11 promoter in 
ASMC of healthy subjects and patients with asthma 
Having shown that dexamethasone suppresses TNFα-induced CCL11 release 
(4.3.2.1) and mRNA expression (4.3.2.4) in ASMC, an investigation into the effect of 
dexamethasone on induced p65 recruitment to the gene promoter of CCL11 was 
performed. Cells were pretreated with dexamethasone (10-6 M) for 2 hours and then 
stimulated with TNF-α (10 ng/mL) for one hour. p65 recruitment to the CCL11 
promoter was measured by ChIP assay. In ASMC of healthy subjects, TNFα-induced 
a 15-fold increase in the recruitment of p65, which tended to be partly suppressed by 
IFN-γ (Fig. 6.11A; p=0.061). This effect was similar in ASMC of a patient with non-
severe asthma, in which IFN-γ suppressed TNFα-induced p65 recruitment by 38% 
(Fig. 6.11B). 
Figure 6.11. Effect of IFN-γ on TNFα-induced p65 recruitment to the CCL11 
promoter in ASMC of healthy subjects and patients with asthma. Cells were 
stimulated with TNF-α and/or IFN-γ (10 ng/mL each) for one hour. p65 recruitment to 
the CCL11 promoter in ASMC of (A) heathy subjects and (B) a patient with non-
severe asthma was measured by ChIP assay. Bars represent mean ± SEM.           
*** p<0.001. 
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6.2.3 Investigation of mechanisms by which TNFα-induced p38 activation 
modulates corticosteroid response in ASMC 
6.2.3.1 Effect of TNF-α on dexamethasone-induced nuclear translocation of GR 
in ASMC of healthy subjects and patients with non-severe and severe asthma 
Given the observation that i) p38 phosphorylation induced by TNF-α is associated 
with the suppressive effect of dexamethasone in ASMC (5.3.5) and ii) induced GR 
nuclear translocation is impaired in ASMC of patients with severe asthma (6.3.1.5), 
the effect of TNF-α on nuclear translocation of GR was investigated. Cells were 
stimulated with dexamethasone (10-7 M) or TNF-α (10 ng/mL) alone or in 
combination for 30 minutes. GR and TBP in the nuclear extracts were measured by 
Western Blot. In ASMC of healthy subjects, dexamethasone, but not TNF-α, 
increased nuclear abundance of GR by 3-fold. However, this induction was not 
modulated by TNF-α (Fig. 6.12A). This effect was similar in ASMC of patients with 
non-severe (Fig. 6.12B) and severe asthma (Fig. 6.12C), where induced nuclear 
translocation of GR was not altered by TNF-α. 
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Figure 6.12. Effect of TNF-α on induced nuclear translocation of GR in ASMC. 
Cells were stimulated with dexamethasone (10-7 M) and/or TNF-α (10 ng/mL) for 30 
minutes. GR and TBP in the nuclear extracts in (A) the healthy and patients with (B) 
non-severe and (C) severe asthma were measured by Western Blot. Bars represent 
mean ± SEM. *** p<0.001. 
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6.2.3.2 Effect of p38 inhibition on dexamethasone-induced nuclear 
translocation of GR in ASMC 
Given the observations that i) corticosteroid sensitivity in ASMC of patients with 
severe asthma is restored by p38α inhibition (5.3.6) and ii) nuclear translocation of 
GR is impaired in cells of patients with severe asthma (6.3.1.5), the effect of p38 
inhibition on induced GR nuclear translocation was examined. ASMC of patients with 
severe asthma were stimulated with dexamethasone (10-7 M), in the presence or 
absence of the p38α inhibitor GW856553, for 30 minutes to 2 hours. GR and TBP in 
the nuclear extracts were measured by Western Blot. Dexamethasone increased 
nuclear abundance of GR at 30 minutes, which was maintained to 2 hours, whereas 
GW-856553 did not modulate this effect (Fig. 6.13). 
Figure 6.13. The effect of p38α inhibitor on nuclear translocation of GR in 
ASMC. Cells were stimulated with dexamethasone (10-7 M) with or without GW-
856553 for time indicated. GR and TBP in the nuclear abstracts were assessed by 
Western Blot. A representative blot of ASMC from 2 patients with severe asthma is 
shown. 
221 
6.3 Discussion 
Summary of results: 
GR abundance was reduced in ASMC of patients with asthma. GR expression was 
not modulated by dexamethasone until 24 hours post-stimulation. Nuclear 
translocation of GR was impaired in ASMC of patients with asthma compared to 
those of healthy and non-severe asthmatic subjects. Phosphorylation of GR at S211 
was not different between groups. In addition, p65 expression was suppressed by 
dexamethasone. Whereas dexamethasone did not modulate p65 nuclear 
translocation, it attenuated recruitment of p65 to the CCL11 promoter. Finally, TNFα-
induced p38 activation did not modulate nuclear translocation of GR. 
 
6.3.1 Differential expression and regulation of GR in ASMC 
The mechanism underlying decreased expression of GR in ASMC of patients with 
asthma (6.2.1.1) is uncertain, yet this might account for failure of corticosteroid 
suppression of serum-induced ASMC proliferation in those of asthma (Roth, Johnson 
et al. 2004). In contrast, the statistical equivalence of GR expression  in ASMC 
between patients with non-severe and severe asthma is supported by reports of no 
difference in either GRα or GRβ mRNA expression in peripheral lymphocytes of 
severe or moderate asthmatic subjects (Jakiela, Bochenek et al. 2010) and similar 
protein and mRNA expression of both GRα and GRβ in PBMC of steroid-dependent 
or well-controlled asthma (Gagliardo, Chanez et al. 2000). 
 
The abundance of GR is reduced by dexamethasone at 24 hours post-stimulation 
(6.2.1.2), suggestive of a down-regulatory effect of glucocorticoids on GR expression. 
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GR mRNA is also exposed to negative regulation by glucocorticoids (Shimojo, Hiroi 
et al. 1995). This might be explained by the presence of negative GRE, AP-1, NF-κB, 
and CREB regulatory motifs in the promoter of GR, all of which are negatively 
regulated by glucocorticoids (Duma, Jewell et al. 2006). Alternatively, glucocorticoids 
may regulate the expression of the GR gene post-transcriptionally, perhaps via 
destabilization of the GR mRNA (Vedeckis, Ali et al. 1989). Moreover, ligand-
activated GR protein is degraded upon prolonged exposure to glucocorticoids by the 
proteasome-ubiquitin degradation pathway (Alarid 2006). 
 
The observation of reduced dexamethasone-induced nuclear abundance of GR in 
severe asthma (6.2.1.5) extends impaired GR nuclear translocation from PBMC 
(Matthews, Ito et al. 2004; Mercado, To et al. 2011) to ASMC of patients with severe 
asthma. The defective GR nuclear translocation in corticosteroid insensitive severe 
asthma may be partly attributed to hyper-phosphorylation of GR (Mercado, To et al. 
2011), and this can contribute to impaired effect of corticosteroids via either 
decreased GR-GRE binding (Adcock, Lane et al. 1995) or failure to suppress HAT 
activity induced by inflammatory stimuli (Matthews, Ito et al. 2004). Nuclear 
translocation of GR could also be affected by i) GR nitrosylation, which leads to 
reduced dissociation of GR from hsp90 (Galigniana, Piwien-Pilipuk et al. 1999); ii) 
GR phosphorylation by MAPK p38, JNK and ERK (Barnes 2010) and iii) involvement 
of JAK3/STAT5 pathway (Goleva, Kisich et al. 2002). The roles of these signalling 
pathways for corticosteroid insensitivity in severe asthma have yet to be determined. 
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Whereas phosphorylated GR at S211 is proposed as a hallmark for the 
transcriptional potential of GR (Beck, Vanden Berghe et al. 2009), absence of 
differential degrees of phosphorylation between groups (6.2.1.7) suggests GR 
phosphorylation at this serine residue may not contribute to corticosteroid 
insensitivity in severe asthma. 
 
6.3.2 Regulation of NF-κB (p65) by dexamethasone in ASMC 
TNFα-induced expression of the p65 and p50 components of NF-κB is suppressed 
by dexamethasone in ASMC of healthy subjects at both protein and mRNA levels 
(Kang, Tirumurugaan et al. 2006). This is further confirmed in those of asthma 
(6.2.2.1). Interestingly, whereas corticosteroid insensitivity is displayed in ASMC of 
patients with severe asthma in terms of suppressing some of the NFκB-mediated 
genes such as CCL11 and CXCL8 (4.2.2.1, 4.2.2.2, 4.2.2.5 and 4.2.2.6), the 
suppressive effect of dexamethasone on p65 expression is not dissimilar between 
any of the groups (6.2.2.1). This suggests that reduced response to corticosteroids in 
severe asthma is not displayed in terms of suppression of overall NF-κB expression. 
 
Inability of dexamethasone to inhibit induced p65 nuclear translocation in ASMC 
(6.2.2.2) has been previously reported (Nie, Knox et al. 2005) and is consistent in 
A549, a human lung epithelial cell line (Bhavsar, Sukkar et al. 2008). Interestingly, in 
human lung myofibroblasts, TNFα-induced nuclear translocation of NF-κB is inhibited 
by fluticasone (Baouz, Giron-Michel et al. 2005). This suggests the existence of cell-
specific regulatory effects of corticosteroids on NF-κB nuclear translocation. 
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Consistent with the absence of a modulatory effect of dexamethasone on p65 
nuclear translocation, the literature reports that dexamethasone does not prevent 
TNFα-induced NF-κB DNA binding or NFκB-mediated reporter activity in ASMC 
(Amrani, Lazaar et al. 1999). Intriguingly, TNFα-induced p65 recruitment to the 
CCL11 promoter is attenuated by dexamethasone (6.2.2.3). This regulatory effect is 
consistent with reported studies and is associated with reduced acetylation of H4, 
probably resulting in conformation change of chromatin and prevention of p65 
recruitment (Nie, Knox et al. 2005), and is now extended from ASMC of healthy 
subjects to patients with non-severe asthma. In contrast, induced p65 recruitment to 
the promoter of inflammatory genes, such as CXCL1, is not suppressed by 
dexamethasone (Issa, Xie et al. 2006), suggesting that despite widespread 
recognised corticosteroid suppression of NF-κB activity (Barnes 2006), the 
regulatory signalling pathways are sophisticated and gene-specific.  It would be 
worthwhile to examine whether the effect of dexamethasone on p65 recruitment to 
the CCL11 promoter in ASMC of patients with severe asthma is different, based on 
the observation of impaired corticosteroid suppression of induced CCL11 expression 
in those of severe asthma (4.2.2.1 and 4.2.2.5). 
 
6.3.3 Role of p38 MAPK activity for GR nuclear translocation in ASMC  
Dexamethasone-induced nuclear translocation of GR is not modulated by TNF-α in 
ASMC (6.2.3.1), which is supported by evidence from confocal microscopic studies 
(Issa, Xie et al. 2006). In addition, p38 inhibition does not modulate nuclear 
translocation of GR in response to dexamethasone in ASMC of patients with severe 
asthma (6.2.3.2), suggesting impaired GR nuclear translocation is not an effect of 
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heightened p38 activity in ASMC of severe asthma. This is in contrast to the findings 
in T-cells, where p38 inhibition reverses corticosteroid insensitivity and reduced GR 
nuclear translocation induced by IL-2 and IL-4 (Goleva, Li et al. 2009). This suggests 
while IL-2 and IL-4 display greater expression in the airways of severe asthma 
(Leung, Martin et al. 1995) and contribute to corticosteroid insensitivity in vitro, the 
cytokines may not underlie the mechanism of corticosteroid in severe asthma.    
 
In summary, there is impaired nuclear translocation of GR in ASMC of patients with 
severe asthma. This may underlie the mechanism of corticosteroid insensitivity in 
severe asthma but it is not mediated by p38 MAPK activity. Whereas 
dexamethasone does not modulate nuclear translocation, DNA binding, or even the 
reporter activity of NF-κB, it suppresses transcription of specific inflammatory gene(s) 
through attenuation of p65 recruitment to the gene promoter. Comparison of the 
regulatory effects between non-severe and severe asthma will provide further 
mechanistic insights into the phenomenon. 
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Chapter 7. General discussion 
Asthma is a chronic disease characterised by airway inflammation, hyper-
responsiveness and remodelling. Airway smooth muscle participates in all of these 
processes, and thus ASMC provide a suitable model for the investigation of the 
pathophysiology of the disease. TNF-α and IFN-γ are important pro-inflammatory 
cytokines involved in the immunopathogenesis of asthma, including exacerbation 
and severe disease (Barnes 2008), but the interaction between the two has yet to be 
fully understood in the context of ASMC. While IFN-γ attenuates TNFα-induced p65 
acetylation (Keslacy, Tliba et al. 2007), TNF-α/IFN-γ mutually up-regulate the 
receptors of their counterpart (Krakauer and Oppenheim 1993; Kost, Mutch et al. 
1999).  The proposed mechanisms based on these observations are contradictory 
and may be too simplified to account for the differential regulation of TNFα-induced 
chemokine expression by IFN-γ in ASMC. Investigations into modulatory effects at 
individual genes, using techniques such as the ChIP assay, are essential for clearer 
insights into the gene-specific regulatory mechanisms. IFN-γ suppresses TNFα-
induced CCL11 (3.2.1.1 and 3.2.1.9) and CXCL8 expression (3.2.1.2 and 3.2.1.10) 
by attenuating p65 recruitment to the gene promoters (3.2.1.12 and 3.2.1.13), while 
the cytokine potentiates TNFα-induced CXCL10 expression (3.2.1.3) by synergistic 
recruitment of CBP (Clarke, Clifford et al. 2010). The mechanisms by which TNF-α 
and IFN-γ synergistically induce CX3CL1 expression (3.2.1.4 and 3.2.1.8) has yet be 
determined.  
 
Patients with non-severe and severe asthma display different clinical phenotypes 
(Wenzel and Busse 2007) and distinct inflammatory profiles (Macedo, Hew et al. 
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2009).  Both baseline and TNFα-induced CCL11 expression is greater in ASMC of 
non-severe asthma (3.2.2.1), indicating inherently different phenotypes between 
healthy subjects and patients with non-severe and severe asthma. In contrast, only 
IFNγ-induced CXCL10 release is increased in cells of severe asthma (3.2.2.3). 
Hence, the differential expression of pro-asthmatic chemokines in ASMC of healthy 
and diseased subjects is displayed in response to specific cytokine stimulation. 
Increased p65 expression in cells of severe asthma (3.2.3.1) does not account for 
individual underlying signalling pathways. Although p65 recruitment to each gene 
promoter is not different (3.2.3.5), the possibility of differential NF-κB activities 
between groups may not be excluded, as the activity of the transcription factor can 
also be regulated by post-translational modification without interfering with DNA-
binding affinity (discussed in 3.3.2). 
 
Patients with severe asthma are barely or even not controlled by high-dose steroid 
treatment (Bousquet, Mantzouranis et al. 2010). The suppressive effects of 
dexamethasone on induced CCL11 and CXCL8 expression are impaired in ASMC of 
patients with severe asthma (4.2.2.1, 4.2.2.2, 4.2.2.5 and 4.2.2.6). This is the first 
study which reveals that ASMC of severe asthma display corticosteroid insensitivity 
and extends the findings from PBMC (Hew, Bhavsar et al. 2006) and alveolar 
macrophages (Bhavsar, Hew et al. 2008; Bhavsar, Levy et al. 2010) to  an airway 
structural cell at passage 4-5, reinforcing inherent differential phenotypes between 
non-severe and severe asthmatic subjects. Furthermore, heightened p38 activity is 
displayed in ASMC of severe asthma (5.2.2), and inhibition of p38, rather than JNK 
or ERK, improves corticosteroid suppression of inflammatory chemokines in those of 
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severe asthma to an extent achieved in non-severe asthma (5.2.6-5.2.8). This 
indicates the therapeutic potential of p38 inhibitors in the treatment of corticosteroid-
insensitive severe asthma.   
 
Despite the observation that TNF-α/IFN-γ (Howarth, Babu et al. 2005; Shannon, 
Ernst et al. 2008) and IL-2/IL-4 (Leung, Martin et al. 1995) display greater expression 
in the airways of severe asthma, and that these cytokine combinations cause 
corticosteroid resistance in association with induction of p38 activity in vitro, their 
involvement in inducing corticosteroid insensitivity in severe asthma is still arguable:  
i) not all of the TNFα-induced chmokines whose response to steroids are  impaired 
by IFN-γ (4.2.3.1-4.2.3.3) are insensitive to corticosteroid suppression in severe 
asthma (4.2.2.3) and ii) while IL2 and IL4-mediated reduction in GR nuclear 
translocation and decreased anti-inflammatory effects is reversed by a p38 inhibitor 
(Goleva, Li et al. 2009), the former effect is not displayed in cells of severe asthma 
(6.2.3.2). These discrepancies highlight the value of studies based on specimens 
obtained from diseased subjects instead of those from the healthy or immortal cell 
lines. Furthermore, whereas nuclear translocation of GR is impaired in ASMC of 
severe asthma (6.2.1.5), the impact on glucocorticoid-regulated genes may vary, 
depending on the cofactors recruited and/or gene-specific GR-DNA binding affinity. 
This may explain the observations that not all glucocorticoid-mediated chemokines 
respond inefficiently to corticosteroids in severe asthma (4.2.2.3, 4.2.2.4 and 4.2.2.7). 
 
One of the limitations of this research is that the cultured human ASMC at passage 
4-5 may not reflect the situation in vivo. However, these in-vitro data are concordant 
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with the clinical observation that these patients with severe asthma are under 
suboptimal control despite corticosteroid therapy. The causes of chronic airflow 
obstruction observed in severe asthma include enhanced airway smooth muscle 
contraction, airway wall inflammation and oedema as well as intraluminal mucus. 
The lack of effect of corticosteroids in suppressing pro-asthmatic chemokine 
expression from ASMC of patients with severe asthma may contribute further to the 
severity of asthma.  Reversibility of corticosteroid insensitivity in airway smooth 
muscle could lead to better control of severe asthma. 
 
The results and discussion of the studies presented herein indicate a number of 
directions for future research, either in the form of new work or to clarify existing 
controversies: 
1) Mechanisms underlying differential expression of CCL11 and CXCL10 in 
ASMC of healthy subjects and patients with non-severe and severe asthma 
Investigate and compare i) IFNγ-induced STAT1 and RNA polymerase II 
recruitment to the CXCL10 promoter, ii) post-translational modification of p65, 
such as phosphorylation and acetylation, and iii) mRNA half-lives in ASMC 
between groups. 
2) Mechanisms underlying corticosteroid insensitivity in terms of suppressing 
CCL11 and CXCL8 in severe asthma 
Investigate and compare the effect of dexamethasone on i) recruitment of p65, 
CBP to the gene promoters and ii) acetylation of histone H4 in ASMC between 
groups 
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3) Mechanisms by which heightened p38 MAPK activity contributes to 
corticosteroid insensitivity in severe asthma 
Investigate and compare i) the effects of dexamethasone on p38 MAPK 
activation and mRNA half-lives of induced CCL11 and CXCL8, ii) a role for p38 
MAPK in mRNA half-lives of the chemokines and iii) a role for MKP-1 in 
regulation of p38 activity and corticosteroid response in ASMC between groups. 
4) Mechanisms by which TNF-α and IFN-γ synergistically induce CX3CL1 
expression 
Investigate i) STAT1, IRF-1, CBP and RNA polymerase II recruitment to the 
CX3CL1 promoter and ii) acetylation of the histone protein H4 in the presence of 
TNF-α or IFN-γ alone or in combination. 
5) Mechanism by which dexamethasone potentiates TNFα and IFNγ-induced 
CX3CL1 expression in ASMC 
Investigate i) recruitment of p65, STAT1, IRF-1, CBP and RNA polymerase II to 
the CX3CL1 promoter in the presence of TNF-α/IFN-γ or dexamethasone alone 
or in combination and ii) compare the regulatory effects between ASMC and 
airway epithelial cells.  
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